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Summary 
The  Security  Forces  Hospital,  Saudi  Arabia  analyses  approximately  10,000  urine  samples 
per  year.  One  of  the  main  problems  with  urine  sample  collection  is  the  possibility  of 
adulteration.  It  has  been  found  that  2-3  %  of  samples  have  had  attempts  at  adulteration, 
usually  by  adding  water.  In  cases  of  suspected  adulteration,  the  possibility  of  analysing  a 
hair  sample  in  conjunction  with  the  corresponding  urine  sample  would  be  beneficial  to 
confirm  the  validity  of  the  specimen  results.  From  available  statistical  records  in  Security 
Forces  Hospital,  Saudi  Arabia  [1],  the  most  common  drugs  of  abuse  used  were 
amfetamines  and  cannabinoids.  These  represent  about  80-90%  of  total  positive  results  of 
drugs  of  abuse.  The  purpose  of  this  study  was  to  develop  a  single  method  to  analyse  these 
drugs  in  hair  and  to  apply  this  to  case  samples  received  from  The  Security  Forces  Hospital, 
Saudi  Arabia. 
First  of  all,  mass  fragments  and  retention  times  for  arnfetamines  and  cannabinoids  were 
identified  by  GC-MS  using  derivatisation  agents,  PFPA  /  ethyl  acetate  (2:  1  v/v)  and  PFPA 
/  PFPOH  (1:  0.75  v/v)  for  arnfetamines  and  cannabinoids,  respectively.  The  results 
showed  good  peak  shape,  good  chromatographic  resolution  and  good  sensitivity  for 
amfetamine  (AF),  methamfetamine  (MA),  3,4-Methylenedioxyamfetainine  (MDA  ),  3,4- 
Methylenedioxymethamfetamine  (MDMA),  3,4-  Methylenedioxyethylamfetamine 
(MDEA),  A?  -tetrahydrocannabinol  (A?  -THQ  and  11-nor-9-carboxy-A?  - 
tetrahydrocannabinol  (A?  -THC-COOH)  compounds. 
The  comparison  of  the  efficiency  of  four  different  pre-treatment  methods  (enzymatic, 
alkaline,  acid  and  methanol)  to  extract  AF,  MA,  MDA,  MDMA,  MDEA,  2 
-THC  and  2 
-THC-COOH  from  hair  samples  obtained  from  known  arnfetarnines  and  cannabinoids 
abusers  was  investigated.  Each  method  was  followed  by  SPE,  derivatisation  and  detection 
using  gas-chromatography  mass-spectrometry.  The  method  giving  the  best  recovery  for 
the  detection  and  quantification  of  cannabinoids  and  amfetamines  simultaneously  was  to 
be  selected  and  fully  validated. 
The  preliminary  results  demonstrated  difficulty  with  the  cannabinoids  recovery  and  the 
lower  concentrations  of  standards  were  not  detected  using  any  of  the  pre-treatment 
methods.  Consequently,  the  calibration  curves  for  all  pre-treatment  methods  could  not  be 
plotted  and  the  initial  method  was  deemed  insufficiently  sensitive  for  cannabinoid 
detection  purposes.  In  order  to  obtain  a  better  recovery  of  the  cannabinoids,  parameters  in 
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the  method  were  modified.  Four  different  eluents  were  compared  for  the  cannabinoids; 
acetone  /chlorofon-n  (1:  1  v/v),  hexane  /  EtOAc  (9:  1  v/v),  hexane  /  EtOAc  (8:  2  v/v)  and 
methanol  using  alkaline  pre-treatment  and  the  pH  of  the  phosphate  buffer  was  also 
changed  (pH5,6,7  and  8). 
However,  the  problem  still  persisted  with  the  cannabinoids  recovery.  Meanwhile,  the 
amfetamines  concentration  showed  no  significant  change  throughout  this  investigation. 
As  a  result  of  the  poor  cannabinoids  recovery,  only  the  amfetamines  were  investigated. 
For  the  comparison  study,  only  one  hair  sample  positive  for  amfetamine  was  available  so 
the  pre-treatment  comparison  study  was  based  on  the  recovery  of  AF  using  the  four  pre- 
treatment  methods. 
The  positive  hair  sample  was  separated  into  portions  and  pre-treatment  methods,  alkaline 
(lM  NaOH),  fl-Glucuronidase  (helix  pomatia),  methanol  (MeOH)  and  acid  (0.1M  HCI) 
were  used  on  these  and  compared.  The  best  recovery  for  amfetamine  was  obtained  using 
the  fl-glucuronidase  pre-treatment  method  and  this  extract  was  also  found  to  be  cleaner 
than  the  alkaline  and  methanol  pre-treatments.  fl-glucuronidase  pre-treatment  was  selected 
as  the  method  of  choice  for  the  extraction  of  amfetamine  content  in  hair.  The  method  was 
validated  to  include  linearity,  recovery,  intra-  and  inter-day  precision,  limit  of  quantitation 
(LOQ)  and  limit  of  detection  (LOD)  for  all  five  amfetainine  compounds.  The  method  was 
shown  to  be  reliable  and  robust  for  these  substances. 
The  stability  of  AF  in  hair  was  investigated  to  assess  the  validity  of  analysing  hair  samples 
for  the  presence  of  AF  in  victims  of  drowning.  Ten  amfetamine  positive  hair  samples  were 
submerged  in  fresh  and  sea  water  for  different  periods  of  time.  The  drug  concentrations  in 
the  samples  were  monitored  over  a  period  of  8  weeks.  Hair  samples  were  analysed  using 
the  validated  method.  The  results  showed  a  significant  decrease  of  amfetamine  in  hair 
with  the  time  submerged  in  sea  water.  Fresh  water  had  a  much  less  significant  effect  over 
the  study  period. 
The  validated  method  was  successfully  applied  to  16  case  samples  obtained  from  living 
volunteers  with  a  known  history  of  fenethylline  (AF  precursor)  abuse  and  6  post-mortern 
case  samples  where  amfetamines  had  been  detected  in  the  post-mortern  blood. 
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1  Introduction 
1.1  Overview  of  drug  use 
The  problem  of  drug  use  and  abuse  has  existed  for  a  very  long  time.  Over  the  last  200 
years,  most  of  the  countries  in  the  world  have  suffered  from  this  problem.  Differences 
vary  from  country  to  country  but  the  epidemic  has  risen  with  time.  There  is  no  doubt  that 
there  are  serious  negative  effects  of  drug  abuse  on  the  health  and  security  of  the  social 
structure  of  all  nations.  It  estimated  that  30,000  premature  deaths  per  year  in  the  United 
States  are  attributed  to  illegal  drugs  and  the  numbers  are  growing  continually  [2].  The 
official  statistics  of  the  British  Crime  Survey  (BCS)  in  2004/5  indicated  that  34.5% 
(approximately  11  million  people)  of  16  to  59  year  olds  in  England  and  Wales  had  used  at 
least  one  illicit  drug  in  their  lifetime.  It  was  reported  that  the  extent  of  cannabis  use 
decreased  between  2003/04  and  2004/05,  and  amfetamines  use  decreased  between  1998 
and  2004/05  in  England  and  Wales  among  this  age  group  (16  to  59  year  old)  [3]. 
1.1.1  Drug  of  Abuse 
There  are  various  definitions  of  a  "drug  of  abuse"  Most  of  them  focus  mainly  on  the  use  of 
a  substance  for  some  purpose  other  than  that  intended.  For  example  a  drug  which  is  used 
therapeutically  but  can  cause  harmful  effects  when  taken  irresponsibly.  Illicit  drugs  are 
restricted  by  the  law,  with  possession  or  supply  carrying  legal  penalties.  As  such  they  are 
prohibited  by  govemments  [4]. 
1.1.2  The  Misuse  of  Drugs  Act  1971 
The  Misuse  of  Drugs  Act  1971  is  an  Act  in  the  United  Kingdom  and  its  aim  is  to  control 
the  possession  and  supply  of  numerous  listed  drugs  and  drug-like  substances  whether  they 
be  illegal  drugs  or  prescription  medications  and  to  enable  international  co-operation 
against  illegal  drug  trafficking.  There  are  different  penalties  for  possession  and  supply  of 
controlled  drugs  under  the  Misuse  of  Drugs  Act  depending  on  the  nature  of  the  offence. 
These  are  summarised  in  Table  I.  I.  This  Act  allows  regulation  in  the  use  of  some 
controlled  drugs  by  various  professional  people  in  different  fields  such  as  doctors  [5]. 
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Table  1.1  Penalties  under  the  Misuse  of  Drugs  Act  [6] 
Class  Drugs 
A  Ecstasy,  LSD,  Heroin,  Cocaine,  Crack, 
Magic  Mushrooms,  Amfetarnines  (if 
prepared  for  injection) 
BI  Amfetamines,  Methylphenidate  (Ritalin), 
Pholcodine 
C  Cannabis,  Tranquillisers,  some  Painkillers, 
Gamma  hydroxybutyrate  (GHB),  Ketamine 
1.1.3  Control  Drugs  Classification 
Penalties 
Possession:  Maxiinum  of  7  years 
in  prison  and/or  unlimited  fine 
Supply:  Up  to  life  in  prison 
and/or  unlimited  fine 
Possession:  Maximum  of  5  years 
in  prison  and/or  unlimited  fine 
Supply:  Maximum  of  14  years  in 
prison  and/or  unlimited  fine 
Possession:  Maximum  of  2  years 
I  in  prison  and/or  unlimited  fine 
Supply:  Maximum  of  14  years 
and/or  unlimited  fine 
In  the  United  Kingdom,  illegal  drugs  are  classified  into  three  classes  A,  B  and  C  depending 
on  their  potential  for  abuse  toxicity.  These  regulations  are  continually  amended  whether 
adding  new  drugs,  upgrading  or  downgrading  these  drugs  in  each  class  [5].  Class  A  has 
the  most  harmful  drugs  and  highest  penalties  and  Class  C  drugs  are  the  least  harmful  and 
have  the  lowest  penalties.  The  regulations  of  controlled  drugs  for  possession,  supply, 
production  and  importation  or exportation  were  made  under  this  Act  to  meet  the  medical  or 
scientific  needs.  These  are  categorised  as  follows: 
Schedule  1:  Drugs  which  are  the  most  stringently  controlled,  not  for  medical  use  and 
usually  for  research  purposes  for  example  cannabis,  coca  leaf,  ecstasy,  LSD  and  raw 
opium. 
Schedules  2  and  3:  Drugs  which  are  illegal  to  possess  without  prescription.  Schedule  2 
drugs  include  arnfetamines,  cocaine,  dihydrocodeine,  diconal,  heroin,  methadone, 
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morphine,  opium  in  medicinal  form,  pethidine  and  ritalin.  Schedule  3  includes 
barbiturates,  rohypnol  and  temazeparn  tranquillisers. 
Schedule  4:  Part  1.  Drugs  which  are  illegal  to  possess  without  a  prescription,  for  example, 
most  minor  tranquillisers.  Part  2.  Drugs  which  are  legal  to  possess  in  their  medicinal  form 
without  a  prescription,  but  it  is  illegal  to  supply  them  to  other  people,  for  example, 
anabolic  steroids. 
Schedule  5:  Drugs  which  are  allowed  to  be  sold  over-the-counter  at  a  phannacy  without  a 
prescription,  and  may  be  bought  by  anyone  with  impunity,  for  example,  cough  medicines, 
anti-diarrhoea  agents  and  mild  painkillers  [7]. 
1.2  Forensic  Toxicology 
1.2.1  Introduction 
Toxicology  is  the  comprehensive  study  of  poisons  and  drugs,  concerned  with  their  effects 
on  living  organisms  and  dealing  with  the  diagnosis  of  poisoned  people. 
Forensic  toxicology  is  the  study  of  the  effects  of  drugs  and  poisons  on  human  beings  in  the 
context  of  the  law.  The  use  of  toxicological  investigations  for  the  purpose  of  medico-legal 
enquiries  for  living  and  deceased  people  depends  on  the  country  [8,9]. 
A  toxicologist  deals  with  different  biological  samples  such  as  urine,  blood,  hair,  sweat, 
saliva,  other  body  fluids  and  organs  such  as  liver,  kidney  and  brain,  to  investigate  the 
presence  of  a  toxic  substancc[9].  Urine  is  the  most  common  specimen  used  for  drug 
testing  [10]. 
The  main  objective  of  toxicological  analysis  is  to  prove  or  exclude  the  presence  of 
undetermined  toxic  substances  in  biological  matrices  and  accurately  identify  them.  The 
analyst  must  be  capable  of  identifying  and  quantifying  these  substances  within  a  specified 
time  period  [I  I]. 
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1.2.2  Systematic  Toxicological  Analysis  (STA) 
Systematic  Toxicological  Analysis  (STA),  is  a  process  which  involves  the  identification 
and  quantitation  of  unknown  substances  [11].  To  analyse  drugs  in  conventional  biological 
matrices,  Systematic  Toxicological  Analysis  involves  three  stages,  pre-treatment  and 
extraction,  detection  and  identification. 
1.2.2.1  Pre-treatment  and  Extraction 
The  biological  samples  undergo  pre-treatment  in  STA  and  this  pre-treatment  depends  on 
the  type  of  the  sample,  for  instance  whether  they  are  biological  fluids  or  tissue  samples. 
Buffer  solutions  are  widely  used  for  dilution  of  plasma  and  serum  [12].  Hydrolysis  and 
protein  removal  are  used  in  the  preparation  of  biological  samples.  Pre-treatment  is  often 
carried  out  by  enzyme  preparations  like  fl-glucuronidase  or  strong  acid  and  basic  agents 
which  are  necessary  to  split  conjugated  metabolites.  Enzyme  pre-treatment  is  preferable 
because  strong  acid  and  base  can  cause  substances  to  decompose.  Protein  removal  can 
also  cause  low  recoveries  due  to  drug  molecules  being  bound  to  the  precipitated  protein. 
An  extraction  method  is  required  to  concentrate  drugs  of  interest  and  to  remove  any  matrix 
compounds.  This  is  done  using  a  variety  of  techniques  such  as  Liquid-Liquid  Extraction 
(LLE)  and  Solid-Phase  Extraction  (SPE).  In  order  to  achieve  optimum  results  extraction 
procedures  should  have  high  recoveries,  be  capable  of  separately  extracting  a  wide  variety 
of  target  analytes  (acidic,  neutral  and  basic),  have  clean  extracts  and  be  reproducible  and 
rapid.  SPE  can  be  used  for  the  extraction  of  single  drugs  or  groups  of  related  drugs,  and 
has  become  the  most  popular  extraction  technique  [I  I]. 
1.2.2.2  Derivatisation  Methods 
Analysis  of  drugs  by  GC  or  GC-MS  may  require  derivatisation  to  make  substances 
appropriate  for  analysis.  It  is  essential  for  the  analysis  of  polar  and  thermally  labile 
compounds  to  make  them  volatile  and  thermally  stable.  The  main  purpose  of  the 
derivatisation  step  is  to  improve  chromatographic  properties  such  as  better  peak  shapes  and 
increased  resolution  from  related  compounds.  This  is  achieved  by  increasing  the  volatility 
and  stability,  while  decreasing  the  polarity  of  the  compounds.  Another  benefit  is  often  the 
formation  of  ions  at  higher  mass/charge  ratios,  giving  more  diagnostic  mass  spectra. 
Greater  sensitivity  can  be  obtained  by  introducing  groups  of  high  electron  affinity  (such  as 
halogen  atoms),  these  increase  the  ionisation  efficiency.  The  optimum  derivatisation 
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reaction  should  be  simple,  rapid  and  complete,  and  produce  a  stable,  single  derivative  with 
good  reproducibility.  The  derivatisation  of  different  functional  groups  on  analytes  can 
include  hydroxyl  groups,  ketones,  carboxylic  acids  and  amines.  The  three  most  common 
derivatisation  methods  are  silylation,  acylation  and  alkylation. 
1.2.2.2.1  Silylation 
Silylation  occurs  when  an  active  proton  in  -OH,  -SH  or  -NH  groups  is  displaced  with  an 
alkylsilyl  group  from  the  silylation  reagent.  Some  protic  functional  groups  on  the 
compound  are  converted  to  either  silyl  ethers  or  esters.  The  ability  of  various  functional 
groups  to  form  silyl  derivatives  was  found  to  be  as  follows,  alcohols  >  phenols  > 
carboxylic  acids  >  amines  >  amides.  Trimethylsilylation  is  the  most  commonly  used 
procedure  for  silylation.  There  are  a  variety  of  trimethylsilylating  reagents  available  such 
as  trimethylhalosilanes,  TMS-amines,  TMS-esters  and  TMS-amides,  which  are  varied  in 
their  properties,  for  instance:  volatility,  reactivity  and  selectivity.  MSTFA  is  the  most 
volatile  TMS-amide  used  to  form  TMS  derivatives  of  alcohols  and  phenols. 
Trimethylsilylimidazole  (TMSIm)  is  another  silylation  reagent  used  for  hydroxyl  and 
carboxyl  groups  and  tert-Butyldimethylsiyl  (TBDMS)  derivatives  are  used  to  increase 
hydrolytic  stability  and  to  give  useful  mass  spectrometric  fragmentation.  All  silylation 
reagents  and  derivatives  are  sensitive  to  moisture  [13].  This  is  the  general  silylation 
reaction  in  the  formation  of  trialkylsilyl  derivatives  [14]: 
R3Si-X  +R'-H  -  R3Si-  R'+  HX 
1.2.2.2.2  Acylation 
Acylation  occurs  by  introducing  an  acyl  group  on  to  a  molecule  containing  a  reactive 
hydrogen.  There  are  many  functional  groups  that  may  be  acylated  to  produce  derivatives 
such  as  alcohols,  amines,  amides,  thiols,  phenols,  enols,  sulfonamides.  The  acylation 
reactions  can  be  carried  out  by  acyl  halides,  acid  anhydrides  or  reactive  acyl  derivatives. 
acyl  halides  are  highly  reactive.  Perfluoroacyl  derivatives  such  as  trifluoroacetyl  (TFA), 
pentafluoroproionyl  (PFP)  and  heptafluorobutyryl  (HFB)  are  the  most  commonly  used. 
These  perfluoroacyl  derivatives  lead  to  an  increase  in  the  abundance  of  high  m/z  ions  [13]. 
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The  general  acylation  reaction  is  as  follows  [141: 
00 
11  11 
R-C-X  +  RT-H  3m  R-C-RY'  +  HX 
1.2.2.2.3  Alkylation 
Alkylation  is  another  commonly  used  derivatisation  method,  which  replaces  an  active 
hydrogen  as  in  carboxylic  acids,  alcohols,  thiols  and  amines  with  an  alkyl  or  an  aryl  group. 
Alkyl  halides,  iodides  (methyl,  ethyl,  propyl,  isopropyl)  or  benzyl  and  most  substituted 
benzyl  bromides  are  the  most  common  reagents  used  to  obtain  alkyl  derivatives  [13].  One 
type  of  alkylation  reaction  is  as  follows  [  141: 
R-COOH  +  R'X  -  R-COOR'+  HX 
1.2.2.3  Detection 
After  biological  sample  preparation,  the  analysis  of  drugs  in  biological  matrices  usually 
involves  several  analytical  techniques  for  qualitative  or  quantitative  analysis  of  drugs. 
There  are  several  types  of  commercial  techniques  available.  For  screening  purposes 
immunoassays  (IA)  and  occasionally  thin-layer  chromatography  (TLC)  can  be  used.  For 
confirmation  purposes  gas  chromatography  (GQ,  with  a  detector  such  as  flame  ionisation 
detection  (FID),  nitrogen-phosphorous  detection  (NPD),  electron  capture  detection  (ECD) 
and  mass  spectrometry  (MS)  can  be  used.  Also  high-performance  liquid  chromatography 
(HPLQ,  with  detectors  such  as  ultraviolet  spectrometry  (UV),  diode  array  detection 
(DAD),  electrochemical  detection  (ECD)  and  mass  spectrometry  (MS)  can  be  used  for 
confirmation  [15]. 
GC-MS  is  the  technique  of  choice  in  forensic  toxicology  and  can  be  used  for  STA  [111. 
The  major  advantages  are  good  sensitivity  and  specificity. 
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1.2.2.4  Identification 
Commonly  encountered  drugs  have  well  defined  mass  spectra  which  are  reproducible 
between  instruments.  Identification  of  unknown  substances  is  not  easy  due  to  the  large 
number  of  possibilities.  Comprehensive  libraries  do  exist  but  need  to  be  updated  regularly 
to  cover  as  many  drugs  as  possible. 
1.2.3  Solid  Phase  Extraction 
1.2.3.1  Introduction 
SPE  is  a  physical  extraction  process  for  rapid  sample  preparation  in  which  a  solid 
(stationary  phase)  is  used  to  selectively  extract,  concentrate,  and  purify  the  analyte  of 
interest  in  the  biological  matrix  prior  to  chromatographic  analysis. 
SPE  was  introduced  commercially  in  1970  as  a  technique  for  urine  sample  preparation  and 
in  1979  the  small  size  columns  of  modem  SPE  was  first  used.  Its  applications  included 
pharmaceutical,  industrial,  environmental,  clinical,  and  forensic  fields  for  the  extraction  of 
substances.  In  the  last  few  years,  there  has  been  a  trend  toward  replacing  the  classical  LLE 
by  SPE  due  to  its  potential  advantages,  there  are  visible  practical  advantages  of  SPE 
compared  to  LLE  which  could  be  useful  in  drug  extraction,  including  the  following: 
o  high  specificity 
*  high  analyte  recoveries 
e  cleaner  extracts  and  enhanced  removal  of  interferences  and  particulates,  lead  to  less 
equipment  contamination 
9  elimination  of  emulsions 
better  reproducibility  of  results 
reduced  solvent  consumption,  as  well  as  reduction  in  hazardous  and  environmental 
wastes 
ease  of  use  and  the  SPE  extraction  can  be  automated 
enhanced  analytical  sensitivity  and  reduced  LOD  and  LOQ 
*  lower  sample  quantities  and  shorter  sample  extraction  times  [12,16,17] 
As  a  result  of  the  difficulty  in  extracting  a  wide  range  of  drugs  by  a  single  mode  column, 
the  mixed  mode  bonded  silica  SPE  columns  such  as  Bond  Elut  CertifyTm  and 
CleanScreenTm  can  be  used.  These  columns  contain  both  hydrophobic  and  cation 
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exchange  functional  groups  properties,  which  allow  the  extraction  of  a  broad  range  of 
drugs  including  acidic,  neutral  and  basic  drugs  by  selectively  eluting  with  various  clution 
solvents.  The  majority  of  reviews  have  focused  on  the  use  of  SPE  to  extract  individual 
drugs  or  classes  of  drugs  [12]. 
1.2.3.2  Principles  of  Solid  Phase  Extraction 
SPE  sorbent  (base  support)  plays  a  major  role  in  SPE  extraction  efficiency  and  separation 
quality,  there  are  various  sorbent  materials  in  use  like  silica  or  bonded  silica,  alumina  and 
polymers,  but  bonded  silica  is  the  most  popular  sorbent  used  [12,16]. 
The  functional  group  bonded  to  the  silica  determines  the  interaction  mechanism 
(extraction)  between  the  functional  groups  of  the  sorbent  with  the  analyte  of  interest.  The 
common  interaction  mechanisms  between  sorbent  and  analytes  are  as  follows: 
1.2.3.2.1  Non-polar  Interactions  (Reversedphase) 
Non-polar  interactions  are  carried  out  between  the  hydrocarbon  chains  of  hydrophobic  or 
polar  organic  analytes  and  the  sorbent.  These  interactions  are  caused  by  low  energy  Van 
der  Waals  (dispersion  forces).  Saturated  hydrocarbon  chains  such  as  C18  and  C8,  or 
aromatic  rings  such  as  phenyl  (PH)  are  usually  used  in  non  polar  sorbents.  These  sorbents 
have  the  ability  to  retain  a  wide  range  of  organic  compounds,  due  to  the  non  specificity  of 
the  interaction  [12,16]. 
1.2.3.2.2  Polar  Interactions  (Normalphase) 
Polar  interactions  are  used  to  extract  polar  analytes  from  non-polar  organic  solvents.  The 
analytes  are  retained  on  the  sorbent  due  to  hydrogen  bonding,  dipole-dipole  and  7r-7r 
interactions  between  polar  analytes  and  the  polar  sorbent.  A  high  degree  of  specificity  is 
obtained  by  optimizing  the  polarity  of  the  conditioning  solvent  and  the  elution  solvent  [12, 
16]. 
1.2.3.2.3  Ion  Exchange  Interactions 
Ion  exchange  interactions  take  place  between  charged  sorbents  and  the  analytes  from  low 
ionic  strength  aqueous  or  organic  samples  with  the  opposite  charges,  for  example  a 
negatively  charged  sorbent  (cation  exchangers)  will  retain  positive  charged  analytes  and  in 
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contrast  a  positively  charged  sorbent  (anion  exchangers)  will  retain  negatively  charged 
analytes.  This  mechanism  has  a  high  degree  of  specificity,  therefore,  the  contamination  in 
the  matrix  is  easy  to  wash  out  [  12,16]. 
1.2.3.3  Solid  Phase  Extraction  steps 
1.2.3.3.1  Column  Preconditioning 
To  prepare  the  column  sorbent  to  receive  and  interact  with  analytes,  the  column  sorbent 
needs  suitable  conditioning  prior  to  the  sample  application  in  order  to  improve 
reproducibility  and  recovery.  This  is  done  using  polar  solvents  to  activate  and  open  up  the 
coiled  hydrophobic  portion  of  the  sorbent.  The  sorbent  conditioning  can  vary  depending 
on  the  type  of  analyte  [12,18]. 
1.2.3.3.2  Sample  Application 
Sample  application  follows  the  column  precondition.  A  low  flow  rate  is  required  to  allow 
the  drugs  of  interest  to  have  adequate  time to  interact  with  the  sorbent,  consequently  more 
drugs  are  retained  on  the  column  and  selectively  eluted,  thereby  increasing  recovery  [12]. 
1.2.3.3.3  Column  Wash 
In  order  to  remove  endogenous  components  rather  than  the  drugs  of  interest  which  have 
bound  to  the  sorbent  during  sample  application,  the  column  is  washed.  An  appropriate 
wash  solvent  has  to  be  chosen  very  carefully  in  order  to  avoid  loss  of  the  target  analyte 
during  the  wash  process.  At  this  step,  the  pH  of  the  column  is  adjusted  as  some  of  the 
drugs  are  dependant  on  the  pH  for  their  elution  [12]. 
1.2.3.3.4  Column  Drying 
Residual  water  should  be  removed  from  the  SPE  column  prior  to  the  elution  of  the  drugs  of 
interest  and  prior  to  analysis  by  washing  with  a  suitable  organic  solvent  or  drying  the 
sorbent  with  air  under  vacuum.  The  presence  of  water  prevents  the  optimal  elution  of  the 
drugs  as  a  result  of  the  immiscibility  of  the  elution  solvent  with  water,  on  the  other  hand, 
the  presence  of  water  may  react  with  the  stationary  phase  of  the  column,  consequently 
causing  damage  to  the  GC  column  [  12,17]. 
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1.2.3.3.5  Elution  ofRelevant  Drugs 
The  final  step  in  extraction  of  the  drugs  of  interest  should  be  elution  with  the  appropriate 
solvents.  These  have  to  be  strong  enough  to  elute  the  drugs  of  interest  completely  with  a 
small  eluent  volume  and  should  be  selective  to  avoid  elution  of  interfering  compounds 
[12]. 
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2  Hair  Analysis 
2.1  Introduction 
Hair  analysis  is  useful  for  detecting  and  monitoring  past  drug  use  over  a  period  of  weeks  to 
several  months  depending  on  the  length  of  the  hair  sample  and  on  the  stability  of  the  drug 
in  the  hair  specimen.  It  has  been  shown  to  be  useful  in  the  detection  of  chronic  drug  abuse 
in  forensic  and  clinical  applications  and  has  been  used  for  the  purpose  of  employment 
screening,  monitoring  compliance  for  drug  treatment  programs,  in  cases  involving  criminal 
responsibility,  detection  of  drug  use  in  utero  and  the  passive  exposure  of  the  fetus,  in  cases 
of  driving  license  suspension  and  in  the  investigation  of  abstinence  for  chronic  drug 
abusers.  Hair  analysis  can  be  used  as  a  complementary  technique  to  urine  and  blood 
analysis  which  show  relatively  recent  usage.  The  combined  information  from  these  types 
of  sample  and  hair  will  provide  information  regarding  acute  and  chronic  use  [  19]. 
The  exact  time  of  drug  ingestion  cannot  be  determined  from  hair  analysis  results.  The 
estimation  of  the  ingestion  time  is  only  possible  in  intervals  of  months  not  in  weeks,  days 
or  hours.  This  is  because  there  are  many  varying  factors  involved  in  the  incorporation  of 
drugs  into  hair  [20].  These  are  discussed  later  on  in  section  2.5.  The  time  of  drug 
consumption  can  be  approximated  in  months  by  knowing  the  rate  of  hair  growth  in  an 
individual  and  the  location  of  the  drug  along  the  hair  shaft  [21]. 
The  first  poisonous  substance  to  be  determined  in  hair  was  arsenic  in  1857  by  Casper.  It 
was  found  in  the  hair  of  a  body  exhumed  eleven  years  after  burial  [22].  In  1954,  the  first 
organic  drug  (AF)  was  detected  in  guinea-pig  hair  [23].  Due  to  the  capability  of  atomic 
absorption  spectroscopy  to  detect  low  concentrations  of  elements  (nanograms  per 
milligram),  hair  analysis  was  used  in  1960s  and  1970s  to  detect  toxic  heavy  metals,  such  as 
lead  or  mercury  in  hair  [24]. 
The  first  report  of  the  detection  of  opiates  (heroin/morphine)  in  hair  was  reported  in  1979 
using  a  radioimmunological  method.  This  publication  was  the  first  method  which  dealt 
with  drugs  of  abuse  in  human  hair  and  it  led  to  many  further  investigations  in  this  area 
[22].  The  first  paper  to  confirm  radioimmunological  results  with  a  chromatographic 
method  was  printed  in  1980  [25].  The  availability  of  more  sensitive  and  selective 
analytical  methods  allowed  for  the  detection  of  low  levels  of  drugs  which  were 
incorporated  into  the  hair  in  the  picogram  per  milligram  range. 
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The  role  of  hair  drug  testing  in  toxicological  applications  has  been  widely  discussed  by 
different  scientific  communities  such  as  the  Society  of  Forensic  Toxicologists  (SOFT)  and 
the  Society  of  Hair  Testing  (SOHT)  [26].  These  scientific  conferences  are  important  to 
address  controversial  issues  surrounding  hair  analysis.  SOHT  in  2004  set  out 
recommendations  for  testing  of  drugs  in  hair.  A  consensus  was  reached  to  include  points 
on  sampling,  shipping  and  storage,  decontamination,  hair  disintegration,  the  screening  test, 
criteria  for  mass  spectrometric  analysis,  specific  drug  classes  (opiates,  cocaine, 
amfetamines,  cannabinoids),  internal  quality  control,  external  quality  control  [27].  These 
provide  guidelines  for  laboratories  carrying  out  hair  analysis  for  drugs. 
The  potential  advantages  of  hair  analysis  over  other  conventional  or  unconventional 
biological  specimens  are: 
"  collection  of  hair  specimens  is  easy. 
"  sampling  is  less  intrusive.  It  is  less  embarrassing  than  urine  collection  which 
requires  close  supervision. 
"  adulteration  is  difficult. 
*a  second  sample  can  be  obtained  if  there  is  any  doubt  about  the  integrity  of  the 
sample. 
long  time  stability  of  hair  specimens  at  room  temperature.  This  means  they  can  be 
stored  and  transported  indefinitely  without  refrigeration  and  quick  analysis  is  not 
required. 
it  has  a  wider  window  of  detection  than  blood  or  urine.  The  window  of  detection 
will  depend  on  the  length  of  the  hair. 
*  periods  of  abstention  can  be  identified. 
parent  drugs  and  metabolites  are  incorporated  into  hair.  Urine  and  blood  samples 
often  only  have  the  metabolites  present  [28-3  1  ]. 
2.2  The  Anatomy  and  Physiology  of  Hair 
2.2.1  Introduction 
The  interpretation  of  drug  concentration  results  in  hair  is  complex.  To  avoid  the 
misinterpretation  of  results,  an  understanding  of  hair  biology  such  as  the  anatomy, 
physiology,  biochemistry  and  growth  cycle  is  necessary  to  provide  the  correct  scientific 
interpretation  of  the  drug  results  in  the  hair. 
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2.2.2  Structure  of  hair 
Hair  is  a  cylindrical  shaft  which  grows  from  a  small  sac  called  the  hair  follicle.  Hair  varies 
morphologically  from  individual  to  individual,  within  the  same  individual  as  well  as  within 
a  single  region  within  an  individual.  Hair  emerges  from  the  skin  either  in  single  strands  or 
in  groups  [32].  Hair  consists  of  three  layers  of  cells  as  shown  in  Figure  2.1. 
The  cuticle  is  the  outermost  layer  of  the  hair  shaft,  which  plays  a  role  in  anchoring  the  hair 
shaft  in  the  hair  follicle  and  acts  to  protect  the  interior  layers  of  the  hair  shaft.  The  cuticle 
consists  of  a  single  layer  of  elongated,  overlapping  cells  and  is  free  of  pigment.  The 
thickness  and  length  of  each  cuticle  cell  is  around  0.5  to  1.0  ýLrn  and  45  gm,  respectively. 
Exposure  of  the  hair  to  harmful  substances  and  environments  such  as  chemical,  heat,  light 
or  mechanical  treatment  can  damage  or  destroy  the  cuticle.  The  cuticle  acts  as  a  strong 
barrier  against  the  loss  of  drug  integrity.  When  the  cuticle  is  damaged  drugs  may  be 
removed  more  easily  from  the  hair  [  19,3  3,3  4]. 
The  cortex  is  the  middle  layer  and  the  bulk  of  the  hair  shaft.  It  contains  lengths  of 
keratinised  cells  and  also  melanin  granules  which  are  the  principle  pigment  in  hair,  eyes 
and  skin.  Hair  colour  depends  on  the  quantity,  distribution  and  type  of  pigment  in  hair.  In 
the  cortex  there  are  small  air  spaces  between  the  cortex  cells  called  fusi  which  are  filled 
with  fluid  and  replaced  by  air  as  the  hair  grows  and  dries  out  [33]. 
The  medulla  is  the  innermost  layer  of  the  hair  shaft.  This  layer  exists  in  human  hair  and 
can  be  continuous,  discontinuous  or  absent.  The  medulla  layer  contains  many  keratinized 
cells.  Intra  and  intercellular  air  spaces  are  also  found  in  this  layer  as  well  [32,33]. 
Melanin  granules  may  also  be  present  in  the  medulla. 
There  are  two  types  of  melanin  in  human  hair,  ears  and  in  certain  brain  structures  in  man. 
They  play  an  essential  role  in  the  protection  of  internal  tissues  against  UV  radiation  [35]. 
Their  structures  can  be  very  simple  or  very  complex  [36]  and  some  of  these  are  still  not 
fully  understood  [37].  In  hair  they  are  attached  to  the  protein  matrix  [38]. 
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Figure  2.1  Cross-section  of  a  hair  shaft  [39] 
2.2.3  Hair  Composition 
Human  hair  contains  proteins  called  keratin  that  are  bound  together  tightly  to  form  long 
fibres,  producing  a  stable  structure.  The  proteins  are  rich  in  sulphur.  Proteins,  water, 
lipids  and  minerals  represent  approximately  65  to  95%,  15  to  35%,  1  to  9%  and  0.25  to 
0.95%  of  hair  content  respectively.  These  percentages  depend  on  the  moisture  in  the  hair. 
Trace  elements  and  heavy  metals  are  also  present. 
2.2.4  The  Hair  Follicle 
The  hair  follicle  is  a  small  sac  that  surrounds  the  hair  root.  It  is  found  3  to  4  mm  below  the 
skin's  surface  and  is  embedded  in  the  epidermal  epithelium  of  the  skin. 
Sebaceous  and  apocrine  glands  surround  the  hair  follicle.  Their  ducts  secrete  into  the 
follicle.  In  addition  to  these  glands,  the  eccrine  sweat  gland  also  surrounds  the  hair  follicle 
in  axillary  and  pubic  areas.  Its  duct  does  not  secrete  into  the  follicle  but  near  to  the  exit  of 
the  hair  follicles,  onto  the  surface  of  the  skin.  The  secretion  of  these  glands  may  be  a 
source  of  trace  elements  and  drugs  in  hair.  The  sebaceous  gland  and  eccrine  sweat  gland 
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are  located  and  distributed  near  the  surface  of  the  body.  The  apocrine  gland  is  located  in 
the  axilla,  the  external  auditory  meatus,  the  eyelids  and  perineal  region. 
There  are  three  regions  in  the  hair  follicle.  The  first  region  is  the  innermost  region  (lower 
segment)  in  and  around  the  bulb.  In  this  region  the  biological  synthesis  of  hair  cells  is 
carried  out.  The  second  region  (middle  segment)  is  the  keratogenous  region.  This  region 
extends  from  above  the  bulb.  Keratinization,  hair  hardening  and  solidification  take  place 
in  this  region  and  the  final  region  (upper  segment)  is  the  permanent  hair  region.  In  this 
region  dehydrated  cornified  cells  make  up  the  hair  shaft.  Figure  2.2  shows  a  cross  section 
of  the  skin  surrounding  a  hair  follicle  [33]. 
Hair  shaft 
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Figure  2.2  A  cross  section  of  the  skin  surrounding  a  hair  follicle  [40] 
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2.2.5  The  Hair  Growth  Cycle 
Hair  grows  in  a  cycle  which  consists  of  three  phases: 
The  first  phase  is  the  anagen  phase.  It  is  known  as  the  growth  phase  due  to  the  metabolic 
activity  of  the  matrix  cells  increasing  and  hair  being  produced  in  the  follicle.  Hair  cells  are 
produced  and  the  keratinzation  process  begins.  This  phase  lasts  around  2  to  3  years  and  its 
growth  rate  is  dependent  on  the  anatomical  region.  The  nutrients  and  extraneous  materials 
such  as  trace  metals  and  drugs  supplied  by  capillary  blood  are  incorporated  into  the  hair 
shaft  at  this  phase. 
The  second  phase  is  the  catagen  phase.  It  is  a  transition  period  of  about  4  to  6  weeks, 
between  active  growth  and  a  resting  phase.  This  phase  produces  a  fully  keratinized  root 
which  is  club  end  formed  and  separate  from  the  bulb  of  the  hair  follicle,  the  club  hair 
becomes  a  white  node,  then  cell  division  stops  and  the  follicle  becomes  shorter. 
The  third  phase  is  the  telogen  phase.  This  phase  is  characterized  as  the  club  and  is 
completely  separated  from  the  bulb  becoming  close  to  the  scalp  surface.  No  hair  grows 
and  it  is  easily  removed  by  pulling.  It  lasts  a  period  of  between  2  to  3  months  depending 
on  the  hair  type  and  age.  The  anagen  phase  and  telogen  phase  represent  approximately 
85%  and  10  to  15%  of  hair  growth  on  the  scalp  of  adult  respectively,  in  the  catagen  phase 
some  hair  is  passed.  A  new  hair  shaft  begins  to  grow,  while  the  old  hair  is  forced  out  [19, 
33,41].  Figure  2.3  shows  the  hair  growth  cycle  phases. 
Anagen  phase  Catagen  phase  Telogen  phase  New  anagen  phase 
Figure  2.3  Hair  growth  cycle  phases  [34] 
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2.2.6  Rate  of  hair  growth 
Hair  growth  rate  varies  between  individuals  and  also  within  an  individual.  Thus,  the 
precise  determination  of  hair  growth  rate  is  difficult.  The  average  growth  rate  of  human 
head  hair  is  I  cm.  /month.  In  general,  hair  growth  rate  depends  on  a  number  of  factors  such 
as  hair  type  and  anatomical  location.  For  example,  scalp  hair  grows  much  faster  than  hair 
in  the  pubic  or  axillary  regions  which  in  turn  grows  faster  than  beard  hair.  Many  others 
factors  affect  the  hair  growth  rate.  These  include  race,  sex  and  age.  Scalp  hair  in  women 
tends  to  grow  faster  than  in  men  and  there  is  a  decrease  of  hair  growth  rate  as  adults  age. 
Therefore,  these  factors  have  to  be  taken  into  account  when  interpreting  hair  drug  results 
[33].  The  time  taken  for  the  drug  to  appear  in  the  hair  shaft  at  the  skin's  surface  for  a 
medium  growth  rate  of  1  cm/month  was  estimated  to  be  between  9  and  14  days.  It  was 
reported  in  another  study  that  codeine  was  detected  between  15  and  21  days  after  a  120  mg 
dose  for  a  segment  >1  cm  from  the  skin  surface  [34]. 
2.2.7  Types  of  Hair 
There  are  three  basic  hair  types  on  the  human  body.  These  are  vellus,  terminal  and 
intermediate  and  each  has  their  own  individual  properties.  These  differ  in  length,  texture, 
colour,  diameter  and  shape.  Vellus  hair  is  fine,  short,  non-pigmented  and  has  a  small 
cross-sectional  area.  This  type  of  hair  is  found  on  the  eyelids,  the  forehead  and  on  the  bald 
scalp.  Terminal  hair  is  coarse,  long,  pigmented  hair  with  a  large  cross-sectional  area  found 
in  scalp,  beard,  eyebrow,  eyelash,  armpit  and  pubic  areas.  Intermediate  hair  is  of 
intermediate  length  and  shaft  size  and  is  found  on  the  arms  and  legs  of  adults. 
There  are  three  kinds  of  follicles  which  produce  different  hair  types  on  the  human  body. 
Intermediate  hair  is  produced  from  nonsexual  hair  follicles  which  are  not  influenced  by 
hormones  and  do  not  change  after  puberty.  While  ambosexual  hair  follicles  are  influenced 
by  hormones  and  therefore  will  change  during  puberty.  These  affect  hair  in  the  axilla, 
pubic  regions  and  on  the  temple  area  of  the  scalp.  Male  hair  follicles  exist  in  males  and 
affect  hair  in  beard  area,  cars,  nose,  chest,  abdomen  and  top  of  the  head  [33]. 
2.3  Hair  sample  collection 
The  posterior  vertex  region,  at  the  back  of  the  head,  is  the  preferred  site  of  collection  of  a 
hair  sample  rather  than  other  samples  such  as  beard,  axillary,  pubic  hair  and  other  areas  of 
the  head.  This  is  because  this  region  is  characterized  with  a  high  percentage  of  follicles  in 
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the  anagen  phase,  which  are  a  uniform  distance  from  the  scalp.  This  is  especially 
important  if  sectional  analysis  is  required.  The  highest  and  the  fastest  growth  rate  is  also 
found  at  the  vertex  region  in  the  scalp,  up  to  3.4  cm/month.  Beard  hair  has  the  slowest 
growth  rate  (approximately  0.8  cm/month)  and  pubic  hair  is  also  slower  than  scalp  hair 
(0.9  cm/month).  In  this  area  the  effect  of  age  and  sex  on  the  incorporation  of  drugs  have 
less  influence.  Pubic  hair  and  axilliary  hair  is  used  as  an  alternative  to  scalp  hair  when  it  is 
not  available.  However  the  problem  of  possible  exposure  to  contamination  by  urine  and 
sweat  should  be  recognised  [  19,33,34,41  ]. 
The  different  concentrations  of  drugs  in  the  pubic,  axillary  and  scalp  regions  has  been 
reported  in  various  studies  and  these  differences  are  attributed  to  a  number  factors  such  as 
presence  of  apocrine  glands,  blood  supply,  different  telogen/anagen  ratios  and  hair  growth 
rate  [24]. 
2.4  Drug  incorporation  into  hair 
In  order  to  interpret  hair  analysis  results  accurately,  the  incorporation  of  drugs  into  hair  has 
to  be  considered.  At  present,  the  exact  understanding  of  the  incorporation  of  drugs  into 
hair  is  unknown.  The  transfer  of  drugs  from  the  body  to  hair  is  suggested  and  carried  out 
by  various  proposed  mechanisms  at  different  times  of  hair  growth  cycle. 
The  first  mechanism  is  simple  passive  diffusion,  in  which  drugs  transfer  from  the  blood 
into  the  growing  hair  cells  and  bind  tightly  with  the  interior  of  hair  shaft  during 
keratogenesis  (during  fonnation). 
The  second  mechanism  suggested  is  transfer  from  sweat,  sebaceous  and  apocrine  gland 
secretions  (after  formation). 
The  third  proposed  method  is  from  the  external  environment  such  as  smoke,  powder  and 
absorption  by  skin  after  formation  and  when  the  hair  has  emerged  from  the  skin. 
Incorporation  of  drugs  into  hair  from  tissues  surrounding  the  hair  follicle  and  deep 
compartments  in  skin  which  can  accumulate  lipophilic  drugs  in  the  epidermis  and  the 
hypodermis  layers  cannot  be  excluded.  Figure  2.4  shows  the  different  proposed 
mechanisms  of  drug  incorporation  during  different  phases  [42,43]. 
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It  was  reported  that  codeine  was  detected  in  the  hair  root  30  minutes  after  administration 
and  detected  in  distal  scalp  hair  for  up  to  10  weeks  after  a  single  dose  of  the  drug.  The 
study  was  only  carried  out  for  a  period  of  10  weeks  [2  1  ]. 
It  has  been  reported  that  methamfetamine  (MA),  methylendioxymethainfetamine  (MDMA) 
and  phencyclidine  were  found  in  rat  hair  root  within  5  minutes  of  administration.  Thus, 
the  hair  root  can  be  used  as  an  indicator  of  recent  drug  use.  It  has  been  reported  that  the 
concentration  of  drug  in  hair  is  dependent  on  the  amount  of  drug  incorporated  into  hair  and 
retained  in  hair,  where  some  of  the  incorporated  drug  is  redistributed  outside  the  hair  shaft 
(44]. 
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Figure  2.4  Diagram  showing  the  possible  mechanisms  for  drugs  incorporation  into  the  hair 
[42] 
2.5  Factors  affecting  drug  incorporation  into  hair 
Lipophilicity,  melanin  affinity  and  pKa  are  important  factors  that  may  influence  the 
incorporation  of  drugs  into  hair.  For  example,  basic  drugs  are  readily  incorporated  into 
hair,  while  acidic  drugs  exhibit  a  weak  incorporation  into  hair  [45].  Another  factor  which 
has  been  suggested  to  influence  the  incorporation  of  drugs  into  hair  is  colour.  For 
example,  the  drug  concentrations  tend  to  be  higher  in  hair  that  contains  pigment  than  hair 
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that  does  not.  It  has  been  reported  that  cocaine  was  incorporated  in  the  hair  of  African 
American  females  with  black  hair  at  concentrations  higher  than  in  the  hair  of  Caucasian 
males  or  females  with  coloured  hair.  This  has  been  reported  as  racial  bias.  Other  possible 
factors  are  gender  differences,  the  structure  of  the  hair  such  as  fine  hair  versus  coarse  hair 
[21,46,47]  and  cosmetic  treatment  (colouring 
, 
bleaching,  penning)  [48]. 
In  addition,  pKa  plays  a  major  effect  in  drug  transport  and  incorporation  of  drugs  into  hair. 
For  example  the  difference  in  pH  between  plasma  (7.4)  and  the  matrices  cells  like 
melanocytes  (3-5)  leads  to  the  accumulation  of  basic  drugs  in  the  matrices  cells,  due  to  a 
negative  concentration  gradient  of  penetrable  non  protonated  basic  drugs  from  plasma  to 
the  cytosol  of  the  matrices  cells.  In  contrast,  acidic  drugs  like  A?  -  tetrahydrocannbinol 
carboxylic  acid  will  be  transported  in  the  opposite  direction.  This  may  be  part  of  the 
reason  why  its  concentration  is  low  in  hair  matrices.  The  binding  of  drug  with  melanin  is 
affected  by  pH  as  well  [34]. 
2.6  Hair  Decontamination 
The  contamination  of  hair  from  external  sources  is  a  problem  in  hair  analysis  for  the 
detection  of  drugs  [43,49-52].  Decontamination  procedures  are  used  to  remove  non-drug 
contaminants  such  as  dirt  and  oils  from  hair  but  are  also  necessary  to  eliminate  external 
contamination  prior  to  hair  analysis  to  avoid  false  hair  positive  results  from  passive 
contamination  for  example  from  being  in  the  environment  of  drug  smoke  or  from  handling 
drugs  and  then  hair. 
There  is  no  set  standard  procedure  to  remove  contamination  from  hair.  Currently,  different 
solutions  such  as  water,  Tween,  SDS,  other  detergents,  phosphate  buffer,  methanol, 
ethanol,  acetone,  dichloromethane,  isopropanol  are  used  in  various  combinations  to 
decontaminate  the  hair.  However,  it  is  difficult  to  fully  validate  decontamination 
procedures.  This  is  because  it  is  not  clear  if  all  of  the  contaminant  is  being  completely 
removed  or  if  drug  which  has  been  incorporated  through  use  is  also  being  removed.  It  has 
been  reported  that  the  decontamination  of  hair  depends  on  the  hair  type,  where  certain 
types  are  more  resistant  than  others  in  removing  environmental  contamination.  For 
example  thick  black  hair  was  demonstrated  to  be  more  resistant  to  decontamination  than 
other  hair  types.  The  basic  concept  of  decontamination  procedures  is  to  remove  potential 
drugs  which  are  loosely  bound  to  the  surface.  However,  it  has  been  shown  that  drugs  from 
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passive  contamination  is  not  only  on  the  surface  of  the  hair  but  also  present  in  the  interior 
of  the  hair  [50]. 
One  study  showed  that  decontamination  procedures  could  not  remove  all  external 
contamination  of  opiates  (heroin,  6-MAM,  morphine,  acetylcodeine  and  codeine)  by  using 
5  ml  of  dichloromethane  for  5  min  at  room  temperature  three  times.  5  mg of  a  powdered 
mixture  of  heroin  hydrochloride  and  acetylcodeine  (10:  1  w/w)  was  applied  to  subjects' 
hands  for  5  minutes  and  this  was  wiped  onto  the  hair.  This  method  of  contamination  may 
not  be  realistic.  The  authors  attempted  to  use  cut-off  values  and  metabolite-to-drug  ratios 
to  evaluate  sample  contamination  but  concluded  these  methods  were  not  practical.  They 
suggest  that  the  reporting  of  a  positive  hair  result  alone  is  not  acceptable  without  other 
evidence  for  example  further  toxicology  tests  such  as  urinalysis  or  clinical  data  [43]. 
In  contrast,  another  paper  [53]  reported  an  extensive  decontamination  procedure  to  remove 
external  contamination  from  hair.  Various  experimental  models  such  as  soaking  and 
coating  with  cocaine,  morphine  and  6-MAM,  PCP  and  methamfetamine  drugs  were  used. 
Attempts  to  identify  the  contamination  of  the  hair  sample  were  carried  out  by  subtracting 
the  multiplied  value  of  the  last  washed  fraction  from  the  amount  of  drug  found  in  the  hair 
sample  following  digestion.  When  the  results  were  less  than  the  cutoff  for  the  parent  drugs 
the  contamination  was  reported  to  be  from  external  contamination  and  the  result  reported 
as  negative.  If  the  result  was  higher  than  the  cutoff  for  the  parent  drugs  this  was  reported 
to  indicate  active  drug  use  and  the  result  reported  as  positive. 
The  effect  was  evaluated  for  four  different  wash  procedures  on  the  quantitative 
measurement  of  cocaine  and  its  metabolites  from  rat  hair.  The  cocaine  was  administered 
by  intraperitoneal  injection.  All  four  methods  showed  different  drug  concentrations  in  hair 
compared  with  unwashed  hair.  This  showed  that  all  four  washes  have  the  potential  to 
remove  systemic  drug  exposure  from  hair.  This  study  proved  that  wash  procedures  are 
capable  of  removing  environmental  contamination  and  incorporated  drug  whether  from 
active  or  passive  use  [54]. 
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3  Arnfetarnines  and  Cannabinoids 
3.1  Amfetamines 
3.1.1  Introduction 
0-phenethylamine  derivatives  such  as  amfetamine  (AF),  methamfetamine 
(MA)  and  'designer  drugs'  such  as  methylenedioxy  derivatives  of 
amfetamine  including  3,4-Methylenedioxyarnfetamine  (MDA),  3,4- 
Methylenedioxymethamfetamine  (MDMA),  3,4-Methylenedioxyethyl- 
amfetamine  (MDEA),  N-methylbenzodioxazolbutanamine  (MBDB)  and  its  methoxy 
derivatives  for  instance  para-methoxyarnfetainine  (PMA),  para-methoxymethamfetarnine 
(PMMA)  and  4-methylthioarnfetamine  (4-MTA)  are  powerful  stimulants  of  the  central 
nervous  system  [55].  AF  and  related  compounds  are  listed  in  Classes  A  and  B  of  the 
Misuse  of  Drugs  Act  1971  [3]. 
The  drugs  are  widely  abused,  primarily  by  young  people,  in  different  areas  of  the  world.  It 
is  reported  that  AF  and  MDMA  are  the  most  common  drugs  used  from  this  class  of 
compounds  and  are  used  either  alone  or  in  combination  with  other  illicit  drugs  [56]. 
Consequently,  these  drugs  are  of  interest  to  forensic  and  clinical  toxicologists  and  to  sports 
scientists.  Traditionally,  these  drugs  would  be  detected  in  blood  or  urine  specimens. 
However,  with  concerns  relating  to  the  human  rights  of  individuals,  privacy  and  dignity, 
less  conventional  biological  specimens  such  as  oral  fluid,  hair,  sweat  and  nails  are 
becoming  more  frequently  used  for  drug  screening,  particularly  in  the  workplace. 
According  to  the  European  Monitoring  Centre  for  Drugs  and  Drug  Addiction  (EMCDDA) 
the  abuse  of  AF  and  related  compounds  comes  second  to  cannabis  misuse  in  Europe  [571. 
3.1.1.1  Amfetamine 
AF  is  a  central  nervous  system  stimulant.  It  is  available  as  amfetamine  phosphate  and 
amfetamine  sulphate  and  is  ingested  as  a  racemic  mixture  [58].  It  was  first  synthesised  in 
1887  and  used  during  World  War  11  to  prevent  fatigue  and  maintain  alertness.  It  has  been 
manufactured  commercially  since  1932.  Its  misuse  was  reported  to  have  spread  to  Japan, 
Europe,  Canada  and  the  US  in  the  1960s.  It  can  be  abused  by  oral,  nasal  or  intravenous 
routes  [55,59].  The  clinical  use  of  AF  was  limited  to  the  treatment  of  narcolepsy  in  adults 
and  attention  deficient  disorder  with  hyperactivity  (ADHD)  in  children.  Also  it  has  been 
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used  in  decongestant  preparations  and  as  an  appetite  suppressant  [60].  The  popularity  of 
AF  competes  with  cocaine  on  the  street  as  a  result  of  it  being  cheaper  and  giving  a  similar 
effect.  For  example,  5-10  milligrams  of  dextroarnfetamine  is  sufficient  to  ward  off  fatigue 
and  produce  mental  and  physical  effects  such  as  euphoria.  Consequently,  it  is  a  popular 
illicit  stimulant  among  students,  truck  drivers,  night  workers  and  athletes.  Side  effects  of 
the  drug  include  dryness  of  the  mouth,  sweating  and  hypertension  [6  1  ]. 
3.1.1.2  Methamfetamine 
MA  is  a  strong  central  nervous  system  stimulant  and  is  available  as  metharnfetamine 
hydrochloride  [58].  MA  was  synthesized  in  the  early  1900s  for  clinical  use.  It  was  highly 
abused  and  caused  problems  in  different  countries  such  as  the  US,  Mexico,  South  America, 
the  Middle  East,  Asia  and  Australia.  It  is  abused  through  smoking,  insufflations,  injection 
and  oral  ingestion.  Clinically,  its  use  is  limited  to  weight  loss  programs  and  for  the 
treatment  of  narcolepsy  in  adults  and  to  treat  attention  deficit  disorder  in  children  and 
exogenous  obesity  [62-64].  It  was  reported  that  4%  of  the  US  population  has  tried  this 
drug  during  2000  [65]. 
3.1.1.3  Methylenedioxy  Derivatives 
MDA,  MDMA  and  MDEA  are  methylenedioxy  derivatives  of  amfetarnines.  The 
derivatives  were  synthesised  to  circumvent  the  then  legal  controls  on  amfetamines.  They 
are  abused  for  similar  reasons  and  have  similar  phan-nacological  actions  to  the 
arnfetamines  (see  section  3.1.1.1).  Also,  they  were  found  to  have  some  hallucinogenic 
properties.  Although  there  were  claims  that  MDMA  could  be  used  diagnostically  by 
psychiatrists,  the  drugs  have  no  significant  therapeutic  use.  They  are  available  as 
methylenedioxyamfetamine  hydrochloride,  methylenedioxymethamfetamine  hydrochloride 
and  methylenedioxyethylamfetainine  [58,66].  Methylenedioxy  derivatives  of  amfetamine 
or  methamfetamine  are  abused  to  enhance  understanding  and  empathy  [67).  They  became 
the  most  popular  recreational  drugs  in  the  mid-1980s  [55].  Within  recent  years,  they  have 
become  the  second  most  popular  abused  drugs  in  Europe  and  North  America  especially  at 
dance  clubs  as  "rave"  drugs  [68]. 
MDMA  and  MDA  were  first  synthesised  in  1914  and  1910,  patented  in  1914  and  1940 
respectively.  Since  1986,  clandestine  laboratories  started  to  synthesise  derivatives  of 
MDMA  and  MDA  [69].  Methylenedioxy  derivatives  of  anifetamines  are  mostly  consumed 
orally  and  originally  were  synthesised  for  medical  use  [70,71].  Their  popularity  was  due 
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to  producing  effects  such  as  euphoria,  enhanced  energy,  a  desire  to  socialize  and  their 
reputation  of  being  safe.  Other  studies,  however,  indicated  some  harmful  effects  to 
humans  such  as  hepatotoxicity  and  neurotoxicity  [72].  Following  the  use  of  the 
methylenedioxy  derivatives  of  arnfetamine  the  abuser  may  experience  drowsiness,  muscle 
aches,  general  fatigue,  depression  lasting  1-2  days  and  may  have  difficulty  in 
concentrating  [68]. 
It  has  been  reported  that  the  development  of  new  designer  drugs  has  increased  during  the 
last  few  years.  Approximately  200  different  derivatives  have  been  described.  A  few  of 
them  are  known  to  be  used  in  Europe  where  the  methylenedioxy  derivatives  of  amfetamine 
and  methamfetamine  are  the  largest  designer  drugs  group  abused  [73]. 
3.1.2  Physico  -  Chemical  Properties  of  Amfetamines 
Chemically,  these  compounds  are  derivatives  of  9-phenyl-isopropylamine.  AF  contains  a 
primary  amine  and  MA  has  a  substituted  amine.  Methylenedioxy  derivatives  are  ring- 
substituted.  The  basic  structure  of  amfetamines  and  the  structure  of  all  five  amfetamines 
used  in  this  study  are  shown  in  Figure  3.1  and  Figure  3.2.  Most  of  them  have  pKa  values 
of  approximately  10.  All  are  suitable  for  drug  testing  in  non-conventional  and 
conventional  matrices.  AF  and  related  compounds  have  similar  pharmacological  and  toxic 
effects  such  as  increased  alertness,  insomnia,  energy  and  decreased  fatigue  and  appetite 
with  enhanced  mood  and  euphoria.  The  variations  of  AF  and  related  compounds' 
structures  have  an  effect  on  the  active  drugs  properties,  for  instance  psychomotor  stimulant 
effects,  an  increased  metabolic  half-life  and  diminished  hallucinogenic  activity  [55]. 
For  medico-legal  cases,  particularly  in  relation  to  workplace  drug  testing,  the  effects  of 
metabolically  altering  urinary  pH  and  dilution  of  urine  samples  either  physically  or  using  a 
diuretic  agent,  must  be  taken  in  to  account  and  this  requires  careful  interpretation  of  the 
analytical  results  [74].  The  properties  of  investigated  amfetamines  are  shown  in  Table  3.1. 
Rl  R3 
I 
N 
R2 
R4 
Figure  3.1  Amfetamine  Basic  Structure  (P-phenyi-isopropylamine) 
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Figure  3.2  The  structure  of  Amfetamlne(CqHl3N),  Methamfetamine(ClOH15N), 
MDA(ClOH13NO2)p  MDMA(CIIH15NO2)  and  MDEA(Cl2Hl7NO2) 
Table  3.1  Properties  of  Amfetamines  [58] 
Drug  Street  Name  MW  PK. 
AF  Bennies,  speed  135.2  9.9 
MA  Speed,  ice,  crystal,  crank,  meth,  go,  oxblood  149.2  10.1 
MDA  Speed,  love  pill  179.2  -10 
MDMA  ecstasy,  XTC,  Adam,  M&M,  MDM,  E  193.2 
MDEA  Eve  207.3 
MA 
CH3 
0  CH2CHNHCH3 
0 
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Enantiomers  of  Amfetamines 
AF,  MA  and  all  of  methylenedioxy  derivatives  of  arnfetamine  drugs  contain  a  chiral  centre 
and  they  have  a  pair  of  enantiorners.  There  are  two  possible  enantiomers  for  these 
compounds,  d  and  I  enantiomers  designated  as  S-(+)  and  R-(-),  respectively[75]. 
The  enantiomers  show  differences  in  their  pharmacology  and  toxicology  such  as 
metabolism  rate,  half-life,  psychornotor  performance  and  body  disposition  [55,76].  For 
example,  the  (S)-(+)-isomers  of  AF  and  MA  have  five  times  more  potency  as  CNS 
stimulants  than  the  (R)-(-)-isomer.  The  (S)-isomers  of  MDMA  and  MDE  are  responsible 
for  the  psychostimulant  and  entactogenic  activities  as  compared  with  the  hallucinogenic 
properties  of  the  (R)-isomers  [67,76].  It  has  been  reported  that  most  of  the  immunoassay 
and  confirmation  tests  used  can  not  discriminate  between  the  two  different  enantiomers 
[67] 
AF  and  MA  compounds  are  also  available  by  prescription  or  over  the  counter  in  certain 
countries.  For  example  in  the  United  States,  a  Vicks  Nasal  inhaler  contains  the  (R)-(-)- 
methamfetamine  enantiomer.  Therefore,  the  determination  of  the  individual  enantiomers  is 
important  and  may  play  a  role  in  determination  of  the  potential  source  of  AF  or  MA  [74]. 
3.1.3  Amfetamine  and  Methamfetamine  Precursor  Compounds 
There  are  difficulties  in  the  interpretation  of  AF  and  MA  positive  results  in  biological 
samples  in  clinical  and  forensic  toxicology.  These  difficulties  are  related  to  at  least  14 
compounds  which  are  precursors  of  AF  and  MA.  These  precursors  can  be  converted 
metabolically  to  AF  and  MA  or  both.  A  list  of  precursors  is  shown  in  Table  3.2.  To  avoid 
misinterpretation  of  results  and  distinguish  between  an  illegal  or  legitimate  (prescription) 
use,  it  is  essential  to  consider  the  specific  identification  of  metabolites  and/or  unchanged 
precursor  drugs  [74]. 
There  are  other  precursor  sources  that  may  be  converted  to  AF  such  as  the  monoamine 
oxidase  inhibitor  tranylcypromine  and  I-phenyl-2-nitropropane.  Further  tests  are  needed 
to  prove  or  exclude  that  this  is  the  case  for  these  compounds  [64].  There  are  no  legal 
precursor  drugs  for  the  "designer"  anifetarnines  [75].  Consequently  AF  and  MA  positive 
results  produced  from  preliminary  screening  (immunological  identification)  must  be 
further  investigated  to  identify  the  cause  of  the  positive  preliminary  screening  results  to 
discriminate  between  an  illegal  or  legitimate  use  [77]. 
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Table  3.2  Precursor  Compounds  to  Amfetamine  and  Methamfetamine 
Drug  name  (Brand  Name' 
Amphetaminil 
Benzphetamine 
Clobenzorex 
Deprenyl(selegiline) 
Dimethylamfetamine 
Ethylamfetamine 
Famprofazone 
Fencamine 
Fenethylline 
Fenproporex 
Furfenorex 
Mefenorex 
Mesocarb 
Prenylamine 
Metabolites  in  urine 
AF 
MA,  AF,  Others 
AF,  Others 
MA,  AF 
MA,  AF,  Other 
AF,  Other 
MA,  AF,  Other 
MA,  AF 
AF,  Others 
AF 
MA,  AF,  Others 
AF,  Other 
AF,  Others 
AF,  Others 
3.1.4  Toxicity 
Toxicity  is  an  unwanted  response  to  drug  use  that  can  produce  undesirable  side  effects  and 
at  worst  may  lead  to  fatal  poisoning.  It  is  necessary  to  understand  the  pharmacological  and 
pharmacokinetic  properties  of  drugs  to  predict  their  toxicity  [58].  Chronic  AF  use 
increases  its  toxicity  and  can  cause  mild,  moderate  or  severe  toxicity  such  as  vomiting, 
confusion  and  coma  respectively.  Other  effects  include  neurotoxicity  and  may  lead  to 
impairment  of  brain  function  [55]. 
When  used  therapeutically,  AF  blood  concentrations  are  usually  below  0.1ýtg/mL.  In 
deaths  from  acute  poisoning,  when  used  alone,  measured  concentrations  in  peripheral 
blood  are  generally  above  2pg/mL.  Prescribed  doses  are  up  to  40  mg  daily  whereas  when 
abused,  the  dose  is  estimated  to  be  up  to  2g. 
For  MA,  the  therapeutic  blood  concentration  is  generally  below  0.1  ýtg/mL.  In  fatalities 
when  used  alone,  the  measured  concentration  in  peripheral  blood  has  ranged  between  0.09 
-  18  ptg/mL.  When  abused  the  dose  can  be  up  to  2g  [58,79]. 
Consumption  of  methylenedioxy  derivatives  of  amfetamine  can  cause  fatal  poisoning.  An 
overdose  can  give  rise  to  hallucinations,  coma  and  may  lead  to  death  [80,81].  Doses  of 
between  50  -  250  milligrams  of  MDA  can  result  in  blood  concentrations  up  to  0.4  mg/L. 
Consumption  of  between  100  -  150  milligrams  of  MDMA  has  resulted  in  blood 
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concentrations  up  to  0.3mg/L.  In  fatalities,  concentrations  of  greater  than  O.  lmg/L  have 
been  measured  in  peripheral  blood  for  traffic  accident  victims  [58].  MDMA  abuse  may 
cause  acute  and  severe  toxic  effects  leading  to  complications  and  undesirable  side-effects 
such  as  hyperthermia,  hepatotoxicity  and  may  cause  death  [82].  MDMA  administration 
produced  different  effects  such  as  mental  and  behavioural  effects  compared  to  other 
amfetamine  compounds  [83].  It  is  reported  that  there  are  associations  between  death 
during  dancing  and  MDMA  abuse,  where  a  group  of  young  adults  died  after  ingestion  of 
MDA  and  MDMA  during  their  rave  dancing  [68].  MDEA  has  similar  psychoactive 
effects  to  MDMA  but  at  equivalent  doses  has  less  neurotoxic  effects  [55].  The  dose 
abused  is  estimated  to  be  between  30  and  100  mg  [4]. 
Blood  concentrations  of  AF  and  related  compounds  found  in  fatal  cases  either  alone,  with 
alcohol  or  other  drugs  are  shown  in  Table  3.3  [84].  Also  the  concentrations  of  AF  and 
related  compounds  found  in  related  deaths  in  various  biological  matrices  are  displayed  in 
Table  3.4  [85]. 
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Table  3.3  Fatal  amfetamines  and  related  compounds  concentrations  in  blood 
Compound  Blood  Concentration  (mg/L) 
Alone  With  Alcohol  (EtOH)  With  other  drugs 
AF  0.1-2.6  0.1-0.75  0.02-0.64 
n=5  n=5  n=  12 
MA  0.35  n/a  n/a 
n=I 
MDA  0.04-0.05  0.12-0.30  0.15-1.2 
n=2  n=3  n=4 
MDMA  0.23  0.17-0.60  0.03-8 
n=2  n=3  n=5 
MDEA  0.77  0.22-2  2.44-4.32 
n=I  I  n=3  n=2 
n/a:  not  available 
Table  3.4  Fatal  amfetamine  and  related  compounds  concentrations  in  different  biological 
matrices 
Compound  Urine  Liver  Kidney  Brain  Stomach  Muscle 
(mg/L)  (mg/kg)  (mg/kg)  (mg/kg)  Contents  (mg/kg) 
AF  33.4-700  11.7-45  3.9-48  3-41  21mg  4 
n=4  n=8  n=5  n  =3  n=1  n=1 
3000  mg/kg 
n=1 
MA  1-398.4  0.6-174.7  0.2-87  0.2-101.8  5.8-44  mg  3.6-47.7 
n=  10  n=  19  n=  17  n=  17  n=4  n=6 
17-514.3 
mg/L 
MDA  168-175  11-13  18  10  0.25-1.7  mg  n/a 
n=2  n=2  n=1  n=  I  n=2 
MDMA  14.3-529  6.4-39.7  12.1  13.7-17.4  96  mg/L  4.5 
n=3  n=4  n=1  n=2  n=1  n=1 
I  18  mg/kg 
n=1  I 
MDEA  20  1  1  9  15  28  52  mg/kg  n/a  II 
n=  1  1  n  =  1  n=  n=I  n=l 
n/a:  not  available 
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3.1.5  Disposition  in  the  Body 
Physical  and  chemical  properties  of  drugs  play  a  major  role  in  their  absorption,  distribution 
and  elimination  [55]. 
3.1.5.1  Absorption 
There  are  different  routes  of  amfetamines  administration  (swallowed  or  injected)  but,  AF 
itself  is  usually  consumed  orally  either  as  the  (S)-(+)-enantiomer  (dexamfetamine)  or  the 
racemic  mixture  (eg.  amfetamine  sulphate).  The  tablet  form  of  AF  is  the  most  commonly 
encountered  amongst  abusers.  Amfetamines  are  rapidly  and  readily  absorbed  following 
ingestion.  After  a  single  oral  administration  they  reach  their  plasma  concentration  peak 
within  4  hours.  No  significant  differences  between  racernic  and  individual  isomers  were 
observed  in  pharmacokinetic  parameters  (Cmax  and  Tmax)  during  the  absorption  phase. 
While,  the  general  routes  of  MA  administration  include  the  oral  route,  they  can  be  injected 
intravenously,  snorted  ('speed')  or  can  be  smoked  as  (S)-(+)  -  methamfetamine 
hydrochloride  ('ice',  vapour  inhalation)  through  a  glass  pipe  system.  It  was  observed  that 
the  plasma  concentration  of  smoked  MA  was  higher  than  its  concentration  if  taken  by  the 
oral  administration;  bioavailability  was  90%  and  67%  respectively.  Tmax  values  of 
smoked  and  intravenous  MA  administration  were  shorter  than  the  oral  administration.  I- 
2.5  hours,  these  for  smoked  and  intravenous  and  at  least  3  hours  after  oral  administration. 
Methylenedioxy  derivatives  are  mostly  consumed  orally  and  are  absorbed  into  the  blood 
after  administration.  Pharmacokinetic  properties  of  MDEA  are  similar  to  those  of  MDMA 
when  given  orally  [55].  With  a  typical  dose  (60-120  mg),  MDA  is  more  potent  than 
MDMA  and  MDEA.  The  onset  of  effects  is  from  30  to  60  min  for  MDA  and  30  min  for 
MDMA  and  MDEA  and  the  duration  of  action  of  MDA,  MDMA  and  MDEA  is  about  8  h, 
6h  and  3-4  h  respectively  [68]. 
3.1.5.2  Distribution 
AF  and  related  compounds  have  relatively  low  molecular  weights,  are  weak  bases  and 
have  a  low  protein  binding  (around  20%).  These  parameters  enhance  their  diffusion  across 
cell  membranes,  lipid  layers  and  tissues,  consequently,  increasing  their  accumulation  and 
concentration  in  different  compartments  such  as  tears,  saliva,  sweat,  hair  and  nails. 
Therefore,  it  is  potentially  one  of  the  best  drug  groups  suitable  for  testing  in  these 
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biological  samples.  It  was  noted  that  there  was  no  difference  in  the  protein  binding  and 
distribution  volumes  of  AF  enantiomers  (S  &  R),  while,  the  AF  (S)  enantiomer  exhibits  a 
faster  metabolism  than  the  (R)  enantiomer.  Consequently,  the  elimination  half-life  will  be 
shorter  for  (S)  enantiomer.  There  are  similarities  between  volume  of  distribution  of  MA 
and  AF.  Concurrent  use  of  ethanol  will  cause  a  decrease  in  the  volume  of  distribution  of 
MA  due  to  ethanol  displacing  MA  from  peripheral  binding.  There  are  limitations  in  the 
distribution  of  designer  amfetamines  in  humans  after  administration.  The  passage  of  AF 
and  related  compounds  from  blood  to  other  fluids  is  regulated  and  depends  on  pKa  and  the 
pH  in  each  biological  fluid.  For  example,  AF  tends  to  accumulate  in  saliva  and  sweat,  due 
to  their  pH  being  lower  than  plasma  pH  (7.4).  It  was  noted  that  after  oral  ingestion,  the  AF 
concentration  in  oral  fluid  was  higher  than  its  concentration  in  plasma  [55]. 
3.1.5.3  Metabolism 
3.1.5.3.1  Amfetamine 
P-hydroxyamfetamine  and  benzoic  acid  including  its  glycine  conjugate  are  the  main 
metabolites  of  AF  in  the  body.  Also,  unchanged  AF  can  be  detected  in  urine  [86].  AF  is 
metabolised  after  absorption  whereas,  under  normal  conditions  a  large  fraction  is 
inactivated  by  virtue  of  being  deaminated  to  phenylacetone,  then  oxidized  to  benzoic  acid 
and  excreted  as  conjugates.  A  small  fraction  of  AF  is  converted  by  oxidation  to 
norephedrine.  Norephedrine  and  its  precursor  are  p-hydroxylated  [79].  The  metabolic 
pathway  of  AF  is  shown  in  Figure  3.3. 
CH  CH  330 
CH2CHNH2 
UM  norephedrine  amfetamine  phenýacetone 
p-  hydro4ation  glucuronide  and  COOH 
and  conjugation  glycine  conjugation 
benzoic  acid 
Figure  3.3  The  metabolic  pathway  of  amfetamine  in  human  body  [79] 
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3.1.5.3.2  Methamfetamine 
The  N-  demethylated  form  of  methamfetamine  produces  amfetamine  as  an  active 
metabolite  [79].  The  other  metabolic  pathways  of  MA  when  converted  to  p-hydroxylated 
metabolites  and  benzoic  acid  are  the  same  as  for  AF  metabolism,  but  with  a  lower 
formation  of  benzoic  acid  than  from  AF  [86].  The  metabolic  pathway  of  methamfetamine 
is  shown  in  Figure  3.4. 
9H3 
CH2a-rl-K3-ý 
0- 
L" 
metonfetamine  aTietamine  norepheddne 
deanination,  p-hydnmcylation  and  oonjugation 
Figure  3.4  The  metabolic  pathways  of  methamfetamine  in  human  body  [79] 
3.1-5.3.3  Methylenedioxy  derivatives 
Extensive  metabolism  is  carried  out  for  methylenedioxy  derivatives  of  arnfetamine. 
Monohydroxy  and  dihydroxy  metabolites  are  formed  [55,67].  MDA  and  other  metabolites 
are  produced  from  metabolism  of  MDMA  and  MDEA  [58].  The  metabolic  pathways  of 
MDMA  and  MDEA  are  shown  in  Figure  3.5  and  Figure  3.6.  Limited  information  is 
available  for  methylenedioxyamfetamine  (MDA)  metabolism  in  humans. 
CH3  CH3  CH3 
II-I 
HO-57ý-CIH12CHNHCH3  CH2CHNHCH3  CH2CHNH2 
HO  00 
Dihydroxy  metabolite  MDMA  MDA 
Figure  3.5  The  metabolic  pathways  of  IVIDIVIA  in  human  body  [581 
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Figure  3.6  The  metabolic  pathways  of  IVIDEA  in  the  human  body  [58] 
3.1.5.4  Excretion 
Excretion  of  AF  and  related  compounds  is  pH  dependent.  Due  to  their  weak  basic 
properties,  urinary  acidification  increases  their  excretion  and  urinary  alkalination  decreases 
it.  Consequently,  a  significant  variation  of  plasma  half-life  is  exhibited.  The  values  are 
shorter  in  urinary  acidification  and  longer  in  urinary  alkalination.  It  was  observed  that  the 
excretion  of  unchanged  MA  decreased  with  increasing  doses.  Smaller  amounts  of 
unchanged  methylenedioxy  derivatives  were  excreted  in  urine  than  with  any  of  the  other 
amfetamine  compounds  [55].  Only  a  small  amount  of  AF  was  reabsorbed  under  acid 
conditions,  while,  more  AF  was  reabsorbed  under  alkaline  conditions.  This  may  explain 
the  increase  and  decrease  of  AF  excretion  [60).  30%  of  AF  excreted  was  unchanged  in  24 
hour  urine.  This  increased  to  74%  with  acidic  urine  and  decreased  to  1%  in  alkaline  urine. 
43%  of  MA  was  excreted  unchanged  in  a  24  hour  urine  sample.  A  further  4-7%  was 
recovered  as  AF.  In  acidic  and  alkaline  urine,  these  percentages  were  changed.  Whereas 
76%  and  2%  of  MA  was  recovered  unchanged  in  the  acidic  and  alkaline  urines 
respectively,  the  corresponding  recoveries  for  AF  were  approximately  2%  and  less  than 
0.1%  respectively.  26%  of  MDMA  was  excreted  unchanged  in  24  hour  urine  and  1%  as 
MDA  after  single  oral  dose  administration  (100-125  mg).  19%  of  MDEA  was  excreted 
unchanged  in  32  hour  urine  and  28%  as  MDA  after  single  oral  dose  administration  [79]. 
3.1.6  HairAnalysis  forAmfetamines 
There  are  many  different  validated  analytical  methods  containing  a  variety  of 
decontamination,  pre-treatment,  extraction,  derivatisation  procedures  and  instrumental 
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techniques  which  are  all  suitable  for  amfetarnines  detection  and  have  been  used  for 
amfetamines  analysis  in  hair  [87-112]. 
The  most  routine  decontamination  methods  used  for  hair  containing  arnfetamines  are  acid, 
methanol,  0.1  %  sodium  dodecyl  sulphate  (SDS)  with  water,  water  with  acetone  and 
dichloromethane  [97].  0.1  %  SDS  has  been  used  to  decontaminate  hair  soaked  in  an 
aqueous  solution  of  10  ýtg/ml  of  MA  hydrochloride  for  24  h  [19].  This  was  shown  to 
easily  and  effectively  remove  this  external  contamination.  A  review  of  the  literature 
showed  that  0.1  %  SDS  and  water  have  been  used  frequently  as  wash  solvents  for  MA  and 
its  metabolites  in  hair  [113]. 
Several  pre-treatment  methods  have  been  used  to  extract  drugs  from  the  hair.  These  have 
included  alkaline,  acid,  enzymatic  and  methanol  pre-treatments.  A  GC-MS  method  has 
been  reported  for  the  detection  of  AF,  MA,  MDA  and  MDMA  simultaneously  in  hair  [93]. 
This  involved  digesting  the  hair  using  1M  sodium  hydroxide  followed  by  LLE  and 
derivatisation  with  pentafluoro-propionic  anhydride  /  pentafluoropropanol.  In  this  case  the 
limits  of  detection  were  0.05  ng  /mg  for  AF,  MA  and  MDA  and  0.1  ng/  mg  for  MDMA. 
This  method  showed  high  specificity  and  sensitivity  for  AF,  MA,  MDA  and  MDMA  in 
hair  samples. 
Mild  enzymatic  treatment  (Proteinase  K)  with  Tris  buffer  at  a  pH  of  6.2  was  reported  to 
give  good  recoveries  by  releasing  arnfetamines,  cannabinoids  and  others  drugs  from  hair 
by  using  mass  spectrometric  analysis  (GC-MS)  [28].  An  advantage  of  enzymatic  treatment 
is  that  it  is  more  suitable  for  certain  unstable  drugs  compared  with  other  pre-treatment 
methods  such  as  alkaline  pre-treatment  [19].  A  GC-MS  method  was  developed  for  the 
simultaneous  analysis  of  amfetamines  and  other  compounds  such  as  opiates  and  cocaine  in 
hair  using  fl-glucuronidase  /  aryl-sulfatase  as  pre-treatment  method.  This  was  followed  by 
SPE  and  derivatisation  with  pentafluoro-propionic  anhydride  /  pentafluoropropanol.  The 
limits  of  detection  for  this  method  were  less  than  0.1  ng/mg  for  all  substances  and  the  AF 
recovery  was  50%  for  spiked  control  hair  [95]. 
Methanolic  extraction  with  sonication  was  used  by  another  group  to  extract  AF  and  its 
methylenedioxy-derivatives  (MDA,  MDMA  and  MDEA)  simultaneously  from  hair. 
Propionic  acid  anhydride  (PSA)  or  trifluoroacetic  acid  anhydride  (TFA)  derivatisation 
reagents  are  used.  GC-MS  was  used  in  selected  ion  monitoring  mode  for  the  detection. 
The  limits  of  detection  were  0.01  ng/mg  for  all  compounds.  This  method  proved  that 
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methanolic  extraction  with  sonication  could  be  used  successfully  to  extract  amfetaraines 
simultaneously  with  other  drugs  such  as  opiates  [9  1  ]. 
Two  studies  which  compared  various  extraction  methods  for  the  recovery  of  arnfetamines 
have  been  reported.  The  first  study  showed  that  alkaline  pre-treatment  produced  the 
highest  recoveries  when  followed  by  LLE.  The  second  study  showed  that  acid  pre- 
treatment  produced  the  highest  recoveries  when  followed  by  LLE  and  then  SPE  [92,94]. 
Many  procedures  used  for  the  extraction  of  amfetamines  from  hair  samples  are  similar  to 
those  used  for  blood  analysis  of  amfetamines.  Bond-Elut  Certify  SPE  columns  have  been 
shown  to  give  clean  extracts  from  whole  blood  for  AF  and  MA  [67].  AF,  MA,  MDA, 
MDEA  and  MDEA  were  successfully  extracted  from  hair  using  IsolutJ  Confirm  HCX-3 
(130  mg)  SPE.  The  recoveries  were  greater  than  70%  for  all  five  amfetamines  [114].  LLE 
methods  and  SPE  methods  have  both  been  used  [67,75,93,95,114]. 
Derivatisation  agents  that  have  been  successfully  used  for  derivatisation  of  amfetamines 
following  extraction  of  amfetamines  from  hair  are  typical  of  those  used  routinely  for  the 
derivatisation  of  amfetamines.  These  include  trifluoroacetic  anhydride  (TFA), 
chlorodifluoroacetic  anhydride  (CDFA),  heptafluoro-n-butyryl  (HFB),  pentafluoro- 
propionic  anhydride  (PFPA),  N-methyl-bis-trifluoroacetamide  (MBTFA)  pentafluoro- 
propionic  anhydride  /  pentafluoropropanol  (PFPA  /  PFPOH)  and  propionic  acid  anhydride 
(PSA)  [91,93,113]. 
A  number  of  analytical  methods  have  been  reported  for  screening  AF  and  related 
compounds  in  biological  samples.  These  qualifying  techniques  have  included: 
immunoassay  techniques  such  as  enzyme  multiplied  immunoassay  technique  (EMIT), 
radioinimunoassays  (RIA),  enzyme  immunoassay  (EIA),  enzyme-linked  immunosorbent 
assay  (ELISA)  and  fluorescence  polarization  immunoassay  (FPIA)  [57,115-117]. 
Immunoassay  has  been  used  for  screening  of  amfetamines  in  hair.  These  types  of 
technique  have  included  EMIT  [  118]  and  ELISA  [  119]. 
The  confirmation  techniques  for  amfetamines  in  biological  specimens  have  included:  gas 
chromatography-mass  spectrometry  (GC-MS),  gas  chromatography  tandem  mass 
spectrometry  (GC-MS-MS),  in  electron  impact,  positive  and  negative  chemical  ionisation 
modes,  GC  with  flame-ionisation  detection  (GC-FID),  nitrogen-phosphorus  detection 
(GC-NPD)  or  electron-capture  detection  (GC-ECD)  and  high-performance  liquid 
chromatography  with  ultraviolet  detection  (HPLC-UV)  or  chemiluminescence  detection 
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(HPLC-CD),  capillary  electrophoresis  (CE),  liquid  chromatography  mass  spectrometry 
(LC-MS)  and  liquid  chromatography-tandem  mass  spectrometry  (LC-MS-MS)  [19,115, 
120,121].  GC-MS  has  been  frequently  used  for  the  identification  of  amfetamines  and  it  is 
the  most  common  method  used  for  identification  of  amfetamines  in  hair  [67,91,93,95]. 
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3.2  Cannabis 
3.2.1  Introduction 
The  cannabis  sativa  L.  plant  which  includes  its  sub-species  (hemp 
plant,  variety  Indica)  is  the  source  of  cannabis  (marijuana  and 
hashish).  These  are  dioecious  and  perennial  plants.  They  contain 
over  420  unique  chemical  compounds  of  which  at  least  61 
compounds  are  cannbinoids  [1221.  The  female  plants  produce  more  of  the  main  active 
constituent  A?  -  THC  than  male  plants.  The  commonly  used  "street"  names  of  cannabis  and 
its  products  are  weed,  grass,  dope,  dagga  and  pot  [58].  The  major  cannabinoid  substances 
in  the  cannabis  plant  are  Y-  THC,  cannabidiol  (CBD)  and  cannabinol  (CBN).  The  main 
psychoactive  agent  identified  in  the  plant  is  A?  -  THC  which  was  first  isolated  in  the  1960. 
Its  acid  precursor,  A?  -tetrahydrocannabinolic  acid  (A?  -THCA)  is  not  psychoactive.  It 
does,  however,  account  for  most  of  the  THC  related  substances  present  in  the  plant.  Only 
a  small  amount  is  present  as  neutral  THC  [123].  A?  -THCA  is  converted  to  active  Y- 
THC  by  heat  or  when  cannabis  products  are  smoked  (decarboxylated)  [  124].  In  addition,  it 
was  shown  only  that  2 
-tetrabydrocannabinol  (2  -THC), 
Y 
-tetrahydrocannabivarol 
and  CBN  have  significant  psychoactive  properties  [125]. 
Since  ancient  times,  the  cannabis  plant  and  its  product  were  used  for  recreational, 
medicinal  and  religious  purposes  in  different  cultures  [126].  Also,  it  is  used  as  a  fibre 
source  (hemp)  [127].  In  the  beginning,  marijuana  was  taken  by  the  inhalation  of  volatile 
oils  generated  in  the  smoke.  There  are  reported  usages  for  a  number  medical  conditions 
including  pain,  anxiety,  glaucoma,  nausea  (for  cancer  chemotherapy),  emesis,  muscle 
spasms  and  wasting  diseases  [128].  Dronabinol  and  Marinol  are  prescription  forms  for  2- 
THC  [791.  Y-  THC  is  often  present  at  low  concentration  with  no  psychoactive  effects  in 
shampoo  preparations,  in  foodstuffs  (product)  such  as  oil,  noodles,  crackers  and  in 
beverages  such  as  tea  [129].  Cannabis  material  has  been  used  in  food  products  in  different 
global  markets  as  nutritional  supplements  in  the  last  few  years  [130].  Due  to  its  sedative 
and  anxiolytic  properties,  it  has  been  used  by  athletes  to  reduce  stress  [  13  1  ]. 
The  use  of  a  high  dose  of  cannabis  can  cause  euphoria  and  relaxation  followed  by  a 
depressant  period  [132].  Cannabis  is  available  in  various  preparations.  The  concentration 
of  A9  -THC  depends  on  the  particular  preparation  and  formulation  type.  Marijuana, 
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hashish,  oil  are  prepared  from  dried  plant  (herbal  cannabis),  resin  (cannabis  resin)  and  by 
distillation  respectively.  It  is  usually  mixed  with  tobacco  and  is  rarely  chewed  [133].  It  is 
reportedly  taken  with  other  drugs  such  as  alcohol  to  enhance  the  psychoactive  effect  [132]. 
The  administration  route  of  cannabis  can  be  either  oral,  such  as  marijuana  mixed  with 
food,  e.  g.  brownies,  or  by  inhalation  (smoking)  [134].  Overall,  the  main  administration 
route  is  smoking  [13].  Cannabis  is  the  most  commonly  and  frequently  used  illegal 
substance  worldwide  and  recent  studies  demonstrated  that  about  one  to  two  thirds  of  young 
people  in  Australia,  Germany,  New  Zealand  and  the  United  Kingdom  have  tried  cannabis 
at  least  once  prior  to  young  adulthood  [135].  It  ranked  next  to  alcohol  and  nicotine  [136]. 
In  accordance  with  European  Monitoring  Centre  for  Drugs  and  Drug  Addiction 
(EMCDDA),  Europe,  2001,  Substance  Abuse  and  Mental  Health  Services  Administration 
(SAMHSA),  USA,  2001  and  Australian  Institute  of  Health  and  Welfare,  Australia  2002, 
cannabis  is  the  most  widely  abused  drugs  in  these  countries  [137].  It  was  reported  that 
cannabis  use  has  the  potential  risk  of  leading  to  the  usage  of  other  harder  illegal  drugs 
[138].  It  was  reported  in  2004  that  there  are  approximately  300-400  million  consumers  of 
cannabis  preparations  in  the  world  [122].  According  to  the  BCS,  cannabis  was  the  most 
commonly  used  drug  in  2004/5.  It  was  estimated  that  23.5%  of  16  to  24  year  olds  in 
England  and  Wales  used  this  drug  in  the  last  year  [3]. 
An  association  between  cannabis  consumption  and  psychosis  has  been  reported  [136].  Its 
biological  effect  is initiated  by  its  interaction  with  cannabinoid  receptors  such  as  CB1  and 
C132  which  are  found  in  mammalian  tissue  and  widely  distributed  in  the  CNS  and 
peripheral  tissue  [139].  There  are  various  effects  of  cannabis,  either  acute  effects  such  as 
loss  of  internal  control  and  impairment  of  attention  and  memory  especially,  during 
intoxication  and  adverse  chronic  effects  on  cognition.  This  may  cause  cannabis 
dependence  syndrome  which  is  an  inability  to  control  or  to  abstain  from  cannabis  use 
[127].  It  was  confirmed  as  a  risk  factor  for  arthritis  and  it  is  reported  that  intoxication 
induces  aggressive  behavior  [133].  Dry  mouth,  blurred  vision  and  ataxia  (an  increased 
heart  rate)  can  be  attributable  to  A?  -THC  use  [140]. 
It  has  been  reported  that  one  in  11  cannabis  users  will  become  dependent.  Cannabis 
withdrawal  was  characterised  by  different  sips  and  symptoms  such  as  irritability,  anxiety, 
sleep  disruptions,  aches,  and  pains,  which  lead  to  difficulty  in  maintaining  abstinence. 
Adverse  effects  on  cognitive  function  were  also  reported  and  observed  with  heavy 
cannabis  use  and  it  was  reported  that  pulmonary  dysfunction  was  associated  with  regular 
cannabis  smoking  similar  to  regular  tobacco  smokers  [141] 
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5-10  mg  of  cannabis  smoked  is  enough  to  produce  the  effects  such  as  euphoria, 
hallucinations  and  often  sedation  [134].  At  a  federal  level  in  USA,  medicinal  use  of 
smoked  or  ingested  marijuana  is  prohibited  [128].  Cannabis  has  been  listed  since  January 
2004  in  Class  C  of  the  Misuse  of  Drugs  Act  1971  [3]. 
3.2.2  Chemistry 
The  main  active  component  of  cannabis  is  A?  -THC,  which  exists  in  a  variety  of 
stereochemical  forms.  These  include  (-)-trans-A?  -tetrahydrocannabinoI  isomer,  also  known 
as  dronabinol  or  A?  -THC.  There  are  other  cannabinoid  compound  isomers  which  have 
less  potential  pharmacological  activity  than  A?  -THC  for  instance  Y 
-THC  [140].  The 
chemical  formula  of  A?  -THC  is  C21H3002,  its  molecular  weight  is  314.5  and  its  pKa  is 
10.6.  It  is  insoluble  in  water  [4].  The  chemical  structure  of  A?  -THC  is  shown  in  Figure 
3.7. 
OH 
CH  0 
CH3 
C5Hjj 
THC 
A9  -tetrahydrocannabinol  (A?  -THC) 
Figure  3.7  Chemical  structures  of  A?  -THC 
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3.2.3  Disposition  in  the  Body 
3.2.3.1  Absorption  and  Distribution 
A9  -THC  and  other  cannabinoid  compounds  are  absorbed  by  inhalation  (smoking)  or  by 
ingestion  (orally).  The  concentration  of  its  metabolites  will  depend  on  the  route  of 
administration  [58].  Y 
-THC  is  distributed  widely  in  the  body  to  fat  and  muscle  and  its 
concentrations  in  blood  decline  due  to  its  lipophilic  and  low  water  solubility  properties. 
Within  15  min  of  smoking,  the  peak  plasma  concentrations  of  Y 
-THC  may  exceed  50 
ng/ml  and  reach  200  ng/ml  with  higher  THC  doses  [125]. 
3.2.3.2  Metabolism 
A?  -THC  is  rapidly  oxidized  to  the  psychoactive  metabolite  11-hydroxy-A?  - 
tetrahydrocannabinol  (1  1-OH-THC),  which  is  subsequently  further  oxidized  to  the  non- 
psychoactive  metabolite  A?  -THC-COOH.  Minor  metabolic  pathways  are  carried  out  to 
produce  smaller  quantities  of  the  other  metabolites  8-alpha-OH-THC  and  8,1  1-dihydroxy- 
THC.  A!  -THC  and  its  hydroxylated  and  carboxylated  metabolites  are  conjugated  with 
glucuronic  acid,  and  are  subsequently  excreted  in  urine  as  water  soluble  compounds  [79, 
130,142].  The  metabolism  of  A?  -THC  is  shown  in  Figure  3.8. 
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Figure  3.8  A?  -THC  and  A!  -THC-COOH  Metabolic  Pathway  [79] 
Conjugation 
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3.2.3.3  Excretion 
Often  cannabinoids  and  their  metabolites  are  excreted  as  glucuronic  acid  conjugates, 
therefore  require  hydrolysis  prior  to  analysis  [142].  Conjugated  and  unconjugated  A?  - 
THC-COOH  are  the  major  metabolits  found  in  urine  samples.  Y-THC  and  its  metabolites 
A?  -THC-COOH  and  1  1-OH-THC  are  found  in  blood.  The  main  compound  in  hair  is  Y- 
THC  (13].  Within  72  hours,  70%  of  A?  -THC  dose  is  excreted.  Approximately  40%  in  the 
faeces  and  30%  in  the  urine,  A  small  amount  of  unchanged  A?  -THC  is  excreted  in  urine 
[79].  It  is  reported  that  the  urinary  excretion  half-life  of  A?  -THC  is  3-13  days  and  that  of 
the  main  urinary  metabolite  A?  -THC-COOH  is  12  -25  days,  depending  on  frequency  of  use 
[125]. 
It  is  reported  that  only  A?  -THC  is  detectable  in  saliva  and  sweat.  The  other  metabolites  are 
rare.  CBN,  THC,  CBD  and  A?  -THC-COOH  are  detectable  in  hair,  but  A?  -THC-COOH  is 
at  very  low  concentrations,  while  in  meconium  only  A?  -THC-COOH  is  detectable  [1431. 
3.2.4  Hair  Analysis  for  Cannabinoids 
A  number  of  methods  have  been  described  regarding  cannabinoids  in  hair  samples  [122, 
129,134,144-157].  The  first  method  to  determine  2-THC  and  A!  -THC-COOH  inhuman 
hair  used  gas  chromatography/mass  spectrometry  for  detection.  Dichloromethane  was 
used  to  decontaminate  the  hair.  This  was  followed  by  alkaline  pre-treatment  using  IN 
NaOH,  LLE  (n-hexane/ethyl  acetate)  and  derivatisation  when  was  carried  out  using 
PFPA/PFP-OH.  The  limit  of  detection  of  both  A?  -THC  and  A?  -THC-COOH  were  0.1 
ng/mg  and  their  recoveries  were  75  and  80%,  respectively  [158]. 
A  sensitive  analytical  method  was  developed  for  quantitative  analysis  of  A?  -THC,  A?  -THC- 
COOH,  CBN  and  CBD  in  human  hair.  Internal  standards  used  were  ketarnine  for  CBN 
and  CBD,  and  ketoprofen  for  A?  -THC  and  A?  -THC-COOH.  fl  -glucuronidase  / 
arylsulfatase  was  used  as  pre-treatment  method.  LLE  was  used  for  the  extraction  and 
pentafluoropropionic  anhydride  (PFPA)  and  pentafluoropropanol  (PFPOH)  for 
derivatization.  Gas  chromatography/mass  spectrometry  detection,  with  electron  impact 
ionisation  (GC-MS-EI)  was  used  for  the  analysis  of  all  the  compounds.  The  concentrations 
of  the  main  metabolite  of  A?  -THC,  i.  e.  A?  -THC-COOH  are  very  low  in  hair.  For  this 
reason  gas  chromatography/mass  spectrometry,  in  negative  ion  chemical  ionisation  mode 
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(GC-MS-NCI)  using  methane  as  the  reagent  gas  was  used  to  detect  A?  -THC-COOH. 
Extraction  recoveries  ranged  from  80.9  to  104.0%  for  2-THC,  76.7-95.8%  for  CBN, 
71.0-94.0%  for  CBD  and  85.9-100.0%  for  A!  -THC-COOH  by  GC-MS-NCI  and  77.7- 
98.9%  by  GC-MS-EI.  LOD's  were  20.00  pg/mg  hair  for  A?  -THC  and  cannabidiol,  50.00 
pg/mg  hair  for  cannabinol  and  0.50  ng/mg  hair  for  A?  -THC-COOH  by  GC-MS-El,  while 
A?  -THC-COOH  by  GC-MS-NCI  was  5.00  pg/mg  hair  [  15  3]. 
The  presence  of  A?  -THC-COOH  in  hair  shows  conclusive  proof  of  cannabis  use  and  for 
this  reason  its  identification  in  hair  is  important.  The  finding  of  the  parent  drug  alone 
could  be  as  a  result  of  environmental  (passive)  contamination.  Since,  the  concentrations  of 
the  main  metabolite  of  A?  -THC,  i.  e.  A?  -THC-COOH  are  very  low  in  hair,  high  sensitivity 
techniques,  high-volume  injection  and  good  clean-up  methods  are  required  [122,153]. 
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4  Analysis  of  Arnfetarnines  and  Cannabinoids 
4.1  Aim 
The  purpose  of  the  following  study  was  to  identify  amfetamines  and  cannabinoids 
simultaneously  in  hair  samples  using  a  single  extraction  procedure.  It  was  necessary  to 
investigate  the  pre-treatment  steps  for  all  of  the  compounds  of  interest  to  optimize  a 
method  for  this  purpose.  Four  pre-treatment  procedures  were  chosen  (enzymatic,  alkaline, 
acid  and  methanol)  for  the  comparison  study.  The  optimised  method  giving  the  highest 
recoveries  would  then  be  selected  to  analyse  these  drugs  in  hair.  The  SPE  method 
developed  by  Chen  et  al  using  Bond  Elut  Certify  columns  has  been  shown  to  be  successful 
in  extracting  a  range  of  drugs  (acidic,  neutral  and  basic  drugs)  in  whole  blood  with  good 
recoveries  [159].  This  method  has  also  been  adapted  for  the  extraction  of  drugs  in 
meconium  [  160]  and  in  oral  fluid  samples  [  16  1]  and  could  be  used  as  a  clean-up  method  to 
extract  drugs  from  pre-treated  hair.  For  this  reason  this  SPE  method  was  selected 
following  pre-treatment  by  the  four  different  methods.  The  best  pre-treatment  method 
would  then  be  validated. 
4.1.1  Experimental 
4.1.1.1  Chemicals  and  Reagents 
AF,  MA,  MDA,  MDMA,  MDEA,  A?  -  THC  and  A?  -  THC-COOH  and  their  deuterated 
internal  standards,  AF-ds,  MA-d5,  MDA-d5,  MDMA-d5,  MDEA-d5,  A?  -  THC-d3  and  A?  - 
THC-COOH-d3  were  purchased  from  Radian  (Teddington,  LTK).  The  derivatising  reagents 
pentafluoropropionic  anhydride  (PFPA)  and  pentafluoropropanol  (PFPOH),  9- 
glucuronidase  (activity  =86.900  units/ml,  sulfatase  activity  =  2,210  units/ml)  and  sodium 
dodecyl  sulphate  (SDS)  were  purchased  from  Sigma  (Dorest,  UK)  and  Bond  Elut 
Certif)Jm  from  Crawford  Scientific  (Strathaven,  UK).  HPLC  grade  solvents,  methanol 
(MeOH),  acetone,  chloroform  (CHCIA  distilled  water  (DI  H20),  ethyl  acetate  (EtOAc), 
hexane,  dichloromethane,  analytical-grade  ammonium  hydroxide,  glacial  acetic  acid, 
potassium-dihydrogen  phosphate,  sodium  hydroxide  (NaOH),  hydrochoric  acid  (HCI)  and 
tartaric  acid  were  obtained  from  Merck  (Poole,  UK). 
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4.1.1.2  Stock  Standards 
All  stock  standards  had  concentrations  of  100  gg/mI.  These  were  stored  in  the  freezer  at  - 
20  'C.  An  amfetamine  working  standard  solution  was  prepared  by  measuring  50  [tI  of 
stock  standards  of  AF,  MA,  MDA,  MDMA  and  MDEA  into  a  large  vial.  This  was  made 
up  to  5  ml  with  methanol  to  give  a1  gg/ml  combined  amfetamines  working  standard.  A 
cannabinoids  working  standard  solution  was  prepared  by  measuring  50  PI  of  stock 
standards  of  A?  -  THC  and  A?  -  THC-COOH  into  a  large  vial.  This  was  made  up  to  5  ml 
with  methanol  to  give  aI  gg/ml  combined  cannabinoid  working  standard.  Amfetamine 
and  cannabinoids  deuterated  internal  standard  solutions  were  similarly  prepared  using  AF- 
d5,  MA-d5,  MDA-d5,  MDMA-d5,  MDEA-d5,  and  A?  -  THC-d3  and  A?  -  THC-COOH-d3  to 
give  a  combined  arnfetamine  deuterated  working  standard  and  a  combined  cannabinoid 
deuterated  working  standard  at  1  gg/ml  . 
4.1.1.3  Instrumentation  (GC-MS) 
A  ThermoQuest  Trace  GC  with  a  Finnigan  Trace  MS  was  used,  fitted  with  a  HP-5 
capillary  column  (30  in  x  0.32  min  x  0.25  gm  film  thickness).  This  was  temperature 
programmed  from  100  to  300  'C  at  a  rate  of  12  'C  /  minute  and  held  at  300  'C  for  5  min. 
The  injector  temperature  was  280  'C.  The  splitless  injection  mode  was  used.  The  carrier 
gas  used  was  helium.  The  temperature  of  the  source  and  interface  were  200  OC  and  250'C 
respectively.  The  emission  current  was  350  gV.  The  injection  volume  was  I  gl.  The 
ionisation  mode  was  electron  impact  with  an  electron  energy  of  70  eV. 
4.1.1.4  Identification  of  Retention  Times  and  Fragmentation 
In  order  to  identify  the  retention  times  and  mass  fragments  of  each  compound  and  its 
deuterated  standard,  100  [tl  of  arnfetarnines  working  standard  solution  and  100  1Al  of 
deuterated  amfetamines  working  standard  solution  all  at  1  gg/ml  were  measured  into  a  vial 
along  with  100  gl  (1  mg/ml)  of  tartaric  acid  in  ethyl  acetate.  The  solvent  was  evaporated 
to  dryness  under  a  stream  of  nitrogen  at  room  temperature  and  the  residue  was  derivatised 
using  60  gl  of  PFPA  /  EtOAc  (0.5:  1  v/v)  at  60  OC  for  30  minutes.  This  was  then 
evaporated  under  nitrogen  and  reconstituted  in  30  gI  EtOAc,  1  gl  of  which  was  injected  for 
analysis  by  GC-MS. 
100  gI  of  cannabinoids  working  standard  solution  and  100  gI  of  deuterated  cannabinoids 
working  standard  solution  all  at  1  gg/ml  were  measured  into  a  vial.  The  solvent  was 
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evaporated  to  dryness  under  a  stream  of  nitrogen  at  room  temperature  and  the  residue  was 
derivatised  using  60  gl  of  PFPA  /  PFPOH  (1:  0.75  v/v)  at  60  OC  for  30  minutes.  This  was 
then  evaporated  under  nitrogen  and  reconstituted  in  30  gl  EtOAc,  1  gl  of  which  was 
injected  for  analysis  by  GC-MS. 
Derivatising  agents  which  were  selected  for  the  above  analysis  were  those  that  are  used 
routinely  in  the  Forensic  Medicine  &  Science  laboratory,  University  of  Glasgow  for  the 
identification  and  measurement  of  amfetamines  and  cannabinoids.  Analyses  were 
perfonned  using  repetitive  full  scan  to  identify  the  retention  times  and  mass  fragments  of 
each  compound  and  their  deuterated  standards. 
4.1.1.4.1  Results 
The  retention  times  and  mass  fragments  were  identified.  Good  peak  shape,  good 
chromatographic  resolution  and  sensitivity  were  obtained  for  each  compound.  The 
retention  times  and  ions  for  each  compound  are  shown  in  Table  4.1.  The  underlined  ions 
were  used  for  quantitation  in  further  analyses.  The  chromatograms  and  mass  spectra  for 
each  compound  are  shown  in  Figure  4.1,  Figure  4.2,  Figure  4.3,  Figure  4.4,  Figure  4.5, 
Figure  4.6,  Figure  4.7,  Figure  4.8,  Figure  4.9,  Figure  4.10,  Figure  4.11,  Figure  4.12,  Figure 
4.13,  Figure  4.14,  Figure  4.15,  Figure  4.16,  Figure  4.17,  Figure  4.18,  Figure  4.19,  Figure 
4.20  and  Figure  4.21. 
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Table  4.1  The  retention  times  (tR),  derivatised  analyte  ions  (m/z)  and  their  cleuterated 
standards 
Analyte 
Retention 
time  (min) 
Main  Tons 
(m/Z)  Figures 
AF  4.34  91,118,190  Figure  4.1  and  Figure  4.8 
AF-ds  4.30  194  Figure  4.1  and  Figure  4.15 
MA  5.52  118,160,204  Figure  4.2  and  Figure  4.9 
MA-d5  5.48  208  Figure  4.2  and  Figure  4.16 
MDA  7.86  135,162,325  Figure  4.3  and  Figure  4.10 
MDA-d5  7.83  330  Figure  4.3  and  Figure  4.17 
MDMA  8.96  135,204,339  Figure  4.4  and  Figure  4.11 
MDMA-d5  8.93  344  Figure  4.4  and  Figure  4.18 
MDEA  9.31  190,21&353  Figure  4.5  and  Figure  4.12 
MDEA-d5  9.28  223  Figure  4.5  and  Figure  4.19 
A!  -THC  12.76  377,417,460  Figure  4.6  and  Figure  4.13 
A!  -THC  A3  12.74  380  Figure  4.6  and  Figure  4.20 
A!  -THC-COOH  14.43  445,459,622  Figure  4.7  and  Figure  4.14 
A!  -THC-COOH-d3  14.41  625  Figure  4.7  and  Figure  4.21 
*The  underlined  ions  were  used  for  quantitation 
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Figure  4.1  GC-MS  Chromatograms  of  PFP  derivatives  of  AF  and  AF-d5 
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Figure  4.2  GC-MS  Chromatograms  of  PFP  derivatives  of  MA  and  MA  -d5 
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Figure  4.3  GC-MS  Chromatograms  of  PFP  derivatives  of  MDA  and  MDA-d5 
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Figure  4.4  GC-MS  Chromatograms  of  PFP  derivatives  of  MDMA  and  MDMA-d5 
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Figure  4.5  GC-MS  Chromatograms  of  PFP  derivatives  of  IVIDEA  and  MDEA-ds 
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Figure  4.6  GC-MS  chromatograms  of  PFP  /  PFPOH  derivatives  of  Y-THC  and  L!  -THC  -d3 
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Figure  4.7  GC-MS  chromatograms  of  PFP  /  PFPOH  derivatives  of  Y 
-THC-COOH  and 
THC-COOH-d3 
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Figure  4.8  Full  scan  Mass  Spectrum  of  PFP  derivative  of  AF 
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Figure  4.9  Full  scan  Mass  Spectrum  of  PFP  derivative  of  MA 
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Figure  4.10  Full  scan  Mass  Spectrum  of  PFP  derivative  of  MDA 
Figure  4.11  Full  scan  Mass  Spectrum  of  PFP  derivative  of  MDMA 
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Figure  4.12  Full  scan  Mass  Spectrum  of  PFP  derivative  of  MDEA 
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Figure  4.13  Full  scan  Mass  Spectrum  of  PFP  derivative  of  2-THC 
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Figure  4.14  Full  scan  Mass  Spectrum  of  PFP  /  PFPOH  derivative  of  L?  -THC-COOH 
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Figure  4.15  Full  scan  Mass  Spectrum  of  PFP  derivative  of  AF-ds 
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Figure  4.16  Full  scan  Mass  Spectrum  of  PFP  derivative  of  MA-ds 
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Figure  4.17  Full  scan  Mass  Spectrum  of  PFP  derivative  of  MDA-ds 
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Figure  4.18  Full  scan  Mass  Spectrum  of  PFP  derivative  of  MDMA-ds 
ampWvas  #1220  RT.  11.14  AV.  I  SB:  2  11.19,11.11  NL:  3.34E6 
T'.  (0,0)+cEldet-500.00  Full  ms  [56.00-650.001 
C 
MIZ 
Figure  4.19  Full  scan  Mass  Spectrum  of  PFP  derivative  of  MDEA-ds 
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Figure  4.20  Full  scan  Mass  Spectrum  of  PFP  derivative  of  h!  -THC  -d3 
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Figure  4.21  Full  scan  Mass  Spectrum  of  PFP  I  PFPOH  derivative  of  THC-COOH-d3 
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4.1.1.5  Optimisation  of  Derivatisation 
In  order  to  optimise  the  derivatisation  procedure  for  amfetamines  and  cannabinoids,  100  gl 
of  amfetamines  standard  solution,  cannabinoids  standard  solution  and  their  deuterated 
standards  all  at  1  gg/ml  were  added  to  a  vial  and  prepared  in  duplicate.  The  derivatisation 
was  carried  out  at  three  different  ratios  of  PFPA  /  EtOAc  (2:  1,1:  2,1:  1)  for  amfetamines 
and  three  different  ratios  of  PFPA  /  PFPOH  (1:  1,1:  0.75,1:  2)  for  cannabinoids. 
4.1.1.5.1  Results 
All  chromatograms  gave  good  peak  shape,  but  the  use  of  different  ratios  of  PFPA  /  EtOAc 
and  PFPA  /  PFPOH  gave  different  intensities  for  the  drugs  of  interest.  The  quantitation  ion 
was  used  to  assess  the  intensity.  The  results  are  presented  in  Table  4.2.  PFPA  /  EtOAC 
(2:  1  v/v)  gave  the  highest  intensity  for  all  the  five  amfetamines  (AF,  MA,  MDA  and 
MDEA)  and  this  ratio  was  selected  for  amfetamines  derivatisation. 
PFPA  /  PFPOH  (1:  0.75  v/v)  was  selected  for  the  cannabinoids  because  the  highest 
intensity  ratio  was  achieved  for  A?  -THC.  PFPA  /  PFPOH  (1:  1  v/v)  gave  the  highest 
intensity  for  A?  -THC-COOH.  However,  there  was  little  difference  observed  between  this 
ratio  and  the  one  at  1:  0.75.  The  complete  results  are  presented  in  Table  4.3. 
Therefore,  the  extracted  solution  by  SPE  was  evaporated  at  room  temperature  under  a  slow 
flow  of  nitrogen  and  derivatised  using  60  ýtl  of  PFPA  /  EtOAc  (  2:  1  v/v)  for  amfetarnines 
and  PFPA  /  PFPOH  (  1:  0.75  v/v)  for  cannabinoids  in  a  sealed  vial  which  was  vortexed 
and  then  placed  into  a  60  'C  heating  block  for  30  minutes.  After  derivatisation  was 
completed,  the  reagents  were  evaporated  under  nitrogen  and  reconstituted  in  30  ýd  EtOAc, 
1  ýtl  of  which  was  injected  for  analysis  by  GC-MS. 
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Table  4.2  The  mean  peak  area  of  amfetamines  with  different  ratios  of  derivatising  agent 
(PFPA  I  EtOAc) 
Derivatising  Reagent 
Ratio 
PFPA:  EtOAc 
2:  1 
1:  2 
1:  1 
Av  rage  Peak  Area 
AF  MA  MDA  MDMA 
190  MIZ  204  m/z  325  m/z  339  m/z 
2090826  5102208  776362  357643 
1554504  3993772  460207  224711 
1524217  1296367  714397  329090 
MDEA 
218  mlz 
10384886 
3763808 
6012077 
Table  4.3  The  mean  peak  area  of  cannabinoids  with  different  ratios  of  derivatising  agents 
(PFPA  /  PFPOH) 
Derivatising  Reagent 
Ratio  Avera 
PFPA:  PFPOH  Y-THC 
377  m/z 
1:  1  2768566 
1:  0.75  3349724 
1:  2  1284828 
4.1.1.6  Buffers  and  Solutions 
0.1  Mphosphate  buffer,  pH  60 
of  Peak  Area  Ratios 
I  A7-THC-COOH 
622  m/z 
43103 
42565 
18808 
6.81  g  of  potassium  dihydrogen  phosphate  (KH2PO4,  FW  =136.09)  was  weighed  into  a  0.5 
litre  volumetric  flask  and  approximately  450  ml  of  distilled  water  was  added.  The  pH  was 
adjusted  to  6.0  (+/  -  0.1)  with  10.0  M  potassium  hydroxide  solution  while  stirring  and  the 
solution  was  made  up  to  0.5  litre  with  distilled  water  and  was  stored  at  5  'C.  The  solution 
was  discarded  after  one  month. 
0.01  M  acetic  acid,  pH  3.3 
57.2  ýd  of  glacial  acetic  acid  was  pipetted  into  a  100  ml  volumetric  flask  and  DI  H20  was 
added  up  to  the  100  ml  mark.  This  was  mixed  well  and  stored  at  room  temperature.  The 
solution  was  discarded  after  two  months. 
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Acetone/  Chloroform  (1:  1  v/v) 
50  ml  of  acetone  and  50  ml  chloroform  were  measured  into  a  bottle,  mixed  well  and 
sonicated  for  10  minutes,  stored  at  room  temperature  and  discarded  afler  one  month. 
EtOAc  /concentrated  ammonia  (98:  2) 
98  ml  EtOAc  was  measured  into  a  bottle  and  2  ml  of  concentrated  ammonia  solution 
(ammonium  hydroxide)  was  added  carefully.  This  was  prepared  under  a  fume  hood  and 
sonicated  for  10  minutes.  This  solution  was  made  up  fresh  every  day. 
Tartaric  Acid  in  EtOAc  (I  mglml) 
5  milligrams  of  tartaric  acid  were  weighed  into  a  large  vial  and  5  ml  of  EtOAc  was  added. 
This  was  sonicated  for  10  minutes,  stored  at  room  temperature  and  discarded  afler  one 
month. 
IMsodium  hydroxide  (NaOH) 
4.0  grams  of  NaOH  (MW  40.0)  pellets  were  measured  into  a  100  ml  volumetric  flask  and 
made  up  to  the  100  ml  mark  with  DI  H20.  This  was  mixed  thoroughly,  stored  at  room 
temperature  and  discarded  after  six  months. 
0.1  M  hydrochoric  acid  (HC1) 
4.2  ml  concentrated  HCI  was  added  to  400  ml  of  DI  H20  and  diluted  to  500  ml  with  DI 
H20  and  mixed  thoroughly.  This  was  stored  at  room  temperature  and  discarded  after  six 
months. 
n-hexane  1EtOAc  (9:  1  v/v) 
90  ml  hexane  was  measured  into  a  bottle  and  added  10  ml.  EtOAc  and  mixed  well,  stored  at 
room  temperature  and  discard  after  one  month. 
n-hexane  1EtOAc  (8:  2  v/v) 
80  ml  hexane  was  measured  into  a  bottle  and  to  this  20  ml  EtOAc  was  added  and  mixed 
well.  This  was  stored  at  room  temperature  and  discarded  after  one  month. 
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4.1.1.7  Preparation  and  Decontamination  of  Hair 
Drug  free  hair  was  obtained  from  volunteers  and  tested  by  the  method,  which  has  been 
used  by  Department  of  Forensic  Medicine  and  Science,  University  of  Glasgow,  to  show  it 
was  negative  for  amfetamines  and  cannabinoids.  In  this  study,  the  decontamination 
procedure  chosen  was  one  that  had  been  used  routinely  for  hair  analysis  by  Forensic 
Medicine  &  Science,  University  of  Glasgow.  Blank  hair  and  case  hair  samples  were 
decontaminated  using  the  following  wash  steps: 
Immersion  in  0.1  %  SDS  detergent,  sonication  for  15  minutes.  Solution  discarded 
(X  1) 
Immersion  in  DI  H20,  sonication  for  15  minutes.  Solution  discarded.  (x  2) 
o  Immersion  in  dichloromethane,  sonication  for  10  minutes.  Solution  collected  for 
analysis  (x  3) 
If  the  last  wash  fraction  of  a  case  hair  sample  was  positive  for  any  of  the  drugs  the 
dichloromethane  wash  step  was  repeated  until  the  wash  fraction  was  free  of  drugs.  Once 
the  last  wash  with  dichloromethane  had  tested  negative  for  the  analytes  of  interest  or was 
less  than  its  limit  of  detection,  the  hair  samples  (both  blank  and  case  samples)  were 
allowed  to  air  dry  overnight  and  were  then  weighed.  Washing  takes  place  prior  to  cutting 
the  hair.  After  drying  the  hair  overnight  at  room  temperature,  the  hair  samples  were  cut 
into  small  segments  (1-2  mm)  and  an  appropriate  amount  weighed  out  into  10-ml  screw- 
capped  tubes. 
4.1.1.8  Hair  Pretreatment  Methods 
To  liberate  the  drug  from  the  hair  matrix,  the  following  pre-  treatment  methods  were  used: 
Alkaline  pre-treatment:  Hair  was  incubated  in  I  ml  of  IM  NaOH  at  95  'C  for  10 
minutes.  After  cooling  to  room  temperature,  I  ml  of  1M  HCI  was  added  to  neutralize  the 
solution  and  2  ml  of  phosphate  buffer,  pH  6.0  was  added.  After  adjusting  with  1M  NaOH 
to  pH  6.0  and  centrifuging  for  20  minutes  at  2000  rpm,  the  supernatant  was  transferred  to  a 
clean  large  vial  for  extraction. 
fl-Glucuronidase  pre-treatment  (helix  parnatia,  86,900  unit  /  ml):  Hair  was  incubated  in 
lml  of  phosphate  buffer  pH  6  and  50  [d  fl-glucuronidase  solution  at  45  'C  for  2  hours. 
After  cooling  to  room  temperature,  2  ml  of  phosphate  buffer  pH  6.0  was  added,  vortex 
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mixed  and  centrifuged  for  20  minutes  at  2000  rpm.  The  supernatant  was  transferred  to  a 
clean  large  vial  for  extraction. 
Methanol  pre-treatment:  Hair  was  incubated  in  I  ml  of  (MeOH)  at  45  OC  for  18  hours. 
After  cooling  to  room  temperature,  the  MeOH  was  transferred  into  a  clean  tube,  4  ml  of 
phosphate  buffer  pH  6.0  was  added,  vortex  mixed  and  centrifuged  for  20  minutes  at  2000 
rpm.  The  supernatant  was  transferred  to  a  clean  large  vial  for  extraction. 
Acid  pre-treatment:  Hair  was  incubated  in  Iml  of  dilute  acid  (0.1  HCI)  at  45  T  for  12 
hours.  After  cooling  to  room  temperature,  I  ml  of  0.1  M  NaOH  was  added  to  neutralize  the 
solution  and  2  ml  of  phosphate  buffer  pH  6.0  was  added.  This  was  centrifuged  for  20 
minutes  at  2000  rpm  and  the  supernatant  was  transferred  to  a  clean  large  vial  for 
extraction. 
4.1.1.9  Solid  Phase  Extraction  Method  for  Amfetamines  and  Cannabinoids 
The  SPE  method  developed  by  Chen  et  al  was  chosen  as  the  clean-up  method  because  it 
has  been  used  to  isolate  a  broad  range  of  drugs  (acidic,  neutral  and  basic  drugs)  from 
whole  blood  with  acceptable  recoveries.  Most  drugs  (acidic,  neutral  and  basic  )  are 
retained  on  the  column  at  pH  6  [159].  This  method  was  investigated  as  a  possible  clean-up 
step  for  the  combined  extraction  of  amfetamines  and  cannabinoids  in  hair. 
SPE  was  carried  out  using  Bond  Elut  CertifyTm  columns.  The  SPE  columns  were 
conditioned  with  2  ml  of  methanol  and  2  ml  of  phosphate  buffer  (pH  6,  OAM)  in 
preparation  to  receiving  an  aqueous  sample.  The  samples  were  applied  to  the  column, 
taking  at  least  two  minutes  to  pass  through  the  column.  The  column  was  then  washed  with 
1  ml  DI  H20  to  remove  endogenous  and  interference  components.  0.5  ml  0.01  M  acetic 
acid  (pH  3.3)  was  added  to  adjust  the  pH  of  extraction.  It  was  reported  that  pH  3.3  was  the 
best  choice  to  adjust  the  extraction  system  to  elute  the  acids  or  basic  drugs  selectively  from 
the  column.  The  column  was  dried  under  full  vacuum  for  5-10  minutes  and  50  [LI  of 
methanol  was  added.  This  was  dried  for  a  further  3  minutes  under  full  vacuum.  The 
cannabinoids  were  eluted  with  3.5  ml  of  acetone/chloroform  (1:  1  v/v)  [162].  The 
amfetamines  were  eluted  with  2  ml  of  2%  concentrated  ammonia  in  ethyl  acetate  [159, 
162].  100  R1  tartaric  acid  was  added  to  prevent  amfetamines  from  evaporating  [  114].  The 
elution  solutions  were  evaporated  at  room  temperature  under  a  slow  flow  of  nitrogen  and 
the  acetone  /  chloroform  fraction  residue  was  derivatised  as  described  in  section  4.1.1.5.1 
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for  cannabinoids  and  the  EtOAc  /  ammonia  fraction  residue  was  derivatised  as  described  in 
section  4.1.1.5.1  for  amfetamines. 
Calibration  Curves 
The  purpose  of  this  initial  experiment  was  to  investigate  the  simultaneous  extraction  of 
amfetamines  and  cannabinoids  using  the  four  pre-treatment-methods.  Each  of  the  pre- 
treatment  methods  described  in  section  4.1.1.8  were  used  on  30  mg  hair  samples  which 
were  spiked  with  5,10,25,50,100  and  200  ýd  AF,  MA,  MDA,  MDMA,  MDEA,  A?  -THC 
and  2 
-THC-COOH  of  working  standard  solution  and  100  ýtl  of  deuterated  working 
standard,  all  at  1  gg/ml  to  give  a  six  point  calibration  curve.  A  blank  hair  sample  without 
standard  or  internal  standard  and  a  blank  hair  sample  with  only  100  gl  of  internal  standard 
were  also  prepared  and  extracted.  The  solid  phase  method  described  in  4.1.1.9  was  used  to 
clean  up  the  hair  samples.  These  were  derivatised  as  described  in  sections  4.1.1.5.1. 
4.1.1.10.1  Calibration  Curves  Result 
The  peak  area  ratios  (PAR)  of  AF,  MA,  MDA,  MDMA  and  MDEA  to  their  deuterated 
internal  standards  were  calculated  and  calibration  curves  of  PAR  against  concentration 
were  plotted  for  each  compound.  The  results  demonstrated  that  all  extraction  methods 
worked  well  for  amfetamines  which  had  been  added  to  hair.  The  linearities  are 
summarised  in  Table  4.4  and  Table  4.5,  and  shown  in  Figure  4.22,  Figure  4.23,  Figure 
4.24,  Figure  4.25  and  Figure  4.26. 
In  contrast,  the  cannabinoid  results  were  poor.  The  detection  limits  for  these  appeared  to 
be  low  as  shown  by  their  low  peak  areas  in  comparison  to  unextracted  standards. 
Calibration  curves  could  not  be  plotted  for  these  and  further  investigation  was  required  to 
improve  the  recovery. 
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Table  4.4  Linearity  of  amfetamines  with  different  extraction  methods 
An  Concentration 
1.000 
1.000 
0.999 
0.999 
1.000 
Correlation  coefficients 
AF 
MA 
MDA 
MDMA 
MDEA 
5-  200 
5-  200 
5-  200 
5-  200 
5-  200 
Alkaline  Acid 
0.998  0.994 
0.997  0.994 
0.994  0.999 
0.996  0.999 
0.997  1.000 
Methanol 
0.998 
1.000 
0.992 
0.999 
1.000 
Table  4.5  Linear  Values  of  amfetamines  with  different  extraction  methods 
Analyte  Enzy  matic  Alkaline  Acid  Methanol 
-  Intercept  Slope  Intercept  Slope  Intercept  Slope  Intercept  Slope 
AF  0.0267  0.0121  -0.0100  0.0097  0.0087  0.0092  -0.0494  0.0082 
MA  0.0109  0.0074  -0.0159  0.0097  0.0360  0.0071  -0.0382  0.0125 
MDA  0.0360  0.0121  -0.0524  0.0107  -0.0379  0.0120  -0.1477  0.0145 
MDMA  0.0164  0.0124  0.0124  0.0103  -0.0517  0.0120  -0.0037  0.0113 
MDEA  0.0037  0.0017  -0.0295  0.0118  -0.0219  0.0095  -0.0067  0.0080 
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Figure  4.22  Calibration  curve  of  AF  with  different  pre-treatment  methods 
3 
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Figure  4.23  Calibration  curve  of  MA  with  different  pre-treatment  methods 
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Figure  4.24  Calibration  curve  of  MDA  with  different  pre-treatment  methods 
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Figure  4.25  Calibration  curve  of  MDMA  with  different  pre-treatment  methods 
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Figure  4.26  Calibration  curve  of  MDEA  with  different  pre-treatment  methods 
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4.1.1.11  SPE  Recovery  Study 
As  a  result  of  the  difficulties  in  plotting  the  cannabinoids  calibration  curves,  a  recovery 
study  of  the  SPE  method  was  investigated  for  all  compounds  of  interest.  This  included  the 
recovery  of  AF,  MA,  MDA,  MDMA,  MDEA,  A?  -THC  and  A?  -THC-COOH  without  the 
presence  of  hair  using  the  SPE  method  alone.  200  pI  of  amfetamines  working  standard 
solution  and  200  pI  of  cannabinoids  working  standard  solution  all  at  1  gg/ml  were 
measured  into  a  test  tube.  3  ml  of  0.1  M  phosphate  buffer,  pH  6  were  added  and  the 
solution  was  vortex  mixed.  This  was  prepared  in  triplicate.  The  solutions  were  extracted 
using  the  SPE  method  described  in  section  4.1.1.9.200  pl  of  deuterated  amfetamines 
standard  solution  and  200  gl  of  deuterated  cannabinoids  standard  solution,  all  at  I  gg/ml 
were  added  after  extraction.  The  solution  was  evaporated  to  dryness  and  derivatised  as 
described  in  section  4.1.1.5.1. 
4.1.1.11.1  Recovery  Study  Results 
The  recoveries  were  determined  by  comparing  the  PAR  of  extracted  standards  to  the  PAR 
of  the  unextracted  standards.  The  results  showed  that  the  SPE  was  successful  for  all  of  the 
compounds  and  the  recovery  was  greater  than  64  %  for  all  of  the  compounds.  The  results 
are  represented  in  Table  4.6. 
Table  4.6  Recovery  of  cannabinolds  and  arnfetamines  by  SPE  at  pH  6  without  hair  (n  =  3) 
Analyte  Mean  Peak  Area  Ratio  S.  D  %CV 
_ 
%Recovery 
Ext  Uext  Ext  Uext  Ext  I  Uext 
A!  -  THC  0.10  0.16  0.01  0.01  7.9  3.4  64.2 
2 
-THC-COOH  1.11  1.54  0.23  0.06  20.4  3.8  72.1 
AF  1.31  1.73  0.07  0.35  5.5  20.1  75.4 
MA  0.93  1.20  0.11  0.05  11.6  4.2  77.6 
MDA  0.96  1.17  0.12  0.00  12.8  0.4  82.2 
MDMA  1.35  1.65  0.20  0.01  14.9  0.3  81.5 
MDEA  0.13  0.15  0.01  0.00  5.6  2.2  89.0 
V,  xt:  txtractecl,  Uext:  Unextracted 
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4.1.1.12  Recovery  Study  Using  Alkaline  Digestion  Followed  by  SPE 
The  recoveries  of  AF,  MA,  MDA,  MDMA  and  MDEA,  A?  -THC  and  Y 
-THC-COOH  from 
spiked  hair  using  alkaline  pre-treatment  followed  by  SPE  were  investigated.  Alkaline  pre- 
treatment  was  chosen  initially  because  of  its  ability  to  completely  dissolve  the  hair 
matrices  and  therefore  to  release  the  drugs  completely  from  authentic  hair  samples  [163]. 
200  gI  of  amfetamines  working  standard  solution  and  200  gI  of  cannabinoids  working 
standard  solution  all  at  I  gg/ml  were  measured  into  a  test  tube  containing  30  mg  of  blank 
hair.  1  ml  of  IM  NaOH  was  added  and  the  solution  was  vortex  mixed.  The  solution  was 
incubated  at  95  T  for  10  minutes.  After  cooling  to  room  temperature,  I  ml  of  1M  HCL 
was  added  to  neutralize  the  solution  and  2  ml  of  phosphate  buffer,  pH  6.0  was  added. 
After  adjusting  to  pH  6.0  with  1.0  M  NaOH,  the  solution  was  centrifuged  for  20  minutes  at 
2000  rpra  and  the  supernatant  transferred  to  a  clean  large  vial  for  extraction  as  described  in 
section  4.1.1.9.  This  was  prepared  in  triplicate.  The  deuterated  working  standards  were 
added  after  the  extraction.  The  solution  was  evaporated  to  dryness  and  derivatised  as 
described  in  section  4.1.1.5.1. 
4.1.1.12.1  Recovery  Results 
The  recoveries  were  determined  by  comparing  the  PAR  of  extracted  spiked  blank  hair  (30 
mg)  standards  to  the  PAR  of  the  unextracted  standards.  The  results  showed  that  the 
recovery  of  cannabinoids  had  significantly  decreased  when  alkaline  pre-treatment  was  used 
followed  by  SPE.  On  the  other  hand  the  amfetamines  were  not  affected.  The  results  are 
represented  in  Table  4.7. 
Table  4.7  Recovery  of  cannabinoids  and  amfetamines  by  alkaline  pre-treatment  (n  =  3) 
Analyte  Mean  Peak  Area  Ratio  S.  D  %CV 
Ext  Uext  Ext  I  Uext  Ext  I  Uext 
A?  -  THC  0.21  1.50  0.04  0.11  18.3  7.1 
h?  -THC-COOH  0.24  2.04  0.04  0.35  18.3  17.4 
AF  1.42  1.77  0.05  0.03  3.8  1.8 
MA  0.58  0.66  0.05  0.03  8.0  4.8 
MDA  0.75  0.90  0.01  0.03  0.7  3.4 
MDMA  0.89  1.14  0.02  0.05  2.7  4.2 
MDEA  0.11  0.13  0.00  0.01 
1 
1.3  4.3 
Ext:  Extracted,  Uext:  Unextracted 
%Recovery 
13.8 
11.9 
80.2 
88.7 
82.8 
77.9 
80.7 
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Conclusion 
The  low  recoveries  obtained  for  cannabinoids  after  alkaline  pre-treatment  followed  by  SPE 
showed  that  the  method  was  not  sufficiently  sensitive  for  the  detection  and  quantification 
of  cannabinoids  in  hair.  Consequently,  the  method  required  further  investigation  to 
improve  the  recovery  of  the  cannabinoids  by  this  proposed  method.  Also,  the  inability  to 
plot  calibration  curves  for  all  pretreatment  methods  showed  that  further  investigation  was 
needed. 
4.1.1.14  Method  Modification  for  Cannabinoids 
4.1.1.14.1  Change  in  Eluent 
Further  investigations  were  carried  out  with  a  minor  modification  of  the  method  by  using 
four  different  eluents  for  the  cannabinoids.  These  were  acetone/chloroform  (1:  1  v/v), 
hexane  /  EtOAc  (9:  1  v/v),  hexane  /  EtOAc  (8:  2  v/v)  and  methanol.  Other  studies  have 
used  different  eluents  to  elute  cannabiniods  at  pH  6  by  using  Bond  Elut  Certify  SPE 
columns.  These  gave  acceptable  recoveries  from  saliva,  urine  and  plasma.  For  this  reason, 
the  eluents  hexane  /  EtOAc  (9:  1,  v/v),  hexane  /  EtOAc  (8:  2,  v/v)  and  methanol  were  used 
[164,165]. 
200  pI  of  amfetamines  working  standard  solution  and  200  gl  of  cannabinoids  working 
standard  solution  all  at  1  gg/ml  were  measured  into  a  test  tube  containing  30  mg  of  blank 
hair.  I  ml  of  IM  NaOH  was  added  and  the  solution  was  vortex  mixed.  The  solution  was 
incubated  at  95  'C  for  10  minutes.  After  cooling  to  room  temperature,  1  ml  of  1M  HCI 
was  added  to  neutralize  and  2  ml  of  phosphate  buffer,  pH  6.0  was  added.  After  adjusting 
to  pH  6.0  with  1.0  M  NaOH,  the  solution  was  centrifuged  for  20  minutes  at  2000  rpm and 
the  supernatant  transferred  to  a  clean  large  vial  for  extraction  as  described  in  section 
4.1.1.9.  The  acetone  /  chloroform  step  was  replaced  with  hexane  /  EtOAc  (9:  1  v/v), 
hexane  /  EtOAc  (8:  2  v/v)  or  methanol  to  elute  the  cannabinoids.  Each  eluent  was  tested  in 
triplicate.  The  solution  was  evaporated  to  dryness  and  derivatised  as  described  in  section 
4.1.1.5.1.  The  deuterated  working  standard  was  added  after  extraction,  prior  to 
derivatisation. 
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4.1.1.14.1.1  Results 
The  recovery  of  A?  -THC  did  not  significantly  improve  with  the  change  in  the  eluents  and 
also  gave  poor  reproducibility  as  shown  by  the  high  %  CVs.  The  recovery  of  the  A?  -THC- 
COOH  was  approximately  three  times  higher  using  eluent  Hexane  /  EtOAc  (8:  2  v/v)  than 
the  original  method  using  acetone/chlorofonn  with  good  %  CV  reproducibility.  The 
methanol  eluent  did  not  elute  the  target  compounds.  The  recoveries  of  anifetamines  were 
not  affected  when  the  cannabinoids  eluent  changed.  The  complete  results  are  shown  in 
Table  4.8,  Table  4.9,  Table  4.10,  Table  4.11,  Table  4.12,  Table  4.13  and  Table  4.14. 
Table  4.8  Recovery  of  A!  -THC  with  different  eluents  at  pH  6  (n=3) 
Eluent 
Acetone  /  Chloroform  (1:  1  vIv) 
Hexane  I  EtOAc  (9:  1  v/v) 
Hexane  I  EtOAc  (8:  2  vIv) 
Methanol 
Ext:  Extracted,  Uext:  Unextracted 
A9-  THC 
Mean  Peak  S.  D  %CV 
Area  Ratio 
II 
%Recovery 
Ext  Uext  Ext  I  Uext  I  Ext  I  Uext  I  ----F  -Uext 
0.02  1  0.13  1  0.03  1  0.01  1  14.9  1  4.3  1  12.8 
0.02  0.13  0.01  0.01  35.9  4.3  13.9 
0.02  0.13  0.01  0.01  28.6  4.3  14.6 
0.00 
- 
0.13 
- 
0.00 
- 
0.01 
- 
0.0  4.3  0.0 
Table  4.9  Recovery  of  Y-THC-COOH  with  different  eluents  at  pH  6  (n=3) 
Eluent 
Acetone  /  Chloroform  (1:  1  v/v) 
Hexane  I  EtOAc  (9:  1  v/v) 
Hexane  I  EtOAc  (8:  2  v/v) 
Methanol 
Ext:  Extracted,  Uext:  Unextracted 
9 
A  -THC-COOH 
Mean  Peak  S.  D  %CV 
Area  Ratio 
Ext  Uext  Ext  Uext  Ext  Uext 
0.20  1.66  0.04  0.21  17.1  12.4 
0.06  1.66  0.01 
0.54  1.66  0.03 
0.00  1.66  0.00 
0.21  19.4  12.4 
0.21  5.7  12.4 
0.21  0.0  12.4 
%Recovery 
12.4 
3.8 
32.3 
0.0 
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Table  4.10  Recovery  of  AF  with  different  eluents  at  pH  6  (n=3) 
AF 
Eluent 
Acetone  /  Chloroform  (1:  1  vIv) 
Hexane  /  EtoAc  (9:  1  v/v)) 
Hexane  I  EtoAc  (8:  2  v/v) 
Methanol 
Ext:  Extracted,  Uext:  Unextracted 
Mean  Peak 
Area  Ratio 
S.  D  CV 
%Recovery 
-E  -xt  T  -ue 
xt  Ext  I  Llext  Ext  I  Llext  I 
1.97  1  2.56  1  0.23  1  0.29  1  12.9  1  11.3  1  76.9 
2.09  2.56  0.25  0.29  11.9  11.3  81.5 
2.01  2.56  0.11  0.29  5.6  11.3  78.5 
1.85  2.56  0.11  0.29  6.1  11.3  72.5 
Table  4.11  Recovery  of  MA  with  different  eluents  at  pH  6  (n=3) 
MA 
Eluent 
Acetone  /  Chloroform  (1:  1  v/v) 
Hexane  EtoAc  (9:  1  v/v)) 
Hexane  EtoAc  (8:  2  v/v) 
Methanol 
Ext:  Extracted,  Uext:  Unextracted 
Mean  Peak  S.  D  %  CV 
Area  Ratio 
II 
%Recovery 
Ext  Uext  Ext  I  Uext  I  Ext  I  Uext  I  ----F-Uex 
0.81  1  1.04  1  0.11  1  0.13  1  17.4  1  12.6  1  78.1 
0.79  1.04  0.03  0.13  3.9  12.6  75.5 
0.82  1.04  0.01  0.13  1.7  12.6  79.1 
0.75  1.04  0.08  0.13  10.7  12.6  71.7 
Table  4.12  Recovery  of  MDA  with  different  eluents  at  pH  6  (n=3) 
Eluent 
MDA 
Acetone  I  Chloroform  (1:  1  v/v) 
Hexane  EtoAc  (9:  1  v/v)) 
Hexane  EtoAc  (8:  2  v/v) 
Methanol 
Ext:  Extracted,  Uext:  Unextracted 
Mean  Peak 
Area  Ratio 
S.  D  %  CV 
%  Recovery 
Ext  Uext  Ext  Uext  Ext  Uext 
1.03  1.35  0.12  0.11  13.0  7.9  74.6 
0.97  1.35  0.05  0.11  5.3  7.9  71.7 
1.04  1.35  0.02  0.11  2.0  7.9  77.0 
1.06  1.35  0.16  0.11  15.2  7.9  78.6 
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Table  4.13  Recovery  of  MDMA  with  different  eluents  at  pH  6  (n=3) 
Eluent 
Acetone  I  Chloroform  (1:  1  v/v) 
Hexane  EtoAc  (9:  1  v/v)) 
Hexane  EtoAc  (8:  2  v/v) 
Methanol 
Ext:  Extracted,  Uext:  Unextracted 
MDMA 
Mean  Peak  0 
Area  Ratio 
S.  D  I  /a  CV 
%Recovery 
Ext  I  Uext  Ext  I  Uext  I  Ext  I  Uext  I 
1.15  1  1.45  1  0.10  1  0.07  1  10.0  1  4.7  1  79.4 
1.13  1.45  0.08  0.07  7.1  4.7  77.9 
1.20  1.45  0.03  0.07  2.7  4.7  82.8 
1.07  1.45  0.04  0.07  4.0  4.7  74.1 
Table  4.14  Recovery  of  MDEA  with  different  eluents  at  pH  6  (n=3) 
I 
Eluent 
Acetone  /  Chloroform  (1:  1  v/v) 
Hexane  EtoAc  (9:  1  v/v)) 
Hexane  EtoAc  (8:  2  vIv) 
Methanol 
Ext:  Extracted,  Uext:  Unextracted 
M  DEA 
Mean  Peak  S.  D  %  CV 
Area  Ratio  %  Recovery 
Ext  Uext  Ext  Uext  Ext  Uext 
0.12  0.15  0.02  0.01  19.9  6.08  77.6 
0.11  0.15  0.01  0.01  5.06  6.08  73.7 
0.11  0.15  0.01  0.01  5.41  6.08  76.5 
0.11  0.15  0  0.01  4.21  6.08  72.4 
4.1.1.14.2  Change  in  Phosphate  BufferpH 
A  further  study  was  carried  out  to  investigate  how  the  pH  of  the  phosphate  buffer  affected 
the  recovery  of  the  cannabinoids.  The  pH  of  the  phosphate  buffer  was  changed  to  pH  5,7 
and  8. 
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200  gI  of  amfetamines  working  standard  solution  and  200  gl  of  deuterated  cannabinoids 
working  standard  solution  all  at  1  gg/ml  were  measured  into  a  test  tube  containing  30  mg 
of  blank  hair.  I  ml  of  IM  NaOH  was  added  and  the  solution  was  vortex  mixed.  The 
solution  was  incubated  at  95  'C  for  10  minutes.  After  cooling  to  room  temperature,  I  ml 
of  1M  HCI  was  added  to  neutralize  the  solution.  Phosphate  buffer  was  added  at  either  pH 
5,6,7  or  8.  Each  solution  was  ad  usted  to  pH  5,6,7  or  8  using  either  1.0  M  NaOH  or  1M  i 
HCI  and  centrifuged  for  20  minutes  at  2000  rpm.  The  supernatant  was  transferred  to  a 
clean  large  vial  for  extraction  as  described  in  section  4.1.1.9.  The  solution  was  evaporated 
to  dryness  and  derivatised  as  described  in  section  4.1.1.5.1.  Each  buffer  was  tested  in 
triplicate.  The  deuterated  working  standard  was  added  after  extraction,  prior  to 
derivatisation. 
4.1.1.14.2.1  Results 
The  recoveries  of  the  target  compounds  increased  with  increasing  pH,  pH  8  giving  the 
highest  recoveries.  The  recovery  of  the  A?  -THC  and  A?  -THC-COOH  increased  three  and 
five  times  respectively  from  the  original  method  using  pH  6  and  both  showed  satisfactory 
%  CV  reproducibility.  The  recoveries  of  amfetamines  were  not  affected  and  their  results 
demonstrated  that  pH  6  yielded  the  highest  recoveries  for  all  five  amfetamines.  The  results 
are  shown  in  Table  4.15,  Table  4.16,  Table  4.17,  Table  4.18,  Table  4.19,  Table  4.20  and 
Table  4.21. 
Table  4.15  Recovery  of  Y-THC  with  varying  buffer  pH  (n  =3) 
Mean  Peak  Area  Ratio 
PH  Ext  Uext 
5  0.08  1.5 
610.21  1  1.5 
0.14  1  1.5 
810.73  1  1.5 
Ext:  Extracted,  Uext:  Unextracted 
9  A  -THC 
S.  D  %  cv 
Ext  Uext  Ext  Uext  %  Recov 
0.02  0.11  29.7  7.1  5.3 
0.06  0.11  27.5  7.1  13.7 
0.05  0.11  33.7  7.1  9.0 
0.12  0.11  16.4  7.1  49.0 
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Table  4.16  Recovery  of  Y 
-THC-COOH  with  varying  buffer  pH  (n  =3) 
Mean  Pea  k  Area  Ratio 
PH  Ext  Uext 
5  0.25  2.04 
6  0.26  2.04 
7  0.42  2.04 
8  1.26  2.04 
Ext:  Extracted,  Uext:  Unextracted 
9  A  -THC-COOH 
S 
.D 
%  cv 
Ext  Uext  Ext  Uext 
0.12  0.35  48.1  17.4 
0.05  0.35  17.2  17.4 
0.17  0.35  40.1  17.4 
0.03  0.35  2.6  17.4 
Table  4.17  Recovery  of  AF  with  varying  buffer  pH  (n  =  3) 
AF 
Mean  Peak  Area  Ratio  S 
.D 
PH  Ext  Uext  Ext  Uext 
5  1.42  1.77  0.2  0.03 
6  1.44  1.77  0.05  0.03 
7  1.14  1.77  0.11  0.03 
8  1.05  1.77  0.12  0.03 
Ext:  Extracted,  Uext:  Unextracted 
Table  4.18  Recovery  of  MA  with  varying  buffer  pH  (n  =  3) 
%  cv 
Ext  Uext 
14.2  1.8 
3.3  1.8 
9.2  1.8 
10.9  1.8 
12.2 
12.9 
20.5 
61.8 
Recovery 
80.3 
81.1 
64.1 
59.5 
MA 
Mean  Peak  Area  Ratio  S.  D  %  cv 
PH  Ext  Uext  Ext  Uext  Ext  Uext  %  Reco) 
5  0.55  0.66  0.10  0.03  17.5  4.8  84.4 
6  0.57  0.66  0.03  0.03  5.3  4.8  87.2 
7  0.48  0.66  0.15  0.03  31.3  4.8  72.7 
8  0.49  0.66  0.09 
1 
0.03  17.8  4.8  75.1 
Ext:  Extracted,  Uext:  Unextracted 
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Table  4.19  Recovery  of  MDA  with  varying  buffer  pH  (n  =  3) 
Mean  Peak  Area  Ratio 
PH  Ext  Uext 
5  0.77  0.90 
6  0.79  0.90 
7  0.65  0.90 
8  0.58  0.90 
MDA 
S.  D 
-E-x-t  -TUext 
0.09  0.03 
0.08  0.03 
0.05  0.03 
0.10  0.03 
%  cv 
Ext  Uext 
11.3  0.03 
9.8  0.03 
8.4  0.03 
16.4  0.03 
RecoN 
Ext:  Extracted,  Uext:  Unextracted 
Table  4.20  Recovery  of  IVIDMA  with  varying  buffer  pH  (n  =  3) 
Mean  Peak  Area  Ratio 
PH  Ext  Uext 
5  0.89  1.14 
6  0.91  1.14 
7  0.80  1.14 
8  0.73  1.14 
MDMA 
S.  D 
-Ex-t-  T  Uext 
0.13  0.05 
0.04  0.05 
0.06  0.05 
0.12  0.05 
%  cv 
Ext  Uext 
15.0  4.2 
3.8  4.2 
8.1  4.2 
15.8  4.2 
85.6 
87.6 
71.5 
64.8 
Recove 
Ext:  Extracted,  Uext:  Unextracted 
Table  4.21  Recovery  of  MDEA  with  varying  buffer  pH  (n  =  3) 
Mean  Peak  Area  Ratio 
PH  Ext  Uext 
5  0.11  0.13 
6  0.11  0.13 
7  0.10  0.13 
8  0.09  0.13 
MDEA 
S.  D 
Ext  T  Uext 
0.01  0.01 
0.01  0.01 
0.01  0.01 
0.02  0.01 
%  cv 
Ext  Uext 
12.0  4.3 
6.9  4.3 
5.2  4.3 
18.8  4.3 
78.0 
80.1 
69.8 
64.4 
Reco) 
Ext:  Extracted,  Uext:  Unextracted 
80.0 
84.1 
75.2 
66.5 
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4.1.1.14.3  Recovery  of  Cannabinoids  with  Phosphate  BufferpH  8  and  Eluent  hexanel 
EtOAc  (v/v) 
The  recovery  of  the  cannabinoids  from  hair  using  the  best  eluent  and  best  buffer  pH, 
hexane  /  EtOAc  (8:  2  v/v)  and  phosphate  buffer  at  pH  8  was  investigated.  The  purpose  of 
this  experiment  was  to  check  if  the  modifications  made  an  enhanced  improvement  to  the 
method. 
200  ýtl  of  amfetamines  working  standard  solution  and  200  ýtl  of  deuterated  cannabinoids 
working  standard  solution  all  at  I  gg/ml  were  measured  into  a  test  tube  containing  30  mg 
of  blank  hair.  Alkaline  pre-treatment  and  SPE  were  carried  out  as  before  with  the 
modifications  being  hexane  /  EtOAc  as  eluent  and  pH  of  buffer  8.1  ml  of  IM  NaOH  was 
added  and  the  solution  was  vortex  mixed.  The  solution  was  incubated  at  95  T  for  10 
minutes.  After  cooling  to  room  temperature,  I  ml  of  1M  HCI  was  added  to  neutralize  the 
solution  and  2  ml  of  phosphate  buffer,  pH  8.0  was  added.  After  adjusting  with  1.0  NaOH 
to  pH  8.0  and  centrifuging  for  20  minutes  at  2000  rpm,  the  supernatant  was  transferred  to  a 
clean  large  vial  for  extraction  as  described  in  section  4.1.1.9.  SPE  was  carried  out  as 
before,  but  hexane  /  EtOAc  (8:  2  v/v)  was  used  instead  of  acetone  /  chloroform  (1:  1  v/v)  as 
eluent.  This  was  prepared  in  triplicate.  The  solution  was  evaporated  to  dryness  and 
derivatised  as  described  in  section  4.1.1.5.1.  The  deuterated  working  standard  was  added 
after  extraction,  prior  to  derivatisation. 
The  same  experiment  was  repeated.  Standards  were  made  up  as  previously  described  and 
they  were  measured  into  a  test  tube  without  the  presence  of  hair.  The  purpose  of  this 
experiment  was  to  check  if  there  was  interference  from  hair  matrices  causing  the  decrease 
in  the  cannabinoids  recovery. 
4.1.1.14.3.1  Results 
The  results  demonstrated  that  a  low  recovery  of  cannabinoids  still  persisted  in  the  presence 
of  hair.  The  second  experiment  without  the  presence  of  hair  showed  that  the  cannabinoids 
recovery  was  not  significantly  changed.  Unsatisfactory  %  CV  reproducibility  was  also 
shown  both  with  and  without  the  presence  of  hair.  The  complete  results  are  shown  in 
Table  4.22. 
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Table  4.22  Recovery  of  cannabinoids  and  amfetamines  with  and  without  presence  of  hair  (n 
=3) 
Mean  Peak 
Area  Ratio  S.  D  %  Cv 
Analyte  Ext  Unext  Ext  Unext  Ext  Unext  %Recovery  Comment 
Y-THC  0.21  0.82  0.06  0.02  30.3  2.0  25.4  With  Hair 
Without 
0.24  0.82  0.04  0.02  17.4  2.0  29.2  Hair 
Y 
-THC-COOH  0.05  1.65  0.02  0.06  45.8  3.5  3.2  With  Hair 
Without 
0.16  1.65  0.05  0.06  34.1  3.5  9.5  Hair 
AF  1.78  2.24  0.11  0.03  6.0  1.4  79.3  With  Hair 
Without 
1.82  2.24  0.11  0.03  6.3  1.4  81.4  Hair 
MA  0.94  1.20  0.02  0.02  2.2  1.9  78.0  With  Hair 
Without 
1.01  1.20  0.08  0.02  8.2  1.9  83.9  Hair 
MDA  1.01  1.36  0.03  0.03  2.5  2.6  74.4  With  Hair 
Without 
1.06  1.36  0.04  0.03  3.4  2.6  77.9  Hair 
MDMA  1.22  1.62  0.02  0.01  1.3  0.7  75.2  With  Hair 
Without 
1.37  1.62  0.03  0.01  1.9  0.7  84.6  Hair 
MDEA  0.95  1.20  0.04  0.03  4.4  2.1  79.8  With  Hair 
Without 
1.03  1.20  0.02  0.03  2.0  2.1  85.9  Hair 
4.1.1.14.4  Discussion  and  Conclusion 
The  original  SPE  method  alone  without  the  inclusion  of  pre-treatment  methods  gave 
acceptable  recoveries  for  all  of  the  compounds,  AF,  MA,  MDA,  MDMA,  MDEA,  A?  -THC 
and  A?  -THC-COOH.  With  alkaline  pre-treatment  and  other  pre-treatment  methods  the 
recovery  of  A?  -THC  and  Y 
-THC-COOH  decreased  significantly  as  shown  by  the  lack  of 
detection  of  lower  standard  concentrations  (5-50  ng/30mg).  The  combination  of  alkaline 
pre-treatment  with  SPE  was  not  a  successful  combination  for  the  cannabinoids.  On  the 
other  hand,  the  amfetamines  recoveries  were  not  affected. 
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Modifications  to  the  method  were  made  by  changing  the  eluent  and  pH.  The  eluent  change 
showed  little  improvement  in  recovery  and  unsatisfactory  reproducibility  for  A!  -THC  as 
shown  by  the  high  %  CVs.  The  recovery  of  A?  -THC-COOH  was  improved  and  also  gave 
good  reproducibility  with  Hexane  /  EtOAc  (8:  2  v/v)  as  the  eluent  compared  with  the 
original  eluent,  acetone/chlorofonn.  The  recoveries  of  A?  -THC  and  A!  -THC-COOH  were 
significantly  increased  with  change  in  pH  and  the  highest  recoveries  for  both  compounds 
were  found  at  pH  8  with  satisfactory  reproducibility.  However,  the  improvement  was  still 
insufficient  to  meet  the  required  limits  of  detection. 
With  the  best  eluent  and  best  buffer  pH,  hexane  /  EtOAc  (8:  2  v/v)  and  phosphate  buffer  at 
pH  8,  the  recovery  of  the  A?  -THC  and  A?  -THC-COOH  were  not  improved.  The  recovery 
of  A?  -THC  and  A?  -THC-COOH  with  and  without  the  presence  of  hair  using  the  best  eluent 
and  best  buffer  pH  did  not  show  a  significant  change  and  their  %  CV  reproducibility  was 
also  poor  with  and  without  the  presence  of  hair.  The  results  of  this  experiment 
demonstrated  that  the  presence  of  hair  did  not  affect  the  cannabinoids  recovery. 
The  low  recoveries  of  this  method  meant  that  it  was  not  suitable  for  the  detection  of 
cannabinoids  with  low  concentrations  in  hair  samples,  especially  for  the  metabolite  which 
incorporates  into  hair  at  very  low  concentrations.  The  method  could  possibly  be  improved 
by  using  a  more  sensitive  technique  such  as  GC-MS-NCI  or  GC-MS/MS  [10,134,153, 
155,156].  Further  studies  are  needed  to  investigate  the  influence  of  the  combination  of 
alkaline  pre-treatment  and  other  pre-treatment  methods  with  SPE.  Otherwise,  the  analysis 
of  cannabinoids  must  be  investigated  using  a  separate  validated  method.  The  difficulty  of 
A?  -THC  and  A?  -THC-COOH  determination  in  hair  samples  has  also  been  reported  by 
Moeller  et  al  [95].  This  method  used  fl-glucuronidase/aryl-sulfatase  followed  by  SPE  with 
acetone/dichloro  form  (3:  1)  as  eluent,  PFPA/PFPOH  as  derivatising  agents  and  analysis  by 
GC-MS  with  EI  detection. 
4.2  Comparison  of  Pretreatment  Methods  for  Amfetamine 
Comparison  of  four  pre-treatment  methods,  NaOH,  fl-Glucuronidase,  HCI  and  MeOH  was 
carried  out  for  AF  only.  This  was  because  there  was  a  difficulty  in  obtaining  hair  samples 
that  were  positive  for  all  five  amfetamine  compounds.  An  authentic  case  sample  was  used 
to  investigate  the  recovery  of  AF  by  each  of  the  methods.  This  sample  had  previously 
been  analysed  by  Forensic  Medicine  and  Science,  University  of  Glasgow  and  was  already 
known  to  be  positive  for  AF. 
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Blank  and  case  hair  samples  were  decontaminated  using  the  same  procedure  described  in 
section  4.1.1.7.  For  standard  preparation,  30  mg  samples  of  blank  hair  were  weighed  out 
and  spiked  with  5,10,25,50,100  and  200  [tl  AF  and  100  [d  of  deuterated  working 
standard,  both  at  I  pg/ml  to  give  a  six  point  calibration  curve.  A  blank  hair  sample  without 
standard  or  internal  standard  and  a  blank  hair  sample  with  only  100  ýtl  of  internal  standard 
were  also  prepared. 
The  case  hair  sample  was  cut  into  three  segments  (root  -3  cm,  3-6  cm.  and  6-  9cm),  cut 
into  small  pieces  (1-2  mm)  and  100  pl  of  AF  deuterated  working  standard  was  added. 
Four  different  pre-treatment  methods,  described  in  4.1.1.8,  were  used  in  this  study.  Each 
segment  was  divided  into  two  portions  and  analysed  by  two  different  pre-treatment 
methods.  It  was  not  possible  to  compare  all  four  at  once  because  of  insufficient  sample.  A 
calibration  curve  was  also  plotted  for  each  pre-treatment  method.  The  segment  root  -3  cm. 
was  used  to  compare  P-glucuronidase  and  alkaline  pre-treatment.  The  method  that  gave 
the  better  recovery  was  then  compared  with  methanol  pre-treatment  on  segment  3-6  cm 
and  the  better  of  these  two  methods  was  compared  with  acid  pre-treatment  using  segment  6 
-9  cm.  SPE  as  described  in  section  4.1.1.9  was  used  to  clean  up  the  hair  samples.  The 
solution  was  evaporated  to  dryness  and  derivatised  as  described  in  section  4.1.1.5.  L 
4.2.1  Results  and  Discussion 
Calibration  curves  by  each  method  were  plotted  and  were  shown  to  give  good  linearity  and 
R2  values  similar  to  those  shown  previously  in  4.1.1.10.  The  AF  concentration  results 
obtained  for  the  case  hair  sample  by  these  pre-treatment  methods  were  calculated  and  they 
fell  within  a  range  of  0.21-0.53  ng  /  mg.  The  P-glucuronidase  pre-treatment  method  gave  a 
better  recovery  than  the  alkaline  pre-treatment  method,  the  methanolic  pre-treatment 
method  and  the  acidic  pre-treatment  method.  The  P-glucuronidase  pre-treatment  method 
was  used  as  a  reference  for  the  other  pre-treatment  methods  to  calculate  the  recoveries. 
This  method  was  assumed  to  give  100%  recovery  for  AF  and  the  recoveries  obtained  using 
other  methods  were  compared  to  this.  Alkaline  pre-treatment,  methanol  and  acid  pre- 
treatment  methods  represented  approximately  87%,  70%  and  56%,  respectively,  compared 
with  the  P-glucuronidase  pre-treatment  method.  The  P-glucuronidase  pre-treatment 
method  was  also  found  to  be  cleaner  than  either  the  alkaline  or  methanol  extractions.  The 
full  scan  chromatograms  for  blank  hair  samples  for  each  pre-treatment  method  are  shown 
in  Figure  4.28,  Figure  4.29,  Figure  4.30  and  Figure  4.31.  The  complete  results  for 
comparison  are  summarized  in  Table  4.23  and  Figure  4.27. 
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P-Glucuronidase  pre-treatment  was  selected  as  the  method  of  choice  for  the  extraction  of 
AF  content  in  hair.  It  was  assumed  that  alkaline  pre-treatment  would  give  the  highest 
recovery  because  this  extraction  completely  dissolves  the  hair  sample  and  all  drugs  are 
liberated  from  hair  matrices.  It  has  been  reported  that  an  enzyme  method  is  suitable  to 
extract  all  substances  at  neutral  pH  [  166]. 
It  has  previously  been  reported  [94]  that  four  different  pre-treatment  procedures,  methanol, 
acid  (HCI  0.1  N),  alkaline  (NaOH  I  N)  and  enzymatic  (fl-glucuronidase/arylsulfatase)  pre- 
treatment  were  compared  to  determine  AF,  MDA  and  MDMA  using  powdered  positive 
hair  samples.  The  clean-up  method  was  LLE  with  10  ml  ethyl  acetate.  Derivatisation  was 
carried  out  with  heptafluorobutyric  anhydride/ethyl  acetate  (2:  1,  v/v)  and  analysis  by  GC- 
MS.  The  results  of  this  study  demonstrated  that  alkaline  pre-treatment  gave  the  highest 
recoveries  and  direct  methanol  pre-treatment  gave  the  lowest  recoveries  for  all  three 
compounds.  This  study  concluded  that  the  results  of  this  comparison  study  are  not  enough 
to  detennine  which  extraction  method  is  best.  It  was  reported  that  factors  such  as  the 
precision  and  practicality  of  each  method  should  also  be  taken  into  account,  when 
extraction  comparison  studies  are  carried  out  [70]. 
In  another  study,  three  pre-treatment  methods  were  compared  to  extract  amfetarnines  from 
hair  samples.  These  were  sodium  hydroxide,  methanol  /  HCl  and  methanol  / 
trifluoroacetic  acid.  The  highest  recoveries  of  AF,  MA,  MDA,  MDMA  and  MDEA  from 
hair  were  found  by  acid  pre-treatment  with  SPE  extraction.  In  contrast,  alkaline  pre- 
treatment  was  found  to  give  the  best  recoveries  when  LLE  was  used  before  SPE  [92]. 
Acid  pre-treatment  and  alkaline  pre-treatment  followed  with  ether  extraction  were 
compared  in  another  study  involving  monkey  hair.  This  showed  that  there  were  no 
significant  differences  in  recovery  between  these  extractions  for  AF  and  MA,  but  the  acidic 
method  was  found  to  be  a  cleaner  extract  and  gave  lower  standard  deviations  [97]. 
The  results  of  these  studies  differ  with  the  findings  in  this  investigation  which  showed  that 
the  fl-glucuronidase  method  gave  the  highest  recovery  of  AF.  Although,  alkaline  pre- 
treatment  has  the  ability  to  liberate  the  drugs  from  the  hair  sample  it  requires  extensive 
clean  up  procedures  to  eliminate  hair  matrix  substances  which  can  cause  interference  with 
the  analysis.  This  has  been  highlighted  in  the  previously  mentioned  article  where  both 
LLE  and  SPE  were  used  following  alkaline  pre-treatment  [92].  Obtaining  good  recoveries 
with  alkaline  pre-treatment  is  dependent  on  having  good  purification  of  the  hair  digest  to 
eliminate  more  interfering  substances.  It  would  appear  that  the  combination  of  a  pre- 
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treatment  step  and  a  particular  clean-up  method  may  significantly  affect  the  recovery.  For 
instance,  alkaline  pre-treatment  with  LLE  may  produce  the  highest  recovery  compared 
with  other  pre-treatment  methods  with  the  same  LLE.  However,  another  type  of  pre- 
treatment  method  may  be  better  with  SPE  than  the  alkaline  pre-treatment  with  the  same 
SPE  method  [94]. 
Other  factors  that  need  to  be  considered  when  choosing  a  method  are  the  cost  and  time  of 
sample  preparation.  Extensive  clean-up  procedures  may  significantly  increase  both  of 
these  factors.  It  was  reported  that  there  are  important  considerations  which  should  be  kept 
in  mind  when  selecting  the  pre-treatment  procedures  such  as  type  of  analyte  and  its 
stability,  distribution  ratio  between  analyte  and  its  metabolites  and  finally,  subsequent 
analysis  (qualitative  or  quantitative)  [  167]. 
Table  4.23  The  concentration  of  AF  measured  in  different  segments  of  the  authentic  hair 
sample 
Methods 
Concentration 
Seqment  I  Percentage 
Alkaline  0.46  Root  -3  cm  87% 
Enzymatic  0.53  Root  -3  cm  100% 
Methanol  0.21  3-6  cm  70% 
Enzymatic  0.3  3-6  cm  100% 
Acid  0.26  6  -9  cm  56% 
Enzymatic  0.46  6  -9  cm  100% 
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Figure  4.27  The  concentration  of  AF  in  different  segments  of  the  authentic  hair  sample 
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Figure  4.28  Full  Scan  Chromatogram  of  blank  hair  sample  after  enzymatic  pro-treatment 
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Figure  4.29  Full  Scan  Chromatogram  of  blank  hair  sample  after  acid  pre-treatment 
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Figure  4.30  Full  Scan  Chromatogram  of  hair  blank  sample  after  alkaline  pre-treatment 
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Figure  4.31  Full  Scan  Chromatogram  of  blank  hair  sample  after  methanolic  pre-tretment 
Diagnostic  Use  ofHair  Analysisfor  the  Detection  ofMisuse  ofAmfetamines  and  Cannabinoids Chapter  Four:  Analysis  of  Amfetamines  and  Cannabinoids  Page  98 
4.3  Method  validation 
In  accordance  with  the  results  of  the  comparative  study  in  section  4.2,  the  best  recovery  for 
AF  was  obtained  by  the  fl-glucuronidase  pre-treatment  method.  This  method  as  described 
in  4.1.1.8  was  used  and  validated  for  amfetamines  in  hair. 
Hair  samples  were  decontaminated  using  the  same  procedure  described  in  section  4.1.1.7, 
the  solutions  were  extracted  using  the  SPE  method  as  described  in  section  4.1.1.9  and  the 
solution  was  evaporated  to  dryness  and  derivatised  as  described  in  section  4.1.1.5.1. 
4.3.1  Linearity 
Linearity  was  demonstrated  by  plotting  the  calibration  curves  of  five  amfetamines. 
Standards  were  prepared  by  weighing  30  mg  of  blank  hair  into  a  test  tube  and  spiking  with 
5,10,25,50,100  and  200  pl  of  aI  pg/ml  working  standard  solution  containing  AF,  MA, 
MDA,  MDMA  and  MDEA.  100  pl  of  deuterated  internal  standard  at  1  Pg/ml  was  added  to 
every  standard  to  give  a  six  point  calibration  curve.  A  blank  hair  sample  without  standard 
or  internal  standard  and  a  blank  hair  sample  with  only  100  pI  of  internal  standard  were  also 
prepared.  Calibration  curves  were  plotted  using  concentration  against  PAR  (drug  peak 
area  /  internal  standard  peak  area)  of  each  amfetamine.  The  results  are  presented  in  Table 
4.24,  Table  4.25  and  Figure  4.32. 
4.3.2  Recovety 
The  recoveries  were  determined  and  calculated  at  low,  medium  and  high  concentrations  for 
each  of  the  five  amfetamines,  by  taking  the  mean  PAR  of  extracted  samples  divided  by  the 
mean  PAR  of  the  unextracted  standards  at  the  equivalent  concentration  and  multiplying  by 
100.  Spiked  hair  samples  (30  mg)  were  prepared  in  five  replicates  at  three  different 
concentrations  (10,50  and  200  pl  of  a  l[tg/mI  standard).  Unextracted  standards  were 
prepared  at  the  same  time  as  spiked  hair  samples  and  kept  in  the  fridge  while  the  extraction 
was  carried  out.  Deuterated  internal  standards  (100  pI  of  a1  [tg/ml  standard)  were  added  to 
extracts  and  unextracted  standards  after  the  extraction.  The  results  are  presented  in  Table 
4.26. 
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4.3.3  Intra-day  and  Inter-day  Precision 
4.3.3.1  Intra-day  precision  between  extracts 
The  intra-day  precision  between  extracts  was  carried  out  in  five  replicates.  Spiked  hair 
samples  (30  mg)  were  prepared  on  the  same  day  at  three  different  concentrations  (10,50 
and  200  ýtl  of  aI  ýLg/ml  standard)  in  the  presence  of  deuterated  internal  standard  (100  pl  of 
a1  [tg/ml  standard).  The  results  are  presented  in  Table  4.27. 
4.3.3.2  Intra-day  precision  between  injections 
The  intra-day  precision  between  injections  was  carried  out  by  injecting  the  same  standard 
five  times.  Spiked  hair  samples  (30  mg)  were  at  three  different  concentrations  (10,50  and 
200  ýtl  of  a  Iýtg/ml  standard)  in  the  presence  of  deuterated  internal  standard  (100  ýtl  of  a 
I  ýtg/rnl  standard.  The  results  are  presented  in  Table  4.28. 
4.3.4  Inter-day  Precision 
Inter-day  precision  was  determined  by  using  spiked  hair  samples  (30  mg)  at  three  different 
concentrations  (10,50  and  200  ýtl  of  a  1ýtg/ml  standard)  in  the  presence  of  deuterated 
internal  standard  (100  [tl  of  a  l[tg/ml  standard)  over  a  period  of  five  days.  The  results  are 
presented  in  Table  4.29. 
4.3.5  Limits  of  Quantitation  and  Detection 
The  limits  of  quantitation  (LOQ)  and  detection  (LOD)  were  calculated  from  the  intercept 
and  the  standard  error  of  the  regression  line.  The  equations  used  for  calculation  of  LOQ 
and  LOD  are  shown  in  the  equations  1  and  2  for  LOQ  and  the  equations  3  and  4  for  LOD, 
where  yB  is  intercept,  SB  is  the  standard  error  of  the  regression  line  and  m  is  the  gradient. 
The  calibration  curves  of  all  five  arnfetamines  were  plotted,  by  spiking  blank  hair  samples 
(30  mg)  with  amfetarnine  standards  to  obtain  concentrations  of  0.5,0.75,2,5,10  and  25 
ng/30  mg  of  hair  and  adding  100  ýLl  of  a  1ýtg/ml  deuterated  internal  standard.  A  blank  hair 
sample  without  standard  or  internal  standard  and  a  blank  hair  sample  with  only  100  ýtl  of 
internal  standard  were  also  prepared  and  extracted.  The  limit  of  detection  is  defined  as  the 
intercept  plus  three  standard  errors  of  the  regression  line  and  the  limit  of  quantitation  is 
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defined  as  intercept  plus  five  standard  errors  of  the  the  regression  line  [168].  The  limits  of 
detection  and  quantitation  for  all  arnfetamines  are  presented  in  Table  4.30. 
YLOQ  =  yB+5 
SB  Equation  1 
L.  O.  Q  = 
(YLOQ 
-  YB)  Equation  2 
m 
YLOD  ý  YB+3  SB  Equation  3 
L.  O.  D  = 
(YLOD 
- 
YB)  Equation  4 
m 
Table  4.24  Calibration  concentration  and  peak  area  ratio  for  extracted  amfetamines 
Concentration 
(ng/30mg) 
AF/AF-ds 
1901194 
MA/MA-ds 
204/208 
MDA/MDA-ds 
3251330 
MDMA/MDMA-ds 
339/344 
MDEAIMDEA-d5 
218/223 
5  0.07  0.04  0.09  0.07  0.01 
10  0.15  0.08  0.16  0.15  0.02 
25  0.34  0.19  0.34  0.29  0.05 
50  0.65  0.4  0.67  0.68  0.09 
100  1.22  0.75  1.21  1.25  0.18 
200  2.45  1.48  2.47  2.49  0.35 
Table  4.25  Linear  regression  values 
Analyt 
AF 
MA 
MDA 
MDMA 
MDEA 
R2 
1.000 
0.996 
0.999 
0.999 
1.000 
Interce 
0.0267 
0.0109 
0.0360 
0.0164 
0.0037 
0.0121 
0.0074 
0.0121 
0.0124 
0.0017 
Slo 
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Figure  4.32  Amfetamines  Calibration  curves  (AF,  MA,  MDA,  MDMA  and  MDEA,  0  to  200  ng) 
Table  4.26  Recovery  results  for  the  extracted  Amfetamines  from  hair  (n=5) 
Concentration  Mean  Peak  Area  Ratio  S.  D  %  Cv  % 
Analyte  (ng)  Ext  Unext  Ext  I  Unext  Ext  Unext  Recove!  y 
AF  10  0.09  0.11  0.00  0.01  4.82  7.07  84.2 
50  0.43  0.57  0.02  0.02  4.65  3.08  76.0 
200  1.65  2.35  0.01  0.08  0.86  3.56  71.4 
MA  10  0.08  0.11  0.00  0.00  4.36  4.31  77.7 
50  0.39  0.53  0.02  0.02  5.6  3.55  74.2 
200  1.58  1.80  0.11  0.10  7.27  5.55  87.7 
MDA  10  0.11  0.13  0.00  0.01  4.23  4.69  79.6 
50  0.49  0.65  0.01  0.02  2.42  3.12  75.7 
200  2.12  2.74  0.10  0.09  4.82  3.44  77.3 
MDMA  10  0.01  0.18  0.01  0.01  5.75  5.77  76.0 
50  0.66  0.87  0.01  0.03  2.01  3.2  76.2 
200  2.89  3.72  0.14  0.15  4.83  3.94  77.6 
MDEA  10  0.01  0.02  0.00  0.00  1.33  6.77  82.6 
50  0.07  0.08  0.00  0.00  5.38  3.1  85.2 
200  0.28  0.31  0.02  0.01  6.30  3.68  88.4 
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Table  4.27  Intra-day  Precision  (between  extraction,  n=5) 
knalyte 
Concentration 
ng  /  30mg 
Calculated  Concentration 
Mean  ng  /  30mg  S.  D  C.  V 
AF  10  11.41  0.30  2.61 
50  48.34  2.13  4.40 
200  200.10  15.52  7.76 
MA  10  10.32  0.71  6.86 
50  49.53  2.88  5.81 
200  207.28  19.88  9.60 
MDA  10  10.53  0.50  4.74 
50  48.53  2.53  5.34 
200  199.97  11.66  5.83 
MDMA  10  10.93  1.04  9.52 
50  46.74  3.87  8.29 
200  200.00  9.04  4.52 
MDEA  10  13.28  0.53  3.97 
50  49.00  2.08  4.24 
200  196.62  10.91  5.55 
Table  4.28  Intra-day  Precision  (between  injection,  n=5) 
Anall 
AF 
MA 
MDA 
MDMA 
MDEA 
Concentration 
na/  30ma 
10 
50 
200 
10 
50 
200 
10 
50 
200 
10 
50 
200 
10 
50 
200 
Calculated  Concentration 
Mean  na  /  30ma 
10.75 
49.12 
200.88 
9.04 
50.77 
199.52 
12.46 
46.74 
201.55 
10.07 
49.92 
199.74 
14.34 
49.14 
203.14 
S.  D 
0.75 
0.40 
2.37 
0.34 
0.46 
2.32 
0.57 
2.61 
14.88 
0.58 
3.92 
2.71 
0.37 
0.41 
1.57 
C.  V 
7.01 
0.81 
1.18 
3.75 
0.91 
1.16 
4.57 
5.58 
7.38 
5.78 
7.85 
1.36 
2.56 
0.84 
0.77 
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Table  4.29  Inter-day  Precision  (n=5) 
Analyte 
Concentration 
ng  130mg 
Calculated  Concentration 
Mean  ng  130mg  S.  D  C.  V 
AF  10  11.27  1.76  15.6 
50  47.36  4.29  9.0 
200  201.95  2.01  1.0 
MA  10  11.09  2.06  18.5 
50  47.80  5.22  10.9 
200  203.47  5.24  2.5 
IVIDA  10  11.07  2.13  19.2 
50  49.48  4.43  8.9 
200  202.45  3.39  1.6 
IVIDIVIA  10  11.34  2.09  18.4 
50  48.73  3.31  6.8 
200  202.12  2.34  1.1 
IVIDEA  10  10.90  2.02  18.5 
50  46.28  3.32  7.1 
200  202.31  1.97  0.9 
Ext:  Extracted,  Uext:  Unextracted 
Table  4.30  Limit  of  Quantitation  and  Detection 
AF  MA  MDA  MDMA  MDEA 
(ng/30mg)  (ng/30mg)  (ng/30mg)  (ng/30mg)  (ng/30mg) 
LOD  2.58  0.70  2.19  2.33  1.36 
LOQ  4.30  1.17  3.89  3.65  2.25 
4.3.6  Results  and  Conclusion 
The  method  validation  was  carried  out  for  linearity,  recoveries,  intra  and  inter-day 
precision,  limit  of  quantitation  (LOQ)  and  limit  of  detection  (LOD)  for  all  amfetamines 
compounds.  Linearity  was  obtained  from  5  to  200  ng/30mg  of  hair  with  correlation 
coefficients  (112)  ranging  from  0.999-1.000  for  all  amfetamines.  The  recovery  for  all  five 
amfetamines  was  higher  than  71%.  Coefficients  of  variation  for  the  intra-day  precision 
between  extracts  and  between  injections  were  all  less  than  10  %  at  each  concentration  for 
all  five  amfetamine  compounds.  Coefficients  of  variation  for  the  inter-day  precision  were 
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all  less  than  15  %  at  each  concentration  for  all  five  amfetarnine  compounds.  The  limits  of 
detection  and  quantitation  for  all  five  amfetarnines  were  between  0.7  to  2.58  ng/30mg  and 
1.17  to  4.3  ng/30mg,  respectively.  The  method  validation  results  showed  good  validation 
data  for  all  five  amfetamines  and  indicated  that  this  method  is  adequate  for  the  purpose  of 
the  amfetamines  analysis  in  hair  with  satisfactory  sensitivity.  Consequently,  this  method 
was  applied  to  22  case  hair  samples  to  measure  the  concentration  of  arnfetamines  (Chapter 
6). 
Diagnostic  Use  ofllair  Analysisfor  the  Detection  ofMisuse  ofAmfelamines  and  Cannabinoids Chapter  Five:  Stability  of  Amfetamine  in  Hair  Samples  Page  105 
5  Stability  of  Amfetamine  in  Hair  Samples 
5.1  Introduction 
The  stability  of  drugs  in  biological  fluids  may  be  affected  by  different  factors  such  as 
temperature,  storage  time,  drug  concentration,  sample,  pH,  the  type  of  biological  fluid,  the 
use  of  preservatives  and  the  method  of  storage.  All  of  these  can  lead  to  a  significant 
change  in  the  analyte  concentration  within  the  specimen  and  can  lead  to  misinterpretation 
of  quantitative  results  [169].  Consequently,  the  forensic  toxicologist  must  consider  the 
limited  stability  of  specimens  to  give  the  proper  interpretation  of  analytical  results.  For 
instance  chemical  degradation,  ongoing  enzymatic  metabolism  and  redistribution  happens 
in  postmortem  specimens  between  the  death  and  the  sampling  of  matrices  [80].  It  has  been 
reported  that  all  drug  concentrations  can  change  in  postmortem  specimens  and  that  the 
change  varies  between  drugs  [125]. 
The  stability  of  MDA,  MDMA  and  MDEA  in  pooled  serum,  whole  blood,  water  and  urine 
samples  whilst  stored  at  different  temperatures  (-20,4  or  20  'Q  in  the  dark  over  a  period 
of  21  weeks  has  been  investigated.  It  was  reported  that  there  was  no  degradation. 
Therefore,  MDA,  MDMA  or  MDEA  samples  stored  for  several  weeks  (13  weeks  for 
whole  blood  and  Z!:  21  weeks  for  the  other  matrices,  water,  serum  and  urine)  are  appropriate 
to  analyse.  Severe  matrix  degradation  was  found  for  whole  blood  and  serum  stored  at 
room  temperature  which  could  lead  to  undetectable  concentrations  of  the  drugs, 
particularly  where  the  initial  concentrations  are  low  [80]. 
The  stability  of  drugs  (methoxyphenamine,  as  model  compound  for  methamfetamine)  in 
hair  samples  was  described.  Drug  levels  in  hair  were  measured  in  a  living  subject  over  a 
period  of  6  months.  The  results  obtained  from  this  study  revealed  that  the  drug  decreased 
about  50%  after  5-6  months.  This decrease  is  likely  to  be  a  result  of  drug  being  removed 
from  hair  through  normal  washing  and  possibly  the  decomposition  of  some  of  the  drug 
with  time  [  170]. 
The  stability  of  opiates  in  hair  was  investigated  after  cosmetic  treatment  (bleaching  and 
permanent  waving)  of  hair  spiked  with  opiates  and  authentic  hair  samples  known  to  be 
positive  for  opiates.  The  results  showed  a  decrease  in  the  concentration  of  spiked  hair 
samples  that  ranged  from  82  %  to  98  %  after  bleaching  and  ranged  from  70  %  to  80  % 
after  permanent  waving.  The  drug  concentration  also  decreased  for  authentic  hair  samples, 
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but  was  not  as  significant.  Exposure  of  human  hair  scalp  to  sunlight  and  cosmetic 
treatment  was  also  shown  to  cause  morphological  alterations  in  the  hair  fibres  affecting  the 
drug  concentrations  [  17  1  ]. 
It  has  been  reported  that  the  opiates  were  significantly  decreased  or  even  lost  when  hair 
samples  were  exposed  to  unfavourable  environmental  conditions  such  as  water  and  soil  for 
various  time  intervals  [172]. 
Although  a  number  of  analytical  methods  have  been  reported  for  the  analysis  of  AF  in  hair 
samples  as  mentioned  previously  in  section  3.1.6,  none  of  these  methods  have  reported  on 
the  stability  of  AF  in  hair  in  cases  of  drowning  through  immersion  in  either  sea  or  fresh 
water.  For  this  study,  the  effect  of  sea  water  and  fresh  water  on  the  concentration  of  AF  in 
hair  specimens  was  investigated. 
5.2  Alm 
The  aim  of  this  study  was  to  assess  the  validity  of  analysing  hair  samples  for  the  presence 
of  AF  in  victims  of  drowning. 
5.3  Experimental 
5.3.1  Hair  and  Water  Collection 
AF  positive  hair  samples  were  collected  from  volunteers,  with  known  AF  drug  abuse 
history.  This  was  assessed  using  medical  files.  In  many  of  these  cases  urine  samples  had 
been  previously  analysed  by  the  laboratory  at  the  Alarnal  Medical  Complex  in  Riyadh 
prior  to  subjects  entering  rehabilitation  programs.  The  majority  of  these  samples  were 
found  to  be  positive  for  AF.  Hair  was  obtained  by  cutting  from  the  area  at  the  back  of  the 
head  (posterior  vertex)  and  as  close  to  the  scalp  as  possible.  Once  collected,  a  hair  sample 
was  placed  in  aluminium  foil,  with  the  scalp  end  clearly  identified,  sealed  in  a  paper 
envelope  and  stored  at  room  temperature  until  use. 
The  fresh  and  sea  water  were  obtained  from  Loch  Lomond  and  from  the  River  Clyde 
Estuary,  Gourock  near  Glasgow  in  Scotland,  respectively. 
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5.3.2  Stability  of  Amfetamine  in  Hair  Samples  Submerged  in  Fresh 
Water  and  Sea  Water 
5.3.2.1  Initial  study  for  Arnfetarnine  Stability 
A  preliminary  experiment  was  carried  out  to  assess  the  stability  of  AF  in  hair  samples 
which  had  been  submerged  in  fresh  and  sea  water  for  different  periods  of  time. 
In  order  to  prepare  hair  standards,  30  mg  of  blank  hair  samples  were  weighed  out  and 
spiked  with  5,10,25,50,100  and  200  pl  of  AF  and  100  pl  of  deuteratcd  working  standard, 
both  at  I  gg/ml  to  give  a  six  point  calibration  curve.  A  blank  hair  sarnPle  without  standard 
or  internal  standard  and  a  blank  hair  sample  with  only  100  Itl  of  internal  standard  at  I 
pg/ml  were  also  prepared  and  extracted. 
A  hair  positive  specimen  was  cut  to  give  0-3  cm  length  and  this  was  separated  into  7 
portions.  One  of  these  portions  was  stored  as  an  original  specimen  and  3  portions  were 
immersed  in  5  ml  of  sea  water  and  the  other  3  portions  were  immersed  in  5  ml  of  fresh 
water  for  1  day,  I  week  or  2  weeks  at  5  T.  Hair  samples  were  analysed  using  the 
validated  method  described  in  section  4.3. 
5.3.2.1.1  Initial  Study  Results 
All  wash  fraction  results  were  negative  for  AF.  A  calibration  curve  was  plotted  for  AF  and 
was  shown  to  give  good  linearity  and  W  values  similar  to  that  shown  previously  in  section 
4.1.1.10. 
The  preliminary  results  obtained  in  this  study  showed  that  the  AF  hair  concentration 
significantly  decreased  with  the  length  of  time  in  sea  water,  while  the  AF  hair 
concentrations  showed  no  obvious  change  in  fresh  water.  The  decrease  of  hair  AF 
concentration  in  sea  water  was  approximately  40%  after  one  day,  69%  after  one  week  and 
84%  after  two  weeks.  The  complete  results  for  the  AF  concentrations  found  in  the  hair 
samples  are  summarised  in  Figure  S.  1  and  Table  5.1. 
The  preliminary  data  from  this  study  showed  that  there  was  an  effect  on  the  concentration 
of  AF  in  hair  when  submerged  in  different  types  of  water  (fresh  and  sea).  These  results  led 
to  a  further  investigation  to  assess  the  stability  of  AF  in  hair  samples  submerged  in  these 
types  of  water. 
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Figure  5.1  Effect  of  sea  and  fresh  water  on  AF  concentration 
s  Sea  Water 
a  Fresh  Water 
Table  5.1  Concentration  of  AF  in  hair  after  immersion  in  sea  and  fresh  water  (ng/mg) 
Incubation  Time  I  Sea  Water  i  Fresh  Water 
Original  51.3  51.3 
One  Day  30.8  46.9 
One  Week  15.8  46.7 
Two  Weeks  8.1  46.6 
5.3.2.2  Further  Investigation  into  the  Stability  of  Amfetamine  in  Hair  Samples 
Hair  standards  were  prepared  as  in  section  5.3.2.1.  Ten  hair  samples  from  known  AF  users 
were  collected  and  used  to  assess  the  stability  of  AF  in  hair  samples  which  had  been 
submerged  in  fresh  or  sea  water  for  a  period  time.  Fresh  water  and  sea  water  were 
analysed  for  AF  using  the  0-glucuronidase  validated  method  described  in  section  4.3.  This 
was  to  ensure  that  the  water  samples  were  negative  and  that  any  possibility  of 
contamination  from  the  water  could  be  excluded. 
Hair  positive  specimens  were  cut  to  give  0-3  cm  length.  Six  of  these  specimens  were 
separated  into  8  portions  each.  One  of  these  portions  was  stored  as  an  original  specimen 
and  7  portions  were  immersed  in  5  ml  of  sea  water  for  1,2  days,  1,2,3,4  or  8  weeks  at  5 
T.  The  other  four  specimens  were  separated  into  5  portions,  one  of  these  portions  was 
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stored  as  an  original  specimen  and  4  were  immersed  in  5  ml  of  fresh  water  for  1,2,4  or  8 
weeks  at  5  'C.  Each  portion  was  removed  from  the  water  after  the  period  of  immersion 
and  dried  overnight  at  room  temperature.  Hair  samples  were  analysed  using  the  validated 
method  described  in  section  4.3. 
The  fresh  and  sea  water  samples  which  were  used  to  immerse  the  hair  for  a  period  of  eight 
weeks  were  analysed  following  immersion  to  investigate  the  AF  content.  The  cation  and 
anion  content,  pH  and  conductivity  of  the  two  water  types  were  also  measured,  in 
collaboration  with  the  Department  of  Environmental  Chemistry  at  Glasgow  University. 
Calcium  (Ca2+),  Magnesium  (Mg2+),  Sodium  (Na+),  Potassium  (W-),  Chloride(Cl-)  and 
Sulphate  (SO  4 
2-),  conductivity,  pH  were  measured  using  an  Atomic  Absorption 
spectrophotometer,  Flame  Photometer,  Ion  Chromatography,  Conductivity  Meter  and  pH 
Meter,  respectively. 
5.3.2.2.1  Result  and  Discussion 
A  calibration  curve  was  plotted  for  AF  and  was  shown  to  give  good  linearity  and  R2  values 
similar  to  that  shown  previously  in  section  4.1.1.10.  For  hair  samples  incubated  in  salt 
water,  DCM  wash  fraction  3  was  found  to  be  positive  in  24  out  of  48  segments.  DCM 
wash  fraction  4  was  found  to  be  negative  for  all  segments.  For  hair  samples  incubated  in 
fresh  water,  only  2  out  of  21  segments  were  found  to  be  positive.  These  were  very  low 
positives,  so  these  segments  did  not  require  further  washing.  Washing  the  hair  in  salt  water 
would  appear  to  remove  some  of  the  drug  incorporated  through  use.  It  is  possible  that 
soaking  in  salt  water  may  increase  the  porosity  of  the  cuticle  compared  with  soaking  in 
fresh  water.  The  wash  fraction  results  are  listed  in  Table  5.2  and  Table  5.3 
Fresh  water  and  sea  water  samples  analysed  prior  to  the  immersion  of  hair  were 
detennined  to  be  negative  for  AF. 
The  initial  concentrations  of  the  hair  samples  investigated  ranged  from  0.17  to  57.69 
ng/mg  of  hair.  Hair  samples  that  were  submerged  in  sea  water  showed  a  significant 
decrease  of  AF  concentration  with  time  compared  with  hair  samples  that  were  submerged 
in  fresh  water.  The  decrease  in  hair  AF  concentration  after  one  day  in  sea  water  ranged 
from  0.1-85%  and  after  eight  weeks  ranged  from  88-97%.  In  fresh  water,  after  one  week 
the  concentration  was  found  to  decrease  by  9-17%  and  after  eight  weeks  by  16-60%.  The 
complete  results  for  the  AF  concentrations  found  in  the  hair  samples  are  given  in  Table  5.4 
and  Table  5.5. 
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Figure  5.2  and  Figure  5.3  show  the  general  decrease  in  hair  AF  concentration  with  time  for 
immersion  in  sea  and  fresh  water  respectively.  In  Figure  5.2  the  log  concentration  was 
plotted  against  time. 
The  sea  and  fresh  water  samples  which  were  used  to  immerse  the  hair  for  a  period  of  eight 
weeks  were  found  to  be  positive  for  the  unchanged  drug.  The  original  total  amount  of  drug 
in  the  hair  sample  (ng)  was  calculated  by  multiplying  the  original  concentration  in  hair 
(ng/mg)  by  the  weight  of  the  hair  used.  The  complete  results  are  given  in  Table  5.6  and 
Table  5.7.  These  Tables  show  the  amount  of  drug  washed  out  as  a  percentage  of  the 
amount  of  drug  found  in  the  water  sample  compared  to  the  amount  extracted  from  hair.  In 
all  six  sea  water  cases  and  in  two  out  of  four  fresh  water  cases  this  %  was  greater  than  100 
%.  This  would  tend  to  show  that  the  true  recovery  of  AF  from  hair  is  much  lower  than  the 
recovery  of  AF  from  spiked  hair  samples. 
The  pH  measurements  of  sea  and  fresh  water  were  8.1  and  7.0  respectively.  The 
conductivity  of  sea  and  fresh  water  samples  were  615  and  0.94  mS  respectively.  The 
cation  and  anion  content  of  the  two  water  types  are  given  in  Table  5.8. 
The  results  demonstrated  a  faster  decrease  of  AF  concentration  in  sea  water  than  in  fresh 
water.  A  possible  explanation  could  be  the  displacement  effect  of  metal  ions  in  the  water 
(especially  cations)  with  AF.  For  example,  keratin  and  melanin  present  in  hair  have 
potential  binding  sites  for  binding  drugs  and  metals  [173],  such  as,  inorganic  metal  cations, 
neutral  organic  compounds,  and  organic  cations  [37].  Binding  with  these  substances  can 
be  selective  [35]  and  the  affinity  of  the  interaction  can  be  varied  depending  on  the 
substance  [38].  The  exact  interaction  of  melanin  with  these  substances  is  still  unknown 
[174]. 
The  presence  of  cystine  in  human  hair,  which  represents  approximately  14%  of  the 
structure  is  largely  responsible  for  the  high  affinity  of  hair  for  metals.  The  metals  found  in 
hair  are  bound  either  to  sulphur  atoms  in  cystine  or  to  sulphydryl  groups  present  in  other 
amino  acids. 
Melanins  are  polyanionic  polymers  containing  negatively  charged  carboxyl  groups  and 
serniquinones  at  physiological  pH.  Therefore  cations  can  bind  with  melanin  by  ionic 
interaction.  Moreover,  organic  amines  and  metal  ions  are  positively  charged  at 
physiological  pH  and  bind  with  melanin  by  electrostatic  forces  between  their  cationic 
groups  and  the  negative  charges  in  the  melanin  polymer.  Van  der  waal's  attractions  also 
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enhance  the  ionic  binding.  Also,  uncharged  metals  such  as  mercury,  may  also  bind  to  the 
hydrophobic  core  of  the  melanin  in  the  hair  [175] 
The  competition  between  drugs  to  melanin  binding  sites  has  been  reported.  The  binding  of 
desipramine  to  melanin  was  reduced  in  the  presence  of  haloperidol.  This  study  showed 
that  these  drugs  may  use  similar  binding  sites  in  melanin  and  are  competitive  for  these. 
[176] 
The  binding  of  Mg(II),  Ca(II),  Zn(II),  Cu(II)  and  Fe(III)  to  Ethylenediaminetetraacetic  acid 
(EDTA)-washed  melanin,  obtained  from  cuttlefish,  was  examined  by  enriching  melanin 
with  these  metal  ion  solutions  at  room  temperature  overnight.  It  was  reported  that 
eumelanin  possesses  three  types  of  functional  groups  which  can  act  as  binding  sites  to 
metal  cations,  carboxylic  acid,  hydroxyl  and  amine  groups.  It  was  concluded  that  Mg(II), 
Ca(II),  Zn(II)  bind  to  carboxylic  acid  groups,  Cu(II)  binds  to  hydroxyl(OH)  groups  and 
Fe(III)  binds  to  hydroxyl  or  amine  groups.  Binding  of  metal  cations  with  carboxylic  acid 
will  replace  Na+  which  is  the  bound  metal  cation  in  (EDTA)-washed  melanin,  while 
binding  to  hydroxyl  and  amine  groups  replaces  the  proton  (H),  consequently,  the  pH  will 
changed  by  releasing  protons  in  solutions  [177] 
The  determination  of  the  relative  melanin-affinity  of  metal  ions  was  assessed  by  the  ability 
of  the  metal  ions  to  compete  with  paraquat  for  binding  to  melanin.  It  was  reported  that  the 
affinity  of  the  alkali  metals  and  alkaline  earth  metals  was  Cs+>Rb+>W>Na+>Li+  and 
Ba2+>Sr2+>Ca2+>Mg2+  respectively.  The  presence  of  the  metal  ions  will  decrease  and 
inhibit  of  the  parquet  binding  to  melanin  [178]. 
Melanin  therefore  may  behave  as  a  weak  cationic  exchange  polymer  and  may  bind  with 
cationic  drugs  such  as  AF  both  ionically  and  covalently  [179,180].  Amfetamine  is  a  polar 
drug  and  binds  with  polar  functional  groups  such  as  hydroxyl,  carboxylic  acid,  and  amino 
goups  in  melanin  [IS  I). 
It  has  been  reported  that  while  metal  ions  such  as  Na+,  Ca2+,  Ký  may  compete  for  binding 
sites  in  melanin  and  inhibit  cationic  drugs  from  binding  with  melanin,  especially  when 
competing  for  the  same  binding  sites,  anions  did  not  effect  this  binding  [182]. 
Consequently,  the  high  concentration  of  cations  in  the  sea  water  may  explain  the  increased 
rate  of  removal  of  AF  from  hair  when  compared  to  fresh  water. 
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The  sea  and  fresh  water  samples  used  to  incubate  the  hair  were  extracted  by  SPE  and 
analyzed  after  eight  weeks  of  incubation.  The  analyses  showed  the  presence  of  AF  in  all 
samples  at  reducing  concentrations  with  time  due  to  the  removal  of  the  AF  from  hair  to 
water.  The  unchanged  drug  was  found  in  the  water  samples.  Interestingly,  more  drug  was 
recovered  in  the  water  than  expected  indicating  that  the  analytical  method  used  to  extract 
AF  from  the  real  hair  sample  has  a  much  lower  recovery  than  indicated  by  the  use  of 
spiked  standards. 
It  has  been  shown  that  the  interpretation  of  drugs  found  in  hair  samples  obtained  from 
victims  of  drowning  require  careful  interpretation.  Sea  water  has  the  potential  to  cause  the 
complete  loss  of  drug  from  hair  with  increased  time,  while,  fresh  water  may  cause  partial 
or  possible  complete  loss  with  increased  time. 
6 
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Table  5.2  Concentration  of  AF  in  wash  fractions  for  the  samples  submerged  in  sea  water 
Sample  I  Incubation 
Sea  Water,  Hair  05 
Sea  Water,  Hair  08 
Sea  Water,  Hair  10 
Sea  Water,  Hair  12 
Sea  Water,  Hair  16 
Sea  Water,  Hair  17 
time 
Original 
One  day 
Two  day 
One  week 
Two  week 
Three  week 
Four  week 
Eight  week 
Original 
One  day 
Two  day 
One  week 
Two  week 
Three  week 
Four  week 
Eight  week 
Original 
One  day 
Two  day 
One  week 
Two  week 
Three  week 
Four  week 
Eight  week 
Original 
One  day 
Two  day 
One  week 
Two  week 
Three  week 
Four  week 
Eight  week 
Original 
One  day 
Two  day 
One  week 
Two  week 
Three  week 
Four  week 
Eight  week 
Original 
One  day 
Two  day 
One  week 
Two  week 
Three  week 
Four  week 
Eight  week 
AF  Concentration  in  Wash  Fractions  (ng/mg) 
DCM  Wash  Fraction  I  DCM  Wash  Fraction  4 
14.61  0.00 
1.80  0.00 
0.57  0.00 
0.34  0.00 
0.07  0.00 
0.43  0.00 
0.25  0.00 
0.00  0.00 
0.43  0.00 
0.03  0.00 
0.00  0.00 
0.00  0.00 
0.00  0.00 
0.00  0.00 
0.00  0.00 
0.00  0.00 
0.53  0.00 
0.96  0.00 
0.80  0.00 
0.00  0.00 
0.00  0.00 
0.00  0.00 
0.00  0.00 
0.00  0.00 
0.00  0.00 
0.40  0.00 
0.00  0.00 
0.00  0.00 
0.00  0.00 
0.00  0.00 
0.00  0.00 
0.00  0.00 
6.50  0.00 
0.00  0.00 
1.12  0.00 
0.00  0.00 
0.15  0.00 
0.26  0.00 
0.11  0.00 
0.00  0.00 
31.99  0.00 
19.35  0.00 
0.22  0.00 
0.00  0.00 
7.09  0.00 
0.47  0.00 
1.26  0.00 
0.00  0.00 
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Table  5.3  Concentration  of  AF  in  wash  fraction  for  the  samples  submerged  in  fresh  water 
Sample  No. 
Fresh  Water,  Hair  04 
Fresh  Water,  Hair  09 
Fresh  Water,  Hair  11 
Fresh  Water,  Hair  15 
Incubation 
time 
Original 
One  week 
Two  week 
Four  week 
Eight  week 
Original 
One  week 
Two  week 
Four  week 
Eight  week 
Original 
One  week 
Two  week 
Four  week 
Eight  week 
Original 
One  week 
Two  week 
Four  week 
Eight  week 
AF  Cnneentration  in  Wash  Fractions  (n 
DCM  Wash  Fraction  3 
0.00 
0.00 
0.00 
0.00 
0.00 
0.02 
0.00 
0.00 
0.00 
0.00 
0.04 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
Table  5.4  Concentration  of  AF  in  hair  after  immersion  in  sea  water  (ng/mg) 
Sea  Water  Hair  05  1  Hair  08  Hair  10  Hair  12  Hair  16  Hair  17 
Original  16.52  2.08  1.69  0.17  12.38  57.69 
One  Day  4.68  0.81  0.66  0.17  3.93  8.57 
Two  Days  2.72  0.63  0.57  0.17  1.25  8.32 
One  Week  2.17  0.37  0.34  0.16  1.19  5.34 
Two  Weeks  1.09  0.32  0.22  0.10  0.90  3.18 
Three  Weeks  0.84  0.31  0.18  0.09  0.85  2.55 
Four  Weeks  0.79  0.22  0.16  0.09  0.62  2.18 
Eight  Weeks  0.65  0.13  0.10  0.02  0.49  1.40 
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Amfetamine 
100.00 
10.00 
1.00 
0 L) 
CD  0.10 
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Hair  08 
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x  Hair  12 
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Orginal  1  Day  2  Days  7  Days  14  Days  21  Days  28  Days  56  Days 
Figure  5.2  Effect  of  sea  water  immersion  on  AF  concentration  in  hair 
Table  5.5  Concentration  of  AF  in  hair  after  immersion  in  fresh  water  (ng/mg) 
Fresh  Water  Hair  04  Hair  09  Hair  II 
Original  2.49  11.12  4.73 
One  Week  2.25  9.78  4.09 
Two  Weeks  1.90  9.46  3.95 
Four  Weeks  1.85  9.38  3.24 
Eight  Weeks  1.78  9.29  1.86 
Amfetamine 
14 
E  12 
lo 
a 
0-" 
Orginal  One  week  Two  weeks  Four  Weeks  Eight  Weeks 
Figure  5.3  Effect  of  fresh  water  immersion  on  AF  concentration  in  hair 
Hair  15 
12.12 
10.05 
8.89 
8.29 
6.41 
Hair  04 
Hair  09 
Hair  11 
Hair  15 
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Table  5.6  AF  concentration  in  hair  and  sea  water  after  eight  weeks 
Sample 
No. 
Original 
concentration  in 
hair,  ng/mg 
Original  total 
amount  in  hair 
Sample,  ng 
Incubation  water 
concentration, 
ng/water  sample 
%  Washed 
out 
Hair  05  16.52  256.23  479.84  187.3 
Hair  08  2.08  30.91  110.56  357.7 
Hair  10  1.69  43.60  70.15  160.9 
Hair  12  0.17  2.40  3.58  149.2 
Hair  16  12.38  168.49  336.69  199.8 
Hair  17  57.7  777.8  992.76  127.6 
Table  5.7  AF  concentration  in  hair  and  fresh  water  after  eight  weeks 
Original 
Sample  concentration 
No.  in  hair,  ng/m 
Hair  04  2.49 
Hair  09  11.12 
Hair  11  4.73 
Hair  15  12.12 
Original  total 
amount  in  hair 
Sample,  ng 
37.92 
241.86 
74.88 
161.2 
Table  5.8  Physical  properties  of  water 
Incubation  water 
concentration,  %  Washed 
ng/water  sample  out 
47.28  124.7 
275.81  114.0 
67.8  90.5 
46.56  28.0 
Cation  Concentration  (mg/L)  Anion  Concentration  (mg/L) 
Metal  ions  Sea  Water  Fresh  water  Sea  Water  Fresh  water 
Sodium,  Na+  9,800  6.2 
Calcium,  Ca  2+  313  3.7 
Potassium,  K+  450  0.4 
- 
Magnesium,  Mg  2+  940  0.9 
Chloride,  Cl-  18,625  7.8 
Sulphate,  S04  2-  715  0.8 
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6  Case  studies 
6.1  Introduction 
Hair  samples  were  collected  from  volunteers  with  a  known  history  of  Fenethylline  (AF 
precursor)  abuse  and  were  subjects  in  rehabilitation  programs  at  Alamal  Medical  Complex 
in  Riyadh,  Saudi  Arabia.  Urine  samples  previously  received  from  these  volunteers  had 
been  analysed  by  the  laboratory  at  the  Alarnal  Medical  Complex  in  Riyadh  and  most  of 
these  were  found  to  be  positive  for  AF. 
Hair  samples  were  obtained  by  cutting  from  the  area  at  the  back  of  the  head  and  as  close  to 
the  scalp  as  possible  at  the  posterior  vertex  region  of  the  head.  Once  collected,  these  were 
stored  at  room  temperature  in  aluminium  foil  and  sealed  in  paper  envelopes  until  use.  15 
hair  samples  were  obtained  from  the  Alamal  Medical  Complex.  One  other  case  hair 
sample  collected  from  a  living  individual  within  the  UK  was  received  by  Forensic 
Medicine  and  Science.  The  hair  samples  were  cut  to  give  0-3  cm  lengths.  2  out  of  the  16 
hair  samples  were  cut  to  give  a  further  three  and  six  segments,  each  3  cm  long. 
Case  sample  details  were  collected  for  each  of  the  volunteers.  These  included  sex  and  age 
of  the  individual,  hair  colour,  information  regarding  drug  use,  date  of  admission  to 
rehabilitation  programme  and  the  date  of  hair  collection.  These  results  are  tabulated  in 
Table  6.1. 
Postmortem  hair  samples  were  obtained  from  the  Department  of  Forensic  Medicine  and 
Science,  University  of  Glasgow.  These  hair  samples  were  pulled  from  the  posterior  vertex 
region  of  the  scalp.  Once  collected,  these  were  stored  at  room  temperature  in  aluminium 
foil  and  sealed  in  paper  envelopes  until  use.  Hair  case  samples  were  selected  depending  on 
the  results  of  the  post-mortem  blood  sample  received  from  the  same  case.  If  the  blood  was 
positive  for  AF  or  related  compounds  and  a  hair  sample  was  available  then  these  hair 
samples  were  selected.  6  case  hair  samples  were  obtained  in  these  types  of  cases.  The  hair 
samples  were  cut  to  give  0-3  cm.  lengths. 
For  these  cases,  sex  and  age  of  the  individual,  hair  colour,  information  regarding  drug  use 
and  cause  of  death  were  recorded  where  available  from  police  and  pathology  reports. 
These  are  shown  in  Table  6.2. 
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The  validated  method  as  described  previously  in  section  4.3  was  applied  to  the  22  case  hair 
samples. 
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6.2  Results  and  Discussion 
Thirteen  urine  case  sample  results  which  were  screened  by  the  Alamal  Medical  Complex 
were  positive  for  amfetamine.  In  each  case,  chronic  amfetamine  abuse  was  confirmed  by 
the  result  of  the  hair  analysis,  where  amfetamine  was  found  in  0-3  cm  of  all  hair  samples 
and  also  in  each  segment  of  hair  samples  labelled  as  Hair07  and  Hair18  in  Table  6.1.  All 
other  amfetamines  (MA,  MDA,  MDMA  and  MDEA)  gave  negative  results.  For  all  case 
samples,  these  results  showed  good  qualitative  correlation  between  self-reported  use,  urine 
result  at  admission  and  hair  result  for  AF.  These  hair  sample  results  were  only  positive  for 
AF  which  is  likely  to  have  come  from  the  use  of  the  AF  precursor,  fenethylline,  where 
27%  of  the  fenethylline  dose  is  excreted  as  racemic  amfetamine  [79].  In  this  study,  self- 
report  showed  good  agreement  with  hair  findings.  The  concentration  of  AF  in  hair  ranged 
from  0.15  -  57.69  ng/mg.  The  results  are  summarized  in  Table  6.3.  These  values 
correspond  with  other  studies.  One  study  reported  AF  hair  concentrations  in  the  hair  of  40 
volunteer  subjects  ranging  from  0.01-4.46  ng/mg.  These  individuals  were  on  rehabilitation 
programs  and  were  known  drug  users  [65].  In  another  study  the  concentration  of  AF  in 
hair  ranged  from  0.74-1.02  ng/mg  in  healthy  young  amfetamines  users  [87]. 
It  was  difficult  in  this  study  to  try  and  directly  correlate  the  dose  with  the  amount  of  AF 
found  in  the  hair  because  the  dose  of  fenethylline  in  these  cases  was  unknown.  The  self- 
reports  of  the  volunteers  showed  that  a  variable  number  of  fenethylline  tablets  were  used. 
The  exact  dose  of  fenethylline  in  these  cases  was  unknown  i.  e.  tablets  can  be  of  varying 
doses.  An  attempt  was  made  to  find  if  there  was  any  correlation  between  self-reported  use 
and  the  amount  of  amfetamine  found  in  hair.  For  this  purpose,  the  dose  of  each  tablet  was 
assumed  to  be  the  same.  The  case  hair  samples  were  categorised  into  three  different 
groups  according  to  the  number  of  fenethylline  tablets  used.  These  were  low  (1-2  tablets), 
medium  (3-5  tablets)  and  high  (>  5  tablets).  Self-reports  (amount  of  tablets)  and 
concentration  of  AF  in  hair  was  compared.  These  results  showed  that  there  was  overlap 
between  the  three  levels.  The  lowest  and  highest  levels  found  in  hair  fell  into  the  medium 
category  and  not  into  the  low  and  high  categories  respectively.  This  may  be  explained  by 
by  the  varying  dose  in  tablets  and  the  inaccuracy  of  self-report  data.  These  results  are 
summarised  in  Table  6.5. 
The  effect  of  hair  colour  on  the  incorporation  of  AF  into  hair  was  eliminated  in  this  study, 
because  the  majority  of  hair  samples  (15  out  of  16)  were  the  same  colour  (black). 
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This  study  was  an  initial  attempt  to  provide  information  about  the  accuracy  of  self  reports 
by  analysing  hair  samples.  All  hair  samples  from  individuals  reporting  to  have  abused 
Fenethylline  were  positive  for  AF  showing  that  this  was  a  reliable  method  for  showing 
previous  use  and  could  be  used  to  complement  urine  testing.  Overall,  this  study  indicated 
that  there  was  a  lack  of  correlation  between  self  reported  use  and  concentration  of  AF  in 
hair.  This  will  be  partly  due  to  varying  dosages  of  the  drug  within  tablets. 
Hairl8  (Table  6.3)  was  obtained  from  a  different  source.  Case  details  were  unknown  for 
this  particular  sample.  However,  the  hair  sample  was  found  to  be  positive  along  the  length 
for  AF  indicating  regular  exposure. 
Postmortem  blood  samples  were  analysed  by  Forensic  Medicine  and  Science  at  University 
of  Glasgow  for  amfetamines  and  related  compounds.  Chronic  arnfetamine  or  ecstasy 
abuse  was  confirmed  by  the  results  of  the  hair  analysis.  In  many  of  these  cases  regular  use 
was  not  known.  The  postmortem  hair  samples  were  positive  for  these  drugs  and  in  general 
the  results  showed  that  there  was  good  qualitative  correlation  between  blood  and  hair 
results.  In  some  cases  these  were  also  supported  by  evidence  in  the  police  report. 
Postmortem  hair  samples  that  were  positive  for  MDMA  were  also  positive  for  its  break 
down  product,  MDA.  All  of  these  samples  were  also  positive  for  AF.  This  may  be  a  result 
of  taking  AF  tablets  or  alternatively  as  an  impurity  in  ecstasy  tablets.  All  other 
amfetamines  (MA  and  MDEA)  gave  negative  results  for  hair  samples.  The  concentration 
of  AF  in  hair  ranged  from  0.04  -  4.42  ng/mg.  The  levels  in  hair  ranged  from  0.13-5.39 
ng/mg  for  MDMA  and  0.04-0.78  ng/mg  for  MDA.  The  ratio  of  MDMA/MDA  in  the  hair 
samples  ranged  from  3.25-11.10.  In  all  of  these  cases  the  level  of  MDMA  was  higher  than 
the  level  of  MDA  and  it  is  likely  the  MDA  is  from  the  breakdown  of  MDMA. 
Out  of  the  6  postmortem  hair  cases  that  were  analysed,  ecstasy  was  known  to  be  used  in  2 
cases.  Ecstasy  use  was  not  known  for  the  other  four  cases,  but  MDMA  and  MDA  were 
found  in  these  blood  and  hair  samples.  The  findings  in  the  hair  samples  would  tend  to 
suggest  regular  use.  The  hair  MDMA  levels  found  in  this  study  were  similar  to  those  that 
have  been  found  in  cases  of  known  ecstasy  users.  It  was  reported  that  the  concentration  of 
MDMA  from  15  regular  users  of  MDMA  and  MA  ranged  from  1.20-12.6  ng/mg  in  lcra 
hair.  These  volunteers  had  consumed  1  to  4  tablets  with  varying  doses  in  the  last  month 
[92].  Another  study  found  MDMA  concentrations  ranging  from  0.117-6.44  ng/mg  in  20 
cases  of  known  users  [99]. 
The  results  are  summarized  in  Table  6.4  and  the  chromatograms  of  the  control  sample  for 
all  five  amfetamines  and  one  of  authentic  sample  for  AF,  MDA  and  MDMA  are  shown  in 
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Figure  6.1,  Figure  6.2,  Figure  6.3,  Figure  6.4,  Figure  6.5,  Figure  6.6,  Figure  6.7  and  Figure 
6.8  respectively. 
Table  6.3  Amfetamines  concentration  finding  in  hair  and  urine  case  Samples 
Case  Sample 
HairCOI 
HairC02 
HairC03 
Hair04 
Hair05 
Hair07 
Hair08 
Hair09 
HairlO 
Hairl  1 
Hair12 
Hairl4 
Hair15 
Hairl6 
Hair17 
Hairl8 
AF 
Neg 
Pos 
Pos 
Pos 
Pos 
Neg 
Pos 
Pos 
Pos 
Pos 
Pos 
Pos 
Pos 
Pos 
Pos 
Pos 
Urine 
Cannabinolds 
Pos 
Neg 
Pos 
Pos 
Neg 
Pos 
N/D 
Pos 
Pos 
N/D 
Pos 
N/D 
Pos 
N/D 
Pos 
NID 
Hair  n 
AF 
N/D:  Not  Done 
2.45 
1.64 
3.32 
2.49 
16.52 
0.65  (0-3  cm) 
0.22  (3-6  cm) 
0.39  (6-9  cm) 
0.19  (9-12  cm) 
0.17  (12-15cm) 
0.15  (15-18em) 
2.08 
11.12 
1.69 
4.73 
0.17 
41.25 
12.12 
12.37 
57.69 
0.53  (0-3  cm) 
0.3  (3-6  cm) 
0.46  (6-9  cm) 
Table  6.4  Amfetamines  concentration  finding  in  hair  and  blood  in  postmortem  case  Samples 
AF  MA  M  DA  MDMA  MD  EA 
Case  Blood  Hair  Blood  Hair  Blood  Hair  Blood  Hair  Blood  Hair 
Sample  m  /L  ng/mg  mg/L  ng/mg  mg/L  ng/mg  mg/L  ng/mg  mg  ng/mg 
PMOI  N/D  0.34  0.40  Neg  0.04  0.35  0.40  3.17  N/D  Neg 
PM02  0.62  4.42  N/D  Neg  0.05  0.78  0.45  5.39  0.45  Neg 
PM03  N/D  0.23  N/D  Neg  0.02  0.21  0.36  2.33  N/D  Neg 
PM04  N/D  0.04  N/D  Neg  0.02  0.04  0.75  0.13  N/D  Neg 
PM05  N/D  0.06  N/D  Neg  0.12  0.31  0.07  1.85  N/D  Neg 
PM06  N/D  0.13  N/D  Neg  0.02  0.16  0.75  1.17  N/D  Neg 
N/D:  Not  Done 
Table  6.5  The  concentration  of  AF  and  the  number  of  tablets 
No  of  table 
Low  (1  -2  ) 
Medium  (3-5) 
High  >5 
Concentration  of  AF  in  hair 
2.08-3.32 
0.17-57.69 
12.12-16.52 
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6.3  Case  Abstract 
Reference:  HairC01  Sex:  Male  Age:  27 
Background  circumstances:  According  to  medical  files  and  self  report,  this  man  had  been 
using  cannabis  and  fenethylline  (captagon)  tablets  for  more  than  three  years.  He  smoked  5 
cigarettes  and  took  I  fenethylline  tablet  daily. 
Toxicology: 
Positive  urine  result  for  cannabinoids. 
Negative  urine  result  for  arnfetamine. 
0-3  cm  hair  segment: 
2.45  nanograms  of  amfetarnine  per  milligrams  of  hair. 
All  other  amfetamines  (MA,  MDA,  MDMA  and  MDEA)  analyses  gave  NEGATIVE 
results. 
Reference:  HairC02  Sex:  Male  Age:  25 
Background  circumstances:  According  to  his  medical  files  and  self  report,  this  man  had 
been  smoking  cannabis  and  taking  3-4  fenethylline  tablets  daily  for  more  than  three  years 
Toxicology: 
Negative  urine  result  for  cannabinoids. 
Positive  urine  result  for  arafetamine. 
0-3  cm  hair  segment: 
1.65  nanograms  of  amfetamine  per  milligram  of  hair. 
All  other  arnfetarnines  (MA,  MDA,  MDMA  and  MDEA)  analyses  gave  NEGATIVE 
results. 
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Reference:  HairC03  Sex:  Male  Age:  38 
Background  circumstances:  According  to  his  medical  files  and  self  report,  this  man  had 
been  smoking  1  cannabis  cigarette  daily  for  more  than  ten  years.  He  had  also  been  taking 
1  fenethylline  tablet  daily  for  more  than  five  years. 
Toxicology: 
Positive  urine  result  for  cannabinoids. 
Positive  urine  result  for  amfetamine. 
0-3  cm  hair  segment: 
3.32  nanograms  of  amfetamine  per  milligram  of  hair. 
All  other  arnfetarnines  (MA,  MDA,  MDMA  and  MDEA)analyses  gave  NEGATIVE 
results. 
Reference:  Hair04  Sex:  Male  Age:  24 
Background  circumstances:  According  to  his  medical  report  and  self  report,  this  man  had 
been  smoking  cannabis  daily  for  more  than  seven  years  and  taken  fenethylline  tablets  for 
more  than  eight  years.  He  also  used  alcohol  occasionally. 
Toxicology: 
Positive  urine  result  for  cannabinoids. 
Positive  urine  result  for  amfetamine. 
0-3  cm.  hair  segment: 
2.49  nanograms  of  amfetamine  per  milligram  of  hair. 
All  other  amfetamines  (MA,  MDA,  MDMA  and  MDEA)  analyses  gave  NEGATIVE 
results. 
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Reference:  HairO5  Sex:  Male  Age:  32 
Background  circumstances:  According  to  his  medical  files  and  self  report,  this  man  had 
been  using  7  tablets  of  fenethylline  daily  for  more  than  two  years. 
Toxicology: 
Negative  urine  result  for  cannabinoids. 
Positive  urine  result  for  amfetamine. 
0-3  cm  hair  segment: 
16.52  nanograms  of  amfetamine  per  milligram  of  hair. 
All  other  amfetarnines  (MA,  MDA,  MDMA  and  MDEA)  analyses  gave  NEGATIVE 
results. 
Reference:  Hair07  Sex:  Male  Age:  27 
Background  circumstances:  According  to  his  medical  files,  emergency  room  assessment 
and  self  report  this  man  had  been  using  cannabis  for  more  than  six  years  and  had  taken 
fenethylline  tablets  and  used  alcohol  at  intervals.  He  had  smoked  3-5  cigarettes  daily.  A 
long  strand  of  hair  was  collected  and  cut  into  six  segments  (0-3,3-6,6-9,9-12,12  -15  and 
15-18  cm). 
Toxicology: 
Positive  urine  result  for  cannabinoids. 
Negative  urine  result  for  amfetamine. 
0-  18  cm  hair  segment: 
0.65  nanograms  of  amfetamine  per  milligram  of  hair  in  0-3  cm  segment. 
0.22  nanograms  of  amfetamine  per  milligram  of  hair  in  3-6  cm  segment. 
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0.39  nanograms  of  amfetarnine  per  milligram  of  hair  for  6-9  cm  segment. 
0.19  nanograms  of  amfetamine  per  milligram  of  hair  for  9-12  cm  segment. 
0.17  nanograms  of  amfetamine  per  milligram  of  hair  for  12-15  cm  segment. 
0.15  nanograms  of  amfetamine  per  milligram  of  hair  for  15-18  cm  segment. 
All  other  arnfetarnines  (MA,  MDA,  MDMA  and  MDEA)  analyses  gave  NEGATIVE 
results. 
Reference:  HairO8  Sex:  Male  Age:  32 
Background  circumstances:  According  to  his  medical  files  and  self  report,  this  man  had 
been  using  2  tablets  of  fenethylline  daily  for  more  than  two  years. 
Toxicology: 
Positive  urine  result  for  arnfetamine. 
0-3cm  hair  seginent: 
2.08  nanograms  of  amfetarnine  per  milligram  of  hair. 
All  other  arnfetamines  (MA,  MDA,  MDMA  and  MDEA)  analyses  gave  NEGATIVE 
results. 
Reference:  Hair09  Sex:  Male  Age:  21 
Background  circumstances:  According  to  his  medical  files  and  self  report,  this  man  had 
been  using  cannabis  more  than  three  years  and  had  taken  fenethylline  tablets  for  more  than 
three  years.  He  smoked  1-2  cannabis  cigarettes  daily  and  took  4-5  fenethylline  tablets 
daily. 
Toxicology: 
Positive  urine  result  for  cannabinoids. 
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Positive  urine  result  for  ainfetarnine. 
0-3cm  hair  segment: 
11.12  nanograms  of  amfetamine  per  milligram  of  hair. 
All  other  amfetamines  (MA,  MDA,  MDMA  and  MDEA)  analyses  gave  NEGATIVE 
results. 
Reference:  HairlO  Sex:  Male  Age:  20 
Background  circumstances:  According  to  his  medical  files  and  self  report,  this  man  had 
been  using  cannabis  for  more  than  four  years  and  had  taken  fenethylline  tablets  for  more 
than  four  years.  He  had  smoked  5  cigarettes  daily  and  had  taken  4-5  fenethylline  tablets 
daily. 
Toxicology: 
Positive  urine  result  for  cannabinoids. 
Positive  urine  result  for  amfetamine. 
0-3cm  hair  segment: 
1.69  nanograms  of  arnfetarnine  per  milligram  of  hair. 
All  other  amfetamines  (MA,  MDA,  MDMA  and  MDEA)  analyses  gave  NEGATIVE 
results. 
Reference:  Hairl  1  Sex:  Male  Age:  25 
Background  circumstances:  According  to  his  medical  files  and  self  report,  this  man  had 
been  using  1-5  tablets  of  fenethylline  daily  for  more  than  seven  years. 
Toxicology: 
Positive  urine  result  for  amfetamine. 
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0-3cm  hair  seginent: 
4.73  nanograms  of  arnfetamine  per  milligram  of  hair. 
All  other  amfetamines  (MA,  MDA,  MDMA  and  MDEA)  analyses  gave  NEGATIVE 
results. 
Reference:  Hair12  Sex:  Male  Age:  23 
Background  circumstances:  According  to  his  medical  files  and  self  report,  this  man  had 
been  using  cannabis  for  more  than  five  years  and  fenethylline  tablets  for  more  than  seven 
years.  He  had  smoked  daily  and  had  taken  9  fenethylline  tablets  daily  and  used  alcohol 
occasionally. 
Toxicology: 
Positive  urine  result  for  cannabinoids. 
Positive  urine  result  for  amfetamine. 
0-3cm  hair  segment: 
0.17  nanograms  of  amfetwnine  per  milligram  of  hair. 
All  other  amfetamines  (MA,  MDA,  MDMA  and  MDEA)  analyses  gave  NEGATIVE 
results. 
Reference:  Hair14  Sex:  Male  Age:  34 
Background  circumstances:  According  to  his  medical  files  and  self  report  this  man  had 
been  using  8-9  tablets  of  fenethylline  daily  for  more  than  eight  years. 
Toxicology: 
Positive  urine  result  for  amfetamine. 
0-3cm  hair  segment: 
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41.25  nanograrns  of  arnfetainine  per  milligram  of  hair. 
All  other  arnfetamines  (MA,  MDA,  MDMA  and  MDEA)  analyses  gave  NEGATIVE 
results. 
Reference:  HairI5  Sex:  Male  Age:  35 
Background  circumstances:  According  to  his  medical  files  and  self  report,  this  man  had 
been  using  cannabis  more  than  one  year  and  had  taken  fenethylline  tablets  for  more  than 
three  years.  I  cigarette  was  smoked  daily  and  he  had  taken  2-3  fenethylline  tablets  daily 
and  used  alcohol  occasionally. 
Toxicology: 
Positive  urine  result  for  cannabinoids. 
Positive  urine  result  for  amfetamine. 
0-3cm  hair  segment: 
12.12  nanograrns  of  amfetamine  per  milligram  of  hair. 
All  other  amfetamines  (MA,  MDA,  MDMA  and  MDEA)  analyses  gave  NEGATIVE 
results. 
Reference:  Hairl6  Sex:  Male  Age:  40 
Background  circumstances:  According  to  his  medical  report,  this  man  had  been  using  eight 
tablets  of  fenethylline  daily  for  more  than  fifteen  years. 
Toxicology: 
Positive  urine  result  for  amfetamine. 
0-3cm  hair  segment: 
12.37  nanograms  of  Amfetarnine  per  milligrmn  of  hair. 
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All  other  amfetamines  (MA,  MDA,  MDMA  and  MDEA)  analyses  gave  NEGATIVE 
results. 
Reference:  Hair17  Sex:  Male  Age:  26 
Background  circumstances:  According  to  his  medical  files  and  self  report,  this  man  had 
been  using  cannabis  for  more  than  ten  year  and  he  had  taken  fenethylline  tablets  for  more 
than  ten  years.  2  cigarettes  were  smoked  daily,  3-4  fenethylline  tablets  were  taken  daily 
and  alcohol  was  used  at  intervals. 
Toxicology: 
Positive  urine  result  for  cannabinoids. 
Positive  urine  result  for  amfetamine. 
0-3cm  hair  segment: 
57.69  nanograms  of  arnfetamine  per  milligram  of  hair. 
All  other  arnfetarnines  (MA,  MDA,  MDMA  and  MDEA)  analyses  gave  NEGATIVE 
results. 
Reference:  Hairl8  Sex:  F  Age:  9 
Background  circumstances:  This  child  had  been  given  amfetamine  by  her  mother.  A 
neighbour  called  the  police  and  they  attended  the  house  to  find  that  the  child  was  unwell 
and  in  need  of  medical  treatment.  At  the  hospital,  she  was  treated  accordingly  and  her 
urine  was  found  to  be  positive  for  amfetamine.  Hair  samples  were  taken  shortly  afterwards 
to  establish  if  there  was  any  evidence  of  previous  amfetamine  use. 
Toxicology: 
Positive  urine  result  for  amfetamine. 
0-9  cm  hair  segment: 
0.53  nanograms  of  amfetamine  per  milligram  of  hair  in  0-3  cm  segment. 
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0.3  nanograms  of  amfetamine  per  milligram  of  hair  in  3-6  cm  segment. 
0.46  nanograms  of  amfetamine  per  milligram  of  hair  in  6-9  cm  segment. 
All  other  amfetamines  (MA,  MDA,  MDMA  and  MDEA)  analyses  gave  NEGATIVE 
results  for  all  segments. 
Reference:  PM01  Sex:  Male  Age:  28 
Background  circumstances:  This  young  man  had  a  history  of  alcohol  and  heroin  abuse  and 
had  at  times  been  using  methadone.  He  was  on  a  number  of  medications  including 
antidepressants.  He  returned  to  his  house  from  a  party  and  appeared  to  be  intoxicated.  He 
was  left  lying  on  a  couch  in  the  living  room  and  was  later  found  to  be  unresponsive.  He 
was  taken  to  hospital  and  was  found  to  be  dead  on  arrival. 
Cause  of  Death:  Heroin  and  alcohol  intoxication. 
Toxicology: 
0.4  milligrams  of  methamfetamine  per  litre  of  blood. 
0.04  milligrams  of  methylenedioxyamfetamine  per  litre  of  blood. 
0.4  milligrams  of  methylendioxymethylamfetamine  per  litre  of  blood. 
0.44  milligrams  of  citaloprain  per  litre  of  blood. 
0.02  milligrams  of  desmethyldiazepam  per  litre  of  blood. 
0.06  milligrams  of  codeine  per  litre  of  blood. 
0.1  milligrams  of  morphine  per  litre,  of  blood. 
16.71  milligrams  of  paracetamol  per  litre  of  blood. 
51  milligrams  of  alcohol  per  100  millilitres  of  blood. 
215  milligrams  of  alcohol  per  100  millilitres  of  urine. 
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0-3  cra  hair  segment: 
0.34  nanograms  of  amfetamine  per  milligram  of  hair. 
0.35  nanograms  of  methylendioxyamfetamine  per  milligram  of  hair. 
3.17  nanograms  of  methylendioxymethylamfetamine  per  milligram  of  hair. 
All  other  amfetarnines  (MA  and  MDEA)  analyses  gave  NEGATIVE  results. 
Reference:  PM02  Sex:  Male  Age:  30 
Background  circumstances:  This  young  man  was  known  to  abuse  drugs  but  little  was 
known  about  his  medical  history.  He  was  found  dead  at  his  home  seated  on  a  chair 
slouched  backwards,  and  beside  him  was  a  broken  piece  of  mirror  with  white  powder  on  it. 
Cause  of  Death:  Arnfetarnine  and  MDMA  (ecstasy)  intoxication. 
Toxicology: 
0.62  nanograms  of  amfetamine  per  litre  of  blood. 
0.053  milligrams  of  methylendioxyamfetamine  per  litre  of  blood. 
0.45  milligrams  of  methylendioxymethylamfetamine  per  litre  of  blood. 
0.02  milligrams  of  diazepam  per  litre  of  blood. 
0.17  milligrams  of  benzoylecgonine  per  litre  of  blood. 
0.19  milligrams  of  methadone  per  litre  of  blood. 
0.020  milligrams  of  dihydrocodeine  per  litre  of  blood. 
0-3  cm  hair  segment: 
4.42  nanograrns  of  arnfetarnine  per  milligram  of  hair. 
0.78  nanograms  of  methylendioxyarnfetamine  per  milligram  of  hair. 
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5.39  nanograms  of  methylendioxymethylamfetamine  per  milligram  of  hair. 
All  other  arnfetarnines  (MA  and  MDEA)  analyses  gave  NEGATIVE  results. 
Reference:  PM03  Sex:  M  Age:  21 
Background  circumstances:  This  young  man  had  a  history  of  alcohol  abuse  and  took  drugs, 
including  ecstasy  and  diazepam.  He  was  drinking  heavily  and  smoking  cannabis  and 
subsequently  went  to  bed.  He  was  found  lying  on  his  back  in  bed,  apparently  dead.  An 
ambulance  was  called  but  he  was  confirmed  to  be  dead. 
Cause  of  Death:  Methadone  intoxication. 
Toxicology: 
0.02  milligrams  of  methylendioxyamfetainine  per  litre  of  blood. 
0.36  milligarns  of  mcthylendioxyrnethylarnfctamine  pcr  litrc  of  blood. 
0.08  milligrams  of  desmethyldiazepam  per  litre  of  blood. 
0.04  milligrams  of  diazeparn  per  litre  of  blood. 
0.19  milligrams  of  methadone  per  litre  of  blood. 
0.003  milligrams  of  dihydrocodeine  per  litre  of  blood. 
0.017  milligrams  of  morphine  per  litre  of  blood. 
0-3  cm  hair  segment: 
0.23  nanograms  of  amfetamine  per  milligram  of  hair. 
0.21  nanograms  of  methylendioxyamfetamine  per  milligram  of  hair. 
2.33  nanograms  of  methylendioxyrnethylainfetamine  per  milligram  of  hair. 
All  other  amfetamines  (MA  and  MDEA)  analyses  gave  NEGATIVE  results. 
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Reference:  PM04  Sex:  M  Age:  36 
Background  circumstances:  This  man  had  a  long  standing  history  of  drug  abuse  and  was 
positive  for  hepatitis  B.  He  was  found  lying  on  the  floor,  dead.  An  ambulance  attended  at 
the  scene  but  there  were  no  vital  signs.  An  uncapped  syringe  was  found  lying  close  to  him. 
Cause  of  Death:  Heroin  and  temazepam  intoxication. 
Toxicology: 
0.022  milligrmns  of  methylendioxyamfetamine  per  litre  of  blood. 
0.075  milligrams  of  methylendioxymethyl=fetamine  per  litre  of  blood. 
0.39  milligrams  of  oxazepam  per  litre  of  blood. 
12.55  milligrams  of  temazepam  per  litre  of  blood. 
0.021  milligrams  of  6-monoacetylmorphine  per  litre  of  blood. 
0.164  milligrams  of  codeine  per  litre  of  blood. 
0.984  milligrams  of  morphine  per  litre  of  blood. 
0-3  cm  hair  segment: 
0.04  nanograms  of  arnfetarnine  per  milligram  of  hair. 
0.04  nanograms  of  methylendioxyamfetamine  per  milligram  of  hair 
0.13  nanograms  of  methylendioxymethylamfetamine  per  milligram  of  hair. 
All  other  amfetamines  (MA  and  MDEA)  analyses  gave  NEGATIVE  results. 
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Reference:  PM05  Sex:  M  Age:  40 
Background  circumstances:  This  man  returned  home  apparently  drunk  and  continued 
drinking  at  home.  The  following  morning  he  was  found  to  be  unresponsive  and  not 
breathing.  Subsequent  searching  of  his  clothing  revealed  a  single  white  tablet  in  one  of  the 
pockets,  possibly  thought  to  be  ecstasy. 
Cause  of  Death:  MDMA  (ecstasy)  and  arnitriptyline  intoxication. 
Toxicology: 
0.12  milligrams  of  methylendioxywnfetamine  per  litre  of  blood. 
0.075  milligrams  of  methylendioxymethylamfetamine  per  litre  of  blood. 
0.04  milligrams  of  desmethyldiazepam  per  litre  of  blood. 
0.04  milligrams  of  diazeparn  per  litre  of  blood. 
0.36  milligrams  of  dihydrocodeine  per  litre  of  blood. 
24.74  milligrams  of  paracetamol  per  litre  of  blood. 
3.12  milligrams  of  arnitriptyline  per  litre  of  blood. 
1.99  milligrams  of  nortriptyline  per  litre  of  blood. 
153  milligrams  of  alcohol  per  100  millilitres  of  blood. 
260  milligrams  of  alcohol  per  100  millilitres  of  urine. 
0-3  cm  hair  segment: 
0.06  nanograms  of  arnfetamine  per  milligram  of  hair. 
0.31  nanograms  of  methylendioxyamfetainine  per  milligram  of  hair 
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1.85  nanograms  of  mcthylendioxymcthylamfetaminc  pcr  milligrain  of  hair. 
All  other  arnfetamines  (MA  and  MDEA)  analyses  gave  NEGATIVE  results. 
Reference:  PM06  Sex:  M  Age:  19 
Background  circumstances:  This  man  had  consumed  a  large  amount  of  alcohol  and  was 
seen  to  consume  a  quantity  of  absinthe  spirit  (70%  abv)  and  he  appeared  to  become 
extremely  drowsy  and  fell  asleep.  He  was  placed  in  a  bedroom.  Periodic  checks  were  made 
on  him  but  about  an  hour  and  a  half  after  being  put  on  the  bed  he  appeared  to  turn  blue. 
Despite  resuscitation  attempts  he  was  pronounced  dead. 
Cause  of  Death:  Acute  alcohol  intoxication. 
Toxicology: 
0.02  milligrams  of  methylendioxyamfetamine  per  litre  of  blood. 
0.75  milligrams  of  methylendioxyrnethylamfetarnine  per  litre  of  blood. 
0.046  milligrams  of  lignocaine  per  litre  of  blood. 
350  milligrams  of  alcohol  per  100  millilitres  of  blood. 
422  milligrams  of  alcohol  per  100  millilitres  of  urine. 
0-3  cm  hair  segment: 
0.13  nanograms  of  amfetamine  per  milligram  of  hair. 
0.16  nanograms  of  methylendioxyamfetamine  per  milligram  of  hair 
1.17  nanograms  of  methylendioxyrnethylainfetamine  per  milligram  of  hair. 
All  other  arnfetarnines  (MA  and  MDEA)  analyses  gave  NEGATIVE  results. 
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7  Conclusion 
Hair  analysis  has  been  shown  to  be  effective  in  determining  chronic  use  of  drugs.  This 
biological  sample  is  advantageous  in  cases  where  it  is  suspected  that  urine  specimens  have 
been  adulterated.  Hair  is  difficult  to  adulterate,  but  if  this  is  suspected  then  another  sample 
can  be  requested  easily.  Amfetamines  and  cannabinoids  are  the  two  most  abused 
substances  in  Saudi  Arabia.  For  this  reason  a  method  to  analyse  both  substances  in  hair 
simultaneously  was  investigated.  Initial  experiments  showed  that  hair  samples  spiked  with 
amfetamines  gave  good  linearities  using  four  different  pre-treatment  methods  (alkaline  pre- 
treatment  using  IM  NaOH,  fl-Glucuronidase  using  helix  pomatia,  methanol  and  acid  pre- 
treatment  using  O.  lM  HCl)  followed  by  SPE  and  GC-MS  analysis.  However,  the 
recoveries  of  cannabinoids  using  these  methods  were  poor  as  shown  by  the  inability  to 
detect  low  concentrations  of  standards.  The  recovery  of  these  drugs  using  the  SPE  method 
alone  without  pre-treatment  was  investigated  and  was  found  to  be  acceptable  for  these 
substances.  The  alkaline  pre-treatment  method  was  then  modified  using  different  pH  (5,6, 
7  and  8)  of  the  phosphate  buffer  and  four  different  eluents,  acetone  /  chloroform  (1:  1  v/v), 
hexane  /  EtOAc  (9:  1  v/v),  hexane  /  EtOAc  (8:  2  v/v)  and  methanol  to  improve  the 
cannabinoids  (A?  -THC  and  A?  -THC-COOH)  recovery.  At  the  same  time  the  amfetamines 
recoveries  were  monitored  to  ensure  that  their  recoveries  did  not  significantly  decrease. 
Unfortunately  the  modified  method  demonstrated  no  significant  improvement  of 
cannabinoids  recovery.  A  comparison  study  was  carried  out  for  the  four  pre-treatment 
methods  to  investigate  which  method  gave  the  best  recovery  of  amfetamine  from  hair 
using  a  hair  case  sample  known  to  be  positive  for  AF.  This  work  showed  that  all  four  pre- 
treatment  methods  were  effective  in  the  extraction  of  AF  from  hair.  However,  it  was 
shown  that  the  best  recovery  for  AF  extraction  was  obtained  using  the  9-  glucuronidase 
pre-treatment  method.  The  method  was  successfully  validated  for  all  anifetamine 
compounds. 
To  assess  the  validity  of  analysing  hair  samples  for  the  presence  of  AF  in  victims  of 
drowning,  the  change  in  concentration  of  AF  in  hair  submerged  in  sea  water  and  fresh 
water  over  a  period  of  time  was  investigated.  Ten  amfetarnine  positive  hair  samples  were 
submerged  in  fresh  and  sea  water  for  different  periods  of  time.  Six  of  these  specimens  were 
separated  into  8  portions  each.  One  of  these  portions  was  stored  as  an  original  specimen 
and  7  portions  were  immersed  in  5  ml  of  sea  water  for  1,2  days,  1,2,3,4  or  8  weeks  at  5 
OC.  The  other  four  specimens  were  separated  into  5  portions,  one  of  these  portions  was 
stored  as  an  original  specimen  and  4  were  stored  in  5  ml  of  fresh  water  for  1,2,4  or  8 
Diagnostic  Use  ofHairAnalysisfor  the  Detection  ofMisuse  ofAmfetamines  and  Cannabinoids Chapter  Seven:  Conclusion  Page  143 
weeks  at  5  T.  The  drug  concentrations  in  the  samples  were  monitored  over  this  period. 
Hair  samples  were  analysed  using  the  validated  method.  The  results  showed  a  significant 
decrease  of  AF  in  hair  with  the  time  submerged  in  sea  water.  Fresh  water  had  a  much  less 
significant  effect  over  the  study  period.  The  decrease  in  hair  AF  concentration  after  one 
day  in  seawater  ranged  from  0.1-85%  and  after  eight  weeks  ranged  from  88-97%.  Infresh 
water,  after  one  week  the  concentration  was  found  to  decrease  by  9-17%  and  after  eight 
wccks  by  16-60%. 
The  incubation  water  used  to  submerge  the  samples  after  eight  weeks  was  found  to  be 
positive  for  AF.  The  sea  water  contained  a  higher  concentration  of  metal  ions  than  the 
fresh  water.  The  high  concentration  of  metal  ions  in  sea  water  may  explain  the  increased 
rate  of  removal  of  AF  from  hair  when  compared  to  fresh  water. 
Careful  interpretation  is  required  for  hair  samples  obtained  from  victims  of  drowning.  Sea 
water  has  the  potential  to  cause  the  complete  loss  of  drug  from  hair  with  increased  time, 
while,  fresh  water  may  cause  partial  or  possible  complete  loss  with  increased  time. 
A  total  of  22  living  and  post-mortern  cases  samples  were  analysed  by  the  validated 
method.  Control  hair  samples  were  run  simultaneously  with  case  samples  and  their  results 
were  found  to  be  within  an  acceptable  range.  This  method  is  appropriate  for  the 
identification  of  amfetamines  drugs  in  hair.  Chronic  amfetamine  or  ecstasy  abuse  was 
confinned  by  the  results  of  the  hair  analysis.  For  all  case  samples,  these  results  showed 
good  qualitative  correlation  between  self-reported  use,  urine  or  blood  results  and  hair 
results  for  amfetamines. 
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7.1  Further  Work 
In  accordance  with  medical  files  and  self  reports  of  AF  abusers  involved  in  rehabilitation 
programs  at  Alarnal  Medical  Complex  in  Riyadh,  Saudi  Arabia,  positive  AF  results  were 
attributed  to  the  illegal  precursor  of  AF  called  fenethylline  (captagon).  The  development 
of  a  method  capable  of  detecting  the  parent  drug,  fenethylline  and  its  metabolites  AF 
simultaneously  would  be  beneficial  in  order  to  discriminate  between  the  source  of  AF. 
The  extent  of  fenethylline  use  could  then  be  recognized.  Also,  since  theophylline  is 
fenethylline  metabolite,  its  identification  may  be  of  some  use. 
Further  work  could  be  carried  out  on  the  AF  stability  study  to  include  AF  related 
compounds  using  different  storage  temperatures  (refrigerator  and  freezer),  different 
incubation  times,  different  ionic  strengths  and  different  incubation  conditions  (dark,  light, 
UV,  pH). 
The  proposed  method  requires  further  investigations  to  improve  the  cannabinoids 
recoveries  to  a  satisfactory  degree  and  to  be  able  to  include  them  in  the  method.  More 
sensitive  instrumentation  would  be  beneficial  to  improve  the  cannabinoids  detection  in 
hair. 
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An  investigation  of  the  stability  of  amphetamine  in  hair  samples  submerged  in  a  fresh 
and  sea  water  environment. 
Fahad  N.  Bin-Eisa,  Fiona  A  Wylie  and  John  S.  Oliver  (Forensic  Medicine  and  Science 
Department,  University  of  Glasgow,  Glasgow,  United  Kingdom) 
Abstract 
To  assess  the  validity  of  analysing  hair  samples  for  the  presence  of  amphetamine  in  victims 
of  drowning,  a  method  was  first  established  to  identify  and  measure  the  concentration  of 
this  drug  in  hair  specimens.  Amphetamine  was  extracted  from  hair  using  enzyme 
treatment  with  fl-Glucuronidase  (helix,  pomatia)  at  45  T  for  2  hours  followed  by  solid 
phase  extraction  using  Bond  Elut  Certify,  mixed-mode  columns.  The  samples  were 
analysed  by  gas  chromatography-mass  spectrometry.  An.  HP-5  capillary  column,  30  in  x 
0.32  mm  x  0.25  ýtrn  film  thickness  was  used  and  the  temperature  was  programmed  from 
100  to  300  T  at  a  rate  of  12'C  /  minute  and  held  at  300  T  for  5  minutes.  The  method  was 
validated  and  found  to  be  linear  over  the  concentration  range  5-200  nanogranis  per  30 
milligrams  of  hair  with  a  correlation  co-efficient  of  0.999.  The  limits  of  detection  and 
quantitation  were  2.7  nanogranis  per  30  milligrams  of  hair  and  4.3  nanograms  per  30 
milligrams  of  hair  respectively.  Intra-day  reproducibility  had  coefficients  of  variation  of 
less  than  10  %  at  3  different  analyte  concentrations  (10,50  and  200  nanograms  per  30 
milligrams  of  hair).  Inter-day  reproducibility  coefficient  of  variation  was  less  than  15% 
and  the  recovery  of  the  method  was  71  %. 
The  effect  of  salt  water  and  fresh  water  on  the  concentration  of  amphetamine  in  hair 
specimens  was  investigated  by  splitting  known  amphetamine  positive  specimens.  These 
were  stored  in  these  types  of  water  at  5  OC  for  specific  time  intervals  ranging  from  one  day 
to  eight  weeks.  The  initial  concentrations  of  the  hair  samples  investigated  ranged  from 
0.14  to  57.70  nanograms  per  milligram  of  hair  The  results  showed  a  significant  decrease  of 
amphetamine  in  hair  with  incubation  time  in  salt  water.  The  decrease  in  the  different 
samples  after  eight  weeks  of  incubation  in  salt  water  ranged  from  60-95%.  Fresh  water  had 
a  much  less  significant  effect  over  the  study  period. 
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